---
document_datetime: 2023-09-21 17:09:51
document_pages: 94
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/daxas-h-c-1179-x-0035-epar-assessment-report-extension_en.pdf
document_name: daxas-h-c-1179-x-0035-epar-assessment-report-extension_en.pdf
version: success
processing_time: 127.0973663
conversion_datetime: 2025-12-14 23:40:47.447011
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

22 February 2018 EMA/154975/2018 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Daxas

International non-proprietary name: roflumilast

Procedure No. EMEA/H/C/001179/X/0035

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Administrative information

| Name of the medicinal product:                  | Daxas                                                                                                                                                                                                                                                                                      |
|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MAH:                                            | AstraZeneca AB SE-151 85 Sodertalje SWEDEN                                                                                                                                                                                                                                                 |
| Active substance:                               | ROFLUMILAST                                                                                                                                                                                                                                                                                |
| International Non-proprietary Name/Common Name: | roflumilast                                                                                                                                                                                                                                                                                |
| Pharmaco-therapeutic group (ATC Code):          | Other systemic drugs for obstructive airway diseases (R03DX07)                                                                                                                                                                                                                             |
| Therapeutic indication(s):                      | Daxas is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment |
| Pharmaceutical form(s):                         | Tablet                                                                                                                                                                                                                                                                                     |
| Strength(s):                                    | 250 µg                                                                                                                                                                                                                                                                                     |
| Route(s) of administration:                     | Oral use                                                                                                                                                                                                                                                                                   |
| Packaging:                                      | blister (PVC/PVDC/alu)                                                                                                                                                                                                                                                                     |
| Package size(s):                                | 28 tablets                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

## Table of contents

| List of abbreviations....................................................................................5                |                                                                                                          |
|---------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1. Background information on the procedure ..............................................7                                |                                                                                                          |
| 1.1. Submission of the dossier......................................................................................7     |                                                                                                          |
| 1.2. Steps taken for the assessment of the product.........................................................7              |                                                                                                          |
| 2. Scientific discussion ................................................................................8                |                                                                                                          |
| 2.1. Problem statement                                                                                                    | ...............................................................................................8         |
| 2.1.1. Disease or condition...........................................................................................8   |                                                                                                          |
| 2.1.2. Epidemiology and risk factors, screening tools/prevention                                                          | ......................................8                                                                  |
| 2.1.3. Biologic features................................................................................................8 |                                                                                                          |
| 2.1.4. Clinical presentation, diagnosis and stage/prognosis                                                               | ..............................................9                                                          |
| 2.1.5. Management.....................................................................................................9   |                                                                                                          |
| 2.2. About the product                                                                                                    | ................................................................................................9        |
| 2.3. The development programme/compliance with CHMP guidance/scientific advice...........9                                |                                                                                                          |
| 2.4. General comments on compliance with GMP, GLP, GCP                                                                    | ...........................................10                                                            |
| 2.5. Type of application and other comments on the submitted dossier............................11                        |                                                                                                          |
| 2.6. Quality aspects                                                                                                      | ..................................................................................................13     |
| 2.6.1. Introduction....................................................................................................13 |                                                                                                          |
| 2.6.2. Active Substance.............................................................................................13    |                                                                                                          |
| 2.6.3. Finished Medicinal Product................................................................................13       |                                                                                                          |
| 2.6.4. Discussion on chemical, pharmaceutical and biological aspects..............................15                      |                                                                                                          |
| 2.6.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                 | ......................16                                                                                 |
| 2.6.6. Recommendations for future quality development ...............................................16                   |                                                                                                          |
| 2.7. Non-clinical aspects                                                                                                 | ............................................................................................16           |
| 2.7.1. Introduction....................................................................................................16 |                                                                                                          |
| 2.7.2. Pharmacology                                                                                                       | .................................................................................................16      |
| 2.7.3. Pharmacokinetics.............................................................................................16    |                                                                                                          |
| 2.7.4. Toxicology                                                                                                         | ......................................................................................................16 |
| 2.7.5. Ecotoxicity/environmental risk assessment                                                                          | .........................................................16                                              |
| 2.7.6. Discussion and conclusion on non-clinical aspects................................................16                |                                                                                                          |
| 2.8. Clinical aspects                                                                                                     | ..................................................................................................17     |
| 2.8.1. Introduction....................................................................................................17 |                                                                                                          |
| 2.8.2. Pharmacokinetics.............................................................................................18    |                                                                                                          |
| 2.8.3. Pharmacodynamics..........................................................................................25       |                                                                                                          |
| 2.8.4. Discussion on clinical pharmacology...................................................................33           |                                                                                                          |
| 2.8.5. Conclusions on clinical pharmacology.................................................................34            |                                                                                                          |
| 2.9. Clinical efficacy                                                                                                    | ..................................................................................................35     |
| 2.9.1. Dose-response studies and main clinical studies                                                                    | ..................................................35                                                     |
| 2.9.2. Discussion on clinical efficacy............................................................................59      |                                                                                                          |
| 2.9.3. Conclusions on clinical efficacy                                                                                   | ..........................................................................63                             |

<div style=\"page-break-after: always\"></div>

| 2.9.4. Clinical safety..................................................................................................64   |
|------------------------------------------------------------------------------------------------------------------------------|
| 2.9.5. Discussion on clinical safety ..............................................................................73        |
| 2.9.6. Conclusions on clinical safety ............................................................................75         |
| 2.9.7. PSUR cycle .....................................................................................................76    |
| 2.10. Risk Management Plan ......................................................................................76          |
| 2.11. Pharmacovigilance............................................................................................84        |
| 2.12. Product information ..........................................................................................85       |
| 2.12.1. User consultation...........................................................................................85       |
| 2.12.2. Additional monitoring .....................................................................................85        |
| 3. Benefit-Risk Balance..............................................................................85                      |
| 3.1. Therapeutic Context ...........................................................................................85       |
| 3.1.1. Disease or condition.........................................................................................86       |
| 3.1.2. Available therapies and unmet medical need.......................................................86                   |
| 3.1.3. Main clinical studies .........................................................................................87     |
| 3.2. Favourable effects ..............................................................................................87     |
| 3.3. Uncertainties and limitations about favourable effects.............................................88                   |
| 3.4. Unfavourable effects...........................................................................................89       |
| 3.5. Uncertainties and limitations about unfavourable effects .........................................90                    |
| 3.6. Effects Table......................................................................................................90   |
| 3.7. Benefit-risk assessment and discussion.................................................................91               |
| 3.7.1. Importance of favourable and unfavourable                                                                             |
| effects..............................................91                                                                      |
| 3.7.2. Balance of benefits and risks.............................................................................91          |
| 3.7.3. Additional considerations on the benefit-risk balance ...........................................92                   |
| 3.8. Conclusions .......................................................................................................92   |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation special term   | or   | Explanation                                                                |
|-----------------------------|------|----------------------------------------------------------------------------|
| AE                          |      | adverse event                                                              |
| ANCOVA                      |      | analysis of covariance                                                     |
| AUC                         |      | Area under the plasma concentration-time-curve                             |
| β 2 -adrenergic agonist     |      | beta 2 adrenergic receptor agonist                                         |
| BMI                         |      | body mass index                                                            |
| BSV                         |      | Between subject variability                                                |
| CAT                         |      | COPD Assessment Test                                                       |
| cAMP                        |      | cyclic adenosine monophosphate                                             |
| CHMP                        |      | Committee for Medicinal Products for Human Use (EMA)                       |
| CI                          |      | confidence interval                                                        |
| C max                       |      | maximum concentration                                                      |
| COPD                        |      | chronic obstructive pulmonary disease                                      |
| COX-2                       |      | cyclooxygenase 2                                                           |
| CSR                         |      | clinical study report                                                      |
| C-SSRS                      |      | Columbia Suicide Severity Rating Scale                                     |
| CYP 3A4, CYP 1A2            |      | cytochrome P450 3A4, 1A2                                                   |
| eC-SSRS                     |      | Electronic C-SSRS questionnaire                                            |
| EMA                         |      | European Medicines Agency                                                  |
| EOD                         |      | every other day (alternate day dosing)                                     |
| EU                          |      | European Union                                                             |
| EXACT-PRO                   |      | Exacerbations of Chronic Pulmonary Disease Tool - Patient Reported Outcome |
| FAS                         |      | Full analysis set                                                          |
| FDA FDC                     |      | Food and Drug Administration (US) fixed-dose combination                   |
| FEV 1                       |      | forced expiratory volume in 1 second                                       |
| FVC                         |      | forced vital capacity                                                      |
| GCP                         |      | Good Clinical Practice                                                     |
| GI                          |      | gastrointestinal                                                           |
| GOLD                        |      | Global Initiative for Chronic Obstructive Pulmonary Disease                |
| HPLC                        |      | High performance liquid chromatography                                     |
| IC 50                       |      | concentration at which 50% inhibition is achieved                          |
| ICS                         |      | inhaled corticosteroid                                                     |
| IMP                         |      | investigational medicinal product                                          |
| ITT                         |      | intent-to-treat                                                            |
| IVRS                        |      | interactive voice response system                                          |
| IWRS                        |      | interactive web response system                                            |
| KF                          |      | Karl Fischer titration                                                     |
| LABA                        |      | long-acting β 2 -adrenergic receptor agonist                               |
| LAMA                        |      | long-acting muscarinic receptor antagonist                                 |
| LOCF                        |      | last observation carried forward                                           |
| LS                          |      | Least squares                                                              |
| mMRC                        |      | Modified British Medical Research Council                                  |
| MedDRA                      |      | Medical Dictionary for Regulatory Activities                               |
| NDA                         |      | New Drug Application                                                       |
| NDA 22-522                  |      | Roflumilast original NDA approval 28 February 2011 (Reference ID 2911527)  |
| OD                          |      | once daily                                                                 |
| PD                          |      | pharmacodynamic                                                            |
| PDE (4)                     |      | phosphodiesterase (4) phosphodiesterase 4                                  |
| PDE4I                       |      | inhibitor                                                                  |
| Ph. Eur.                    |      | European Pharmacopoeia                                                     |
| PK                          |      | pharmacokinetic(s) population pharmacokinetics                             |
| PopPK                       |      | Preferred term                                                             |
| PT PVC                      |      | Poly vinyl chloride                                                        |
| PVDC                        |      | Polyvinilidene chloride                                                    |

<div style=\"page-break-after: always\"></div>

| Abbreviation special term   | or   | Explanation                             |
|-----------------------------|------|-----------------------------------------|
| SAE SAS SE                  |      | serious adverse event                   |
|                             |      | Safety analysis set                     |
|                             |      | Standard error                          |
| SmPC                        |      | Summary of Product Characteristics      |
| sNDA                        |      | supplemental New Drug Application       |
| SOC                         |      | System Organ Class                      |
| TEAE                        |      | treatment-emergent adverse event        |
| tPDE4i                      |      | total PDE4 inhibitory activity          |
| TTE                         |      | time to event                           |
| US                          |      | United States                           |
| USPI                        |      | United States Prescribing Information   |
| UV                          |      | Ultraviolet                             |
| V                           |      | visit                                   |
| VCS                         |      | valid case set                          |
| VPC                         |      | Visual predictive check                 |
| COPD                        |      | Chronic Obstructive Pulmonary Disease   |
| CMC                         |      | Chemistry, Manufacturing, and Controls  |
| GMP                         |      | Good Manufacturing Practice             |
| HPLC                        |      | High Performance Liquid Chromatography  |
| PE                          |      | Polyethylene                            |
| Ph. Eur.                    |      | European Pharmacopoeia                  |
| QP                          |      | Qualified Person                        |
| TSE                         |      | Transmissible Spongiform Encephalopathy |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The MAH AstraZeneca AB submitted on 6 March 2017 an extension of the marketing authorisation.

The MAH applied for an addition of a new strength of 250 µg in a PVC/PVDC/Alu blister of 28 tablets.

Furthermore, the PI is brought in line with the latest QRD template version 10.0. Updated RMP version 18.0 has also been submitted.

## The legal basis for this application refers to:

Article  19  of  Commission  Regulation  (EC)  No  1234/2008  and  Annex  I  of  Regulation  (EC)  No 1234/2008, indent 2 (c) - Extensions of marketing authorisations.

## Information on Paediatric requirements

Not applicable

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal  products  because  there  is  no  authorised  orphan  medicinal  product  for  a  condition related to the proposed indication.

## Scientific Advice

The MAH did not seek scientific advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were: Rapporteur: Concepcion Prieto Yerro Co-Rapporteur:   Jayne Crowe CHMP Peer reviewer(s): N/A

- The application was received by the EMA on 6 March 2017.
- The procedure started on 23 March 2017.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 14 June 2017. The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  9  June 2017. The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on 19 June 2017.

<div style=\"page-break-after: always\"></div>

- During  the  meeting  on  6  July  2017,  the  PRAC  agreed  on  the  PRAC  Assessment  Overview  and Advice to CHMP.
- During the meeting on 20 July 2017, the CHMP agreed on the consolidated List of Questions to be sent to the MAH.
- The  MAH  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  10  October 2017.
- The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CHMP members on 15 November 2017.
- During  the  PRAC  meeting  on  31  November  2017,  the  PRAC  agreed  on  the  PRAC  Assessment Overview and Advice to CHMP.
- During the CHMP meeting on 14 December 2017, the CHMP agreed on a list of outstanding issues to be sent to the MAH.
- MAH submitted the responses to the CHMP List of Outstanding Issues on 22 January 2018.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Outstanding Issues to all CHMP members on 8 February 2018.
- During the meeting on 19-22 February 2018, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for an extension of the marketing authorisation for Daxas on 22 February 2018.

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

Roflumilast,  at  a  500  microgram  once-daily  dose,  is  authorised  in  the  EU  since  05-Jul-2010  for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator  &lt;  50%  predicted)  associated  with  chronic  bronchitis  in  adult  patients  with  a history of frequent exacerbations as add on to bronchodilator treatment.

## 2.1.2. Epidemiology and risk factors, screening tools/prevention

COPD is the fourth leading cause of death in Europe, and is a major public health problem. COPD is generally but not exclusively associated with tobacco smoking. Tobacco smoke is considered the most important risk  factor  for  COPD  worldwide.  Prevalence  and  morbidity  data  greatly  underestimate  the total burden of COPD because the disease is usually not diagnosed until it is clinically apparent and moderately advanced.

## 2.1.3. Biologic features

COPD comprises pathological  changes  in  four  different  compartments  of  the  lungs  (central  airways, peripheral  airways,  lung  parenchyma,  pulmonary  vasculature),  which,  in  turn,  give  rise  to  the physiological abnormalities in COPD: mucous hypersecretion and cilliary dysfunction, airflow limitation and hyperinflation, gas exchange abnormalities, pulmonary hypertension, and systemic effects.

<div style=\"page-break-after: always\"></div>

## 2.1.4. Clinical presentation, diagnosis and stage/prognosis

The most widely accepted classification of the severity of COPD is according to The Global Initiative for Chronic Obstructive Lung Disease (GOLD) (GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD; Available from: http://goldcopd.org/gold-2017-global-strategydiagnosis-management-prevention-copd/). It includes a spirometric and symptoms classification.

The GOLD classification of airflow limitation severity (spirometric classification) recognizes four grades (1: mild; 2: moderate; 3: severe; 4: very severe), being categories 3-4 those corresponding to severe (FEV1 ≤ 50% predicted) and very severe (FEV1 ≤ 30% predicted) airflow limitation, respectively.

It should be noted that there is only a weak correlation between FEV1, symptoms and impairment of a patient's health status. For this reason, formal symptomatic assessment is also required.

Current  GOLD  guidelines  recommend  the  symptomatic  classification  of  COPD  patients  regarding symptoms and risk  of  exacerbations  using  the  'ABCD'  assessment  tool.  Group  D  are  patients  with more symptoms at high risk of exacerbations.

The  prognosis  of  COPD  is  poorer  in  patients  with  severe/very  severe  airflow  limitation  and  it  is correlated with the degree of dyspnoea (GOLD 2017).

## 2.1.5. Management

The most important aspect of management of the condition is educational and social: the avoidance and cessation of tobacco smoking. The medications for COPD currently available can reduce or abolish symptoms, increase exercise capacity, reduce the number and severity of exacerbations, and improve health  status.  At  present  no  treatment  is  shown  to  modify  the  rate  of  decline  in  lung  function. Combining different agents produces a greater change in spirometry and symptoms than single agents alone.

Current GOLD guidelines recommend adding roflumilast to treatment regimens for patients in Group D who  have  chronic  bronchitis  and  forced  expiratory  volume  in  1 second  (FEV1)  &lt;50%  of  predicted whose  exacerbations  are  not  adequately  controlled  on  a  triple  combination  of  a  long-acting  β2adrenergic  agonist  (LABA),  a  long-acting  muscarinic  antagonist  (LAMA),  and  inhaled  corticosteroid (ICS). The indication for roflumilast in clinical practice is therefore for patients with GOLD spirometric grade 3-4 and group D.

## 2.2. About the product

Roflumilast is a selective phosphodiesterase type 4 (PDE4) inhibitor. PDE4 is an important regulator of cyclic AMP in most cell types involved in inflammatory processes. Inhibition of PDE4 reduces the breakdown of cAMP, which in turn down-regulates the inflammatory process.

## 2.3. The development programme/compliance with CHMP guidance/scientific advice

No  formal  CHMP  scientific  advice  was  given.  However,  there  were  several  interactions  between  the Rapporteur and the MAH with respect to defining the design of the OPTIMIZE pivotal study for this line extension.

With  the  proposed  OPTIMIZE  study  (RO-2455-302-RD),  the  marketing  authorization  holder  (MAH) intended to address and fulfill follow-up measure 004 ' The applicant commits to present a program exploring the feasibility of developing alternative doses to minimize the risk of drug interactions, poor

<div style=\"page-break-after: always\"></div>

## tolerability and the influence of factors such as gender, age, smoking status on bioavailability of the product '.

During  the  assessment  of  FUM004,  the  design  of  the  OPTIMIZE  study  was  discussed.  The  primary endpoint  of  'Percentage  of  subjects  prematurely  discontinuing  study  treatment  due  to  any  reason (during main period i.e., Visit V1 to Vend)' was considered adequate to investigate if patients could benefit from an up-titration regimen. Initially proposed key secondary endpoints of the study were

'Percentage  of  subjects  with  adverse  events  of  interest  to  evaluate  tolerability  -  diarrhea,  nausea, headache, decreased appetite, insomnia and abdominal pain (main period, V1 to Vend)' and

'Percentage of subjects prematurely discontinuing study treatment due to any reason (during downtitration period, V0DT to VendDT)'.

In addition, change in forced vital capacity (FVC) and pre-bronchodilator FEV1 and change in subjectassessed treatment satisfaction scores were proposed as secondary efficacy endpoints during the upand down-titration period.

Furthermore, also population PK and PK/PD analysis were proposed to be performed during the whole study (up- and down-titration period) to better understand the relationship between PK and relevant safety (adverse events i.e., diarrhea, nausea, headache, decreased appetite, insomnia and abdominal pain) and efficacy (FEV1) parameters.

While  accepting  that  the  primary  objective  of  the  OPTIMIZE  study  is  to  demonstrate  improved tolerability  of  250mcg  QD  roflumilast  compared  with  500mcg  QD  roflumilast,  it  was  also  considered important that the study was also designed to demonstrate that efficacy is maintained at the lower dose.  Therefore,  FEV1  during  the  down  titration  was  proposed  by  the  rapporteur  as  key  secondary endpoint.

In  this  regard,  the  use  of  the  hierarchical  testing  procedure  was  accepted.  However,  if  statistical significance was not achieved at a given stage, no inferential conclusions could be drawn from any of the  subsequent  analyses  at  the  lower  stages  of  the  hierarchy  even  if  they  were  carried  out  for exploratory purposes.

A mixed model repeated measures (MMRM) analysis was initially proposed by the MAH for the primary analysis of the primary efficacy endpoint, change from baseline FEV1. The Rapporteur did not endorse the proposal, as this method tends to overestimate treatment effects when a considerable amount of data is missing caused by premature discontinuation.

Therefore,  analysis  of  covariance  (ANCOVA)  was  proposed  with  an  appropriate  model  including  the baseline value as a covariate. This method had to be carried out on the ITT population where missing data had to be imputed using a suitable and justified method. Further sensitivity analyses had to be conducted to demonstrate the robustness of the findings.

As requested by the CHMP, the following changes were implemented in the protocol of the OPTIMIZE study :

- Inclusion of FEV1 as key secondary endpoint during down-titration period.

- Change from mixed model repeated measures (MMRM) analysis to analysis of covariance (ANCOVA) for the primary analysis of the primary efficacy endpoint, change from baseline FEV1.

It was planned to extend the existing PK/PD models in a two-step approach by using the data obtained from the REACT study (RO-2455-404-RD) which was performed to address follow-up measures 001 and 003, and the data obtained from the OPTIMIZE study.

Depending on the OPTIMIZE study outcome, the MAH planned to seek for changes of the posology section  of  the  SmPC  to  provide  recommendation  for  up-  and/or  down-titration  regimens  with roflumilast.

## 2.4. General comments on compliance with GMP, GLP, GCP

## GMP

The  authorization  of  manufacturing  for  finished  product  manufacturer,  Takeda  GmbH  dated  15 th February 2017, has been submitted, as well as the certificate of GMP compliance of the manufacturer, dated 14 th February 2017, following an inspection carried out on 22 nd  June 2016.

<div style=\"page-break-after: always\"></div>

A  valid  QP  Declaration  has  been  submitted,  updated  with  more  recent  audit  dates  for  Siegfried Evionnaz SA and Jetpharma SA, dated 6th September 2017.

## GCP

Directive 2001/83/EC (amended) Article 8.3 (ib) requires a statement to the effect that clinical trials carried out outside the European Union (EU) meet the ethical requirements of Directive 2001/20/EC. In the  pivotal  study  supporting  this  line  extension  application  (RO-2455-302-RD  OPTIMIZE  study), subjects were randomized at a total of 161 sites in 15 countries: Bulgaria (11 sites), Germany (9), Greece (5), Hungary (21), Republic of Korea (9), Philippines (4), Poland (15), Romania (19), Russia (17), Slovakia (12), South Africa (14), Spain (2), Thailand (3), Ukraine (14), and United Kingdom (6).

Takeda (sponsor of the clinical trial) and its representative, Quintiles, performed study RO-2455-302RD OPTIMIZE to the same ethical standard in all countries, both within and outside the EU. This ethical standard  is  consistent  with  the  ethical  requirements  of  Directive  2001/20/EC.  In  the  protocol, investigators  were  instructed  to  conduct  the  study  in  accordance  with  the  current  version  of  the Declaration  of  Helsinki,  and  the  International  Conference  on  Harmonization  (ICH),  harmonized tripartite guideline ICH E6 (R1): Good Clinical Practice, and any applicable local regulations.

Takeda procedures, internal quality control measures, and audit programs provide reassurance that the  clinical  study  program  was  carried  out  in  accordance  with  Good  Clinical  Practice  (GCP),  as documented by the International Conference on Harmonization (ICH). AstraZeneca acquired the rights to the OPTIMIZE Study from Takeda following completion of the study.

During the OPTIMIZE study, internal audits found non-compliance potentially affecting patient safety and  study  data  integrity  at  a  single  site  (site  6002),  resulting  in  inspection  by  the  South  African Medicines Control Council in July 2015. A site inspection was also conducted by Authority for Health and Consumer Protection, Free and Hanseatic City of Hamburg, Germany in October 2015, with no significant finding of non-compliance. In addition, data from OPTIMIZE were included in a Medicines and Healthcare Products Regulatory Agency inspection of records for several studies in August 2015. Taking the above into account, the CHMP did not find sufficient reasons to trigger an inspection for this study.

## 2.5. Type of application and other comments on the submitted dossier

## · Legal basis

This application is to extend the marketing authorization for roflumilast (Daxas/Daliresp/Libertek) 500 microgram tablet by adding the new strength of 250 microgram roflumilast tablets.

The application is submitted in accordance with article 8(3) in directive 2001/83/EC (i.e.: dossier with administrative, quality, pre-clinical and clinical data).

The clinical part of this submission is based on clinical data from a single study (Study RO 2455 302RD [OPTIMIZE]) together with updated pop PK analyses based on data from OPTIMIZE and REACT (Study RO-2455-404-RD) to fulfill a Committee for Medicinal Products for Human Use (CHMP) postauthorization measure (FUM004).

The  proposed  indication  is  for  the  250  micrograms  tablet  to  be  taken  once  daily  for  28  days  as  a starting  dose  intended  to  reduce  patient  discontinuation  when  initiating  therapy.  The  recommended maintenance dose is one tablet of 500 micrograms roflumilast to be taken once daily.

This  line-extension  including  the  250  micrograms  roflumilast  tablet  translates  into  the  following changes in the SmPC pertaining to sections 4.2 and 5.1 (track changes).

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 2.6. Quality aspects

## 2.6.1. Introduction

The finished product is presented as tablets containing 250 µg of roflumilast as active substance.

Other ingredients are: lactose monohydrate, maize starch, povidone, and magnesium stearate.

The product is available in PVC/PVDC aluminium blisters as described in section 6.5 of the SmPC

## 2.6.2. Active Substance

The active substance used to manufacture the new strength: 250 µg film tablets is the same as that used in the manufacture of the currently authorised 500 µg film coated tablets

## 2.6.3. Finished Medicinal Product

## Description of the product and pharmaceutical development

Daxas 250 μg tablets are uncoated tablets (immediate release). They are described as white to offwhite, round tablets embossed with 'D' on one side and '250' on the other. The tablet's diameter is 5 mm.

The finished product is currently available as film-coated 500 µg tablets. The applicant is applying for uncoated 250 µg tablets which will have a different composition to the 500 µg film coated tablets. The objective of the pharmaceutical development was to develop an immediate-release, white 250 µg tablet by employing standard manufacturing technologies, to enable a recommended starting roflumilast dosage.

Roflumilast  is  a  white  to  off-white,  crystalline  powder;  it  is  a  very  stable  chemical  substance.  The active substance is poorly soluble in aqueous solutions between pH 1 to 7. Dissolution of the active substance  from  the  dosage  form  depends  mainly  on  its  solubility  as  well  as  its  rate  of  dissolution. Therefore, the particle size of the active substance might affect rate and extent of dissolution. The use of micronized active substance was needed to provide an immediate release dissolution profile.

Different excipients were investigated by preparing binary combinations containing the drug substance and the excipient and stored in different ambient conditions. Only those excipients with a proven compatibility with roflumilast were selected for development.

All excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur standards. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC and in paragraph 2.1.1 of this report.

Tablet formulations were varied in weight and size during drug development by varying the amount of excipients.  Several clinical studies and bioequivalence studies were performed during development. Finally, a small uncoated, white tablet was chosen for marketing authorisation.

Since  the  absorption  of  the  drug  depends  mainly  on  its  release  from  the  tablet  and  on  dissolution under  physiological  conditions,  in-vitro  dissolution  may  be  relevant  to  the  prediction  of  in-vivo performance. In order to establish a suitable dissolution method, different factors have to be taken into account.  These  include  the  physicochemical  characteristics  of  the  drug  as  well  as  different  testing

<div style=\"page-break-after: always\"></div>

conditions.  Importantly,  the  dissolution  method  was  able  to  discriminate  between  different,  bioinequivalent formulations, are consistent with the corresponding pharmacokinetic characteristics.

In order to link the formulation of the finished product used in pivotal clinical trials to the original formulation intended for commercialisation, a bioequivalence study was performed showing bioequivalence. There was also no difference in the in-vitro dissolution profiles of the tablets used in pivotal clinical trials and Formula E film-coated tablets.

Due to the low active substance content of the tablets, special focus was taken on blend and content uniformity  during  manufacturing  development,  scale-up  and  validation,  and  the  homogeneous distribution of the active substance and homogeneity of the granules was determined during release testing  by  content  uniformity.  Therefore,  the  manufacturing  process  for  the  granules  was  adapted during scale-up to the commercial batch scale.

The  primary  packaging  is  PVC/PVDC  aluminum  blisters.  The  material  complies  with  Ph.Eur.  and  EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

## Manufacture of the product and process controls

The manufacturing process consists of 4 main steps: production of the granulation solution, production of  the  granulate,  production  of  the  tableting  mixture,  tableting  and  packaging.  The  process  is considered to be a non-standard manufacturing process.

As a unit-dose form contains less than 2% active substance by weight the manufacturing process is considered non-standard. As such, normally, the granulation should be considered as a critical step however  the  applicant  has  provided  process  validation  data  showing  that  all  batches  comply  with specifications and no deviations were detected. The validation data provided supports the robustness of the manufacturing process and in process controls with regard to blend uniformity and assay of the tablet. It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner. The in-process controls are adequate for this type of manufacturing.

## Product specification

The  finished  product  release  specifications  include  appropriate  tests  for  this  kind  of  dosage  form: appearance (visual),  dimension  (measuring  device),  water  content  (KF),  identity  (HPLC,  UV),  purity (HPLC), microbiological purity (Ph. Eur.), assay (HPLC or UV), content uniformity (Ph. Eur.), dissolution (Ph. Eur.) .

<div style=\"page-break-after: always\"></div>

The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analysis results are provided for 4 commercial scale batches confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

The finished product is released on the market based on the above release specifications, through traditional final product release testing.

## Stability of the product

Stability data from 3 production scale batches of finished product stored for up to 48 months under long term conditions (25 ºC / 60% RH) and for up to 6 months under accelerated conditions (40 ºC / 75% RH) according to the ICH guidelines were provided. Additionally, they were tested at 30 ºC / 75% RH for 48 months.  The batches of the medicinal product are identical to those proposed for marketing and were packed in the primary packaging proposed for marketing.

Samples were tested for the same specification as release. The analytical procedures used are stability indicating.  No  obvious  trends  were  detectable  and  the  results  were  well  within  the  proposed specification under long term and accelerated conditions.

In addition, one batch (stored without primary packaging material) was exposed to light as defined in the ICH Guideline on Photostability Testing of New Drug Substances and Products. No changes were observed. Data confirmed that no additional storage recommendations regarding light protection were necessary.

Based on available stability data, the proposed shelf-life of 48 months without any special storage conditions as stated in the SmPC (section 6.3) are acceptable.

## Adventitious agents

It is confirmed that the lactose is produced from milk from healthy animals in the same condition as those used to collect milk for human consumption and that the lactose has been prepared without the use of ruminant material other than calf rennet according to the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents Via Human and veterinary medicinal products.

## 2.6.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

<div style=\"page-break-after: always\"></div>

## 2.6.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety.

## 2.6.6. Recommendations for future quality development

No applicable

## 2.7. Non-clinical aspects

## 2.7.1. Introduction

The  Applicant  has  submitted  no  additional  nonclinical  data  supporting  a  lower  starting  dose.  No modification of the benefit risk profile of Roflumilast is expected.

With  regards  to  the  Environmental  Risk  Assessment,  no  additional  studies  were  submitted.  The Applicant  estimates  that  no  increase  in  the  environmental  exposure  is  anticipated,  given  that  the proposed starting dose is lower than the previously approved.

## 2.7.2. Pharmacology

## N/A

## 2.7.3. Pharmacokinetics

N/A

## 2.7.4. Toxicology

N/A

## 2.7.5. Ecotoxicity/environmental risk assessment

N/A

## 2.7.6. Discussion and conclusion on non-clinical aspects

The only modification presented in this line extension is the substitution of the starting dose of 500mcg of Roflumilast for a lower one, i.e. 250 mcg. Given the positive risk benefit profile obtained in the initial assessment of the substance, no additional concerns are expected from a nonclinical point of view.

The documentation and rationale for not conducting additional ERA studies is considerable acceptable.

<div style=\"page-break-after: always\"></div>

## 2.8. Clinical aspects

## 2.8.1. Introduction

This line extension application is based on the study  RO-2455-302-RD (OPTIMIZE). This multicentre, randomized, double blind, Phase III study comprised an initial 4 week period in which patients received roflumilast 250 μg once daily (OD), 500 μg every other day (EOD), or the currently approved dosage of  500  μg  OD; followed by 8 weeks of dosing at 500 μg OD for all subjects. For patients unable to tolerate the approved maintenance dose of roflumilast 500 μg OD during the Main Period, the lower dosage of 250 μg OD was to be administered in a Down-titration Period.

Pharmacokinetic (PK) and pharmacodynamic (PD) data were collected in both Main and Down-titration Periods  to  update  the  developed  population  PK  (pop-PK)  and  PK-PD  models,  and  specifically  to evaluate  exposures  in  patients  unable  to  tolerate  roflumilast  500  μg  OD  both  before  and  after transitioning  to  a  250  μg  OD  relative  to  exposures  in  patients  tolerating  the  approved  dosage. OPTIMIZE  was  performed  using  the  US  formulation  of  roflumilast  500  μg  and  250  μg  tablets. Evaluations  included  treatment  discontinuations  for  any  reason  as  a  primary  variable;  other  safety evaluations  included  AEs of  interest  (preferred  terms  associated  with  Diarrhoea,  Nausea,  Headache, Decreased  appetite,  Insomnia,  Abdominal  pain,  Vomiting,  Angioedoema,  Anxiety,  Depression,  and Weight loss), GI tolerability, and patient-assessed outcomes. Other assessments included effects on lung function, PK, and PK-PD relationships with AEs and lung function.

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

Table 1. Tabular overview of clinical studies

| Iype of study                   | Study code; location of studyreport       | Objectives of the study                                                                                                                                                                                  | Study design                                                                                                | Test product; dosage regimen                                                                                                                                                             | Number of subjects randomised /treated   | Population                                                                                                                                                                                                    | Duration of treatment                                                          | Study status type of report   |
|---------------------------------|-------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|-------------------------------|
| Safety, efficacy, PK, and PK/PD | RO-2455-302-RD (OPTIMIZE); Module 5.3.5.1 | Evaluate ffcacya ty, tolerability and PK of: roflumilast 500μg OD in COPD patients using roflumilast 250 μg OD up-titrationregimen and using down-titration regimen in subjects not tolerating 500 μg OD | Randomised, double-blind, active-controlled, parallel-group study with an open-label down- titration period | Main period: roflumilast 250 μg PO/500 μg tablet OD tablet OD PO roflumilast 500 μg tablet EOD PO/500 μg tablet OD PO roflumilast 500 μg tablet OD PO Dow- titration period: roflumilast | Total: 1323/ 1321 N=441/441 N=439/437    | Patients with severe COPD (postbronchodilator FEV1≤50%predicted) associated with chronic productive cough. Patientswereformer or current smokers; all received standard of care COPD mainte- nance treatment. | Total: maximum of20 weeks Main period: 12 weeks Down- titration period: 8weeks | Complete, Full                |
|                                 |                                           |                                                                                                                                                                                                          |                                                                                                             |                                                                                                                                                                                          | N=443/443                                |                                                                                                                                                                                                               |                                                                                |                               |
|                                 |                                           |                                                                                                                                                                                                          |                                                                                                             | 250μg tablet OD PO                                                                                                                                                                       | N=104 treated                            |                                                                                                                                                                                                               |                                                                                |                               |

COPD chronic obstructive pulmonary disease; EOD every other day; FEV forced expiratory volume in 1 second; OD once daily; PD pharmacodynamics; PK pharmacokinetics;PO orally.

<div style=\"page-break-after: always\"></div>

## 2.8.2. Pharmacokinetics

In  the  original  submission,  the  PK  profile  of  roflumilast  and  its  metabolite  were  assessed  using  PK samples taken across 21 Phase I studies, 1 Phase II study and 1 Phase III study.

In  humans,  roflumilast  is  rapidly  metabolised  to  its  N-oxide  metabolite.  The  latter  exerts  PDE4 inhibitory activity (approximately 3-fold lower potency compared with the parent compound) with 10fold higher area under the plasma concentration-time curve (AUC), and a 3-fold higher free fraction in plasma. The N-oxide metabolite contributes about 90% of the overall PDE4 inhibitory activity and is assumed  to  contribute  largely  to  the  pharmacodynamics  (PD)  activity  of  roflumilast.  Thus,  during development, pharmacokinetic (PK) data were evaluated for both the parent compound and its N-oxide metabolite.

Roflumilast is converted to roflumilast N-oxide by cytochrome P450 (CYP) 3A4 and 1A2 isoenzymes (von Richter et al 2007, Lahu et al 2008). CYP3A4 is primarily responsible for clearance of roflumilast N-oxide, with some contribution from CYP2C19 and extrahepatic CYP1A1. The activity of CYP3A4 and CYP1A2 can be affected by covariates such as age and sex (Bebia et al 2004, Mangoni and Jackson 2004, Cotreau et al 2005) and smoking (Funck-Brentano et al 2006), and these covariate effects have been demonstrated on the PK profile of roflumilast.

To estimate the combined PDE4 inhibitory activities of roflumilast and roflumilast N-oxide, the concept of 'total PDE4 inhibitory activity' (tPDE4i) was established and additionally used to characterise the PK of  roflumilast  (Hermann  et  al  2007,  Lahu  and  Facius  2013).  The  tPDE4i  accounts  for  differences  in intrinsic PDE4 inhibitory activity, free concentration in plasma, and in vivo systemic exposures (AUC) of roflumilast and roflumilast N-oxide.

More recently, the population PK model was updated with data obtained in the Phase IIIb/IV REACT study which tested the utility of adding roflumilast 500 μg once daily to a fixed dose combination (FDC) of long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS). Now, the population PK model has been updated with data from OPTIMIZE.

Total PDE4i was calculated according to the following equation:

<!-- image -->

where fu,p/fu,m is the in vitro fraction unbound for parent/metabolite (fu,p=0.011, fu,m=0.034), IC50,p/IC50,m is the in vitro 50% inhibitory concentration for parent/metabolite (IC50,p=0.3 μg/L; IC50,m=0.8 μg/L), CL k p/CL k m is the individual apparent clearance for parent/metabolite (estimated by the population PK model), dose is the daily oral dose, and τ is the dosing interval (24 hours).

The population PK analyses from the original submission described the PK of roflumilast parent and metabolite in 2 independent models. In the population PK covariate analyses, race had the greatest impact  on  tPDE4i,  and  females  were  estimated  to  have  higher  tPDE4i  than  males.  Smokers  were shown to have a lower tPDE4i than non-smokers/former smokers. In addition, an exposure-response relationship was identified for FEV1 from exposure-response analyses using data from 4 Phase II/III studies.  A  significant  exposure-response  relationship  was  identified  for  the  adverse  events  (AEs)  of diarrhoea, nausea and headache.

The new information is generated from the OPTIMIZE study. OPTIMIZE had the following PK-related objectives:

- To characterize the PK of roflumilast and roflumilast N-oxide with an up-titration regimen
- To characterize the PK of roflumilast and roflumilast N-oxide with roflumilast 250 μg once daily in patients not tolerating the 500 μg once daily dose
- To characterize the PK/PD relation with respect to relevant safety and efficacy parameters

In  OPTIMIZE,  the  PK  of  both  roflumilast  and  roflumilast  N-oxide  were  measured.  Bioanalytics  of roflumilast  and  roflumilast  N-oxide  were  performed  using  a  validated  high  performance  liquid

<div style=\"page-break-after: always\"></div>

chromatography tandem mass spectrometer method. The lower limit of quantitation in plasma is 0.100 microg/L using a sample volume of 0.2 mL.

## The OPTIMIZE population PK model

The resulting integrated PK model is shown schematically in Figure 1. The base REACT model consisted of  two  distribution  compartments  with  first-order  absorption  and elimination for  the  parent  and  two additional distribution compartments with first order elimination for the metabolite. The absorption of the parent was described by a first-order process and a lag-time.

In  the  absence  of  IV  data  for  both  roflumilast  and  the  N-oxide,  absolute  bioavailability  cannot  be estimated and therefore only apparent clearances and volumes can be used. This is the reason why in the model roflumilast is transformed completely into the N-oxide metabolite, although other metabolic routes  are  known  to  exist.  In  addition  to  systemic  formation  of  roflumilast  N-oxide,  pre-systemic formation  was  also  identified,  which  is  described  by  first  order  absorption  from  an  additional  dose compartment, with a separate fraction (F5). The bioavailability of the additional dose compartment for the N-oxide metabolite was estimated.

This parameter describes the contribution of pre-systemic formation relative to systemic formation of roflumilast N-oxide. The bioavailability of roflumilast was fixed to 1 (F1).

Figure 1 . Integrated population PK model for roflumilast (parent) and roflumilast n-oxide (metabolite)

<!-- image -->

CLm  clearance  of  metabolite;  CLp  clearance  of  parent;  compartm.  compartment;  F1  the  relative bioavailability of roflumilast, fixed to 1; F5 presystemic formation of metabolite; KAm absorption rate of  metabolite;  KAp  absorption  rate  of  parent;  Qm  intercompartmental  clearance  of  metabolite;  Qp intercompartmental clearance of parent.

The base REACT model was applied on the OPTIMIZE data and the effect of patients versus healthy volunteers were fixed to the values estimated for the REACT study. The base REACT population PK model without covariates described individual plasma concentration data in OPTIMIZE well. Therefore, the model developed on combined REACT and OPTIMIZE data used the same structure while covariates were investigated anew.

Systemic exposure to parent and metabolite were integrated in the tPDE4i, because this parameter is directly derived from model parameters.

Both roflumilast parent and metabolite total plasma concentrations were described by the integrated population PK model with adequate precision. As compared to the final REACT model results obtained on  the  REACT  data  only,  similar  parameter  estimates  were  obtained  for  the  combined  dataset,  the percent change of parameters being overall below 21%. A larger difference (61%) was found between

<div style=\"page-break-after: always\"></div>

the estimates of the Phase II/III effects on the volume of the central compartment for the N-oxide obtained on the REACT data only and on the combined dataset.

The  OPTIMIZE  model  was  able  to  describe  the  between-subject  variability  (BSV)  across  treatment phases (up-titration, maintenance, and down-titration) and dose regimens (OD or EOD), as shown in the  Visual  Predictive  Checks  (VPCs)  (Figure  2  and  Figure  3).  Time  axes  for  the  VPC  plots  were restricted to the period of time where the majority of observations was available (first 30 or 60 hours after dose, depending on the treatment arm).

## Figure 2. Visual Predictive Checks for roflumilast (top panel) and roflumilast Noxide (bottom panel) for patients receiving roflumilast 500 μg OD from all treatment arms in OPTIMIZE

## (a) Roflumilast 500 μg OD from all treatment arms

(b) Roflumilast 500 μg EOD (up-titration phase [Main Period] of treatment arm 2)

<!-- image -->

(c) Roflumilast 250 μg OD (up-titration phase [Main Period] of treatment arm 3)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Time after dose (h)

EOD every other day; OD once daily.

The model is able to describe between-subject variability across dose regimens. Black line and grey area: median prediction and 90% prediction interval, respectively; blue and red dotted lines: median observation  and  5th  and  95th  percentiles  of  observations,  respectively;  grey  dots:  observations  of OPTIMIZE  Source:  see  Module  5.3.4.2,  PK  and  PK/PD  analysis  of  exposure  and  efficacy  report (OPTIMIZE).

Figure 3. Visual Predictive Checks for roflumilast (top panel) and roflumilast Noxide (bottom panel) for patients who started the Down-Titration Period (roflumilast 250 μg OD) in OPTIMIZE

<!-- image -->

EOD every other day; OD once daily.

The model is able to describe between-subject variability in the Down-Titration Period for both parent and metabolite. Black line and grey area: median prediction and 90% prediction interval, respectively; blue  and  red  dotted  lines:  median  observation  and  5th  and  95th  percentiles  of  observations, respectively; grey dots: observations of OPTIMIZE.

## Covariate Effects

A  covariate  analysis  was  performed  on  the  combined  REACT  and  OPTIMIZE  dataset,  and  new covariates of age and sex were added as compared to the final REACT model. Table 4 shows patient counts and characteristics for the combined dataset, as well as for OPTIMIZE and REACT separately.

<div style=\"page-break-after: always\"></div>

Table 2. Demographic and baseline characteristics for OPTIMIZE and REACT.

|                 |                         | OPTIMIZE        | REACT         | Total           |
|-----------------|-------------------------|-----------------|---------------|-----------------|
| Patients, n (%) |                         | 1238 (72.9%)    | 461 (27.1%)   | 1699 (100.0%)   |
| Samples, n (%)  | Roflumilast             | 9416 (85.6%)    | 1589 (14.4%)  | 11005 (100.0%)  |
| Samples, n (%)  | Roflumilast N-oxide     | 9553 (85.8%)    | 1587 (14.2%)  | 11140 (100.0%)  |
| Age (years)     | Mean (SD)               | 64.5 (8.10)     | 64.2 (8.38)   | 64.4 (8.18)     |
| Age (years)     | Median (Min, Max)       | 64.0 (40,90)    | 64.0 (41,92)  | 64.0 (40,92)    |
| Sex, n (%)      | Male                    | 921 (74.4%)     | 354 (76.8%)   | 1275 (75.0%)    |
| Sex, n (%)      | Female                  | 317 (25.6%)     | 107 (23.2%)   | 424 (25.0%)     |
| Smoking, n (%h) | Current                 | 577 (46.6%)     | 220 (47.7%)   | 797 (46.9%)     |
| Smoking, n (%h) | Former                  | 661 (53.4%)     | 241 (52.3%)   | 902 (53.1%)     |
| Race, n (%)     | Asian                   | 82 (6.6%)       | 8 (1.7%)      | 90 (5.3%)       |
| Race, n (%)     | Blackor AfricanAmerican | 9 (0.7%)        | 4 (0.9%)      | 13 (0.8%)       |
| Race, n (%)     | White                   | 1132 (91.4%)    | 447 (97.0%)   | 1579 (92.9%)    |
| Race, n (%)     | Other                   | 9 (0.7%)        | 2 (0.4%)      | 11 (0.6%)       |
| Race, n (%)     | Hispanic                | 6 (0.5%)        | 0 (0.0%)      | 6 (0.4%)        |
| Weight (kg)     | Mean (SD)               | 75.4 (17.80)    | 75.0 (17.60)  | 75.3 (17.74)    |
| Weight (kg)     | Median (Min, Max)       | 74.0 (33.5,160) | 73.0 (39,155) | 74.0 (33.5,160) |

percentages relative to total number in combined dataset

percentages relative to total number in study

Max maximum; Min minimum; SD standard deviation.

:ource: see Module 5.3.4.2, PK and PK/PD analysis of exposure and efficacy report (OPTIMIZE), Table 5, for original table, from which this table has been produced.

The covariate 'race' was tested according to the covariate analysis, and each race category was included in the model as a binary relationship. However, in the single covariate addition procedure, race did not show a statistically significant result.

The covariates included in the model according to the combined dataset showed that:

- The clearance of the N-oxide is 11.2% lower for females
- The clearance of roflumilast and its metabolite are lower for patients older than 60 years old. For example, a 70-year-old patient is characterized by 9% and 8% lower clearance of parent and metabolite, respectively. However, 10% higher clearances were estimated for a 50-yearold patient with respect to the estimate obtained for the 60-year-old patient.
- Concerning the covariates already included in the final REACT model and re-estimated on the combined  dataset,  the  results  showed  that  clearance  of  parent  and  metabolite  were  15.1% higher for current smokers as compared to former smokers.
- Based on a reference value of weight of 70 kg, a patient weighing 80 kg is characterized by a 3.7% and 18% higher clearance of the metabolite and all volume terms, respectively. Lower clearance of N-oxide (-4%) and volume (-17%) were found for a patient weighing 60 kg.

These  differences  were  not  considered  to  be  clinically  relevant,  and  no  changes  to  the  current approved maintenance dose of roflumilast are warranted.

For each covariate included in the final model for the combined dataset, the single covariate effect on the tPDE4i was assessed, assuming a 500 μg once daily treatment.

This analysis showed that tPDE4i values decreased for increasing weight, ranging from 1.012 to 0.681 corresponding to the minimum (i.e., 33.5 kg) and maximum (i.e., 160 kg) body weight, respectively.

<div style=\"page-break-after: always\"></div>

The single effect of age on clearance of parent and metabolite provided tPDE4i values between 0.675 and  1.055  corresponding  to  the  minimum  (40  years)  and  the  maximum  (92  years)  values  of  the covariate AGE.

The smoking status affected both clearances and determined a lower tPDE4i value for current smoker (ie,  0.729)  as  compared to former/never smoker (ie, 0.839). Females were characterized by higher tPDE4i values (ie, 0.937) as compared to males (ie, 0.839).

## Systemic exposure

The tPDE4i was calculated for 1238 patients with quantifiable PK samples in the OPTIMIZE trial. The individual  tPDE4i  was  estimated  for  each  treatment  phase  and  dose  regimen  administered  to  the patients. In the roflumilast 250 μg OD up-titration phase of the Main Period (treatment arm 3), tPDE4i values were found to be approximately half of the values estimated for patients who underwent the 500 μg continuous treatment (treatment arm 1).

Similar  but  slightly  higher  tPDE4i  values  were  obtained  in  the  roflumilast  500  μg  EOD  up-titration phase of the Main Period (treatment arm 2) as compared to the roflumilast 250 μg OD up-titration phase (treatment arm 3). Although similar tPDE4i values were estimated in the up-titration phase of the roflumilast 500 μg EOD and roflumilast 250 μg OD treatment arms, higher maximum and lower minimum concentrations are expected due to the dose regimen.

Furthermore, estimated tPDE4i values were comparable for roflumilast 500 μg OD in the maintenance phase across all treatment arms. As compared to the Down-Titration Period, similar tPDE4i values were estimated in the roflumilast 500 μg EOD and roflumilast 250 μg OD up-titration treatment arms in the Main Period.

## Systemic exposure - Down-Titration

For patients who did not tolerate roflumilast 500 μg OD and enrolled in the Down-Titration Period, the analysis showed that, when receiving 250 μg OD, patients have a tPDE4i exposure approximately half that observed in patients treated with 500 μg OD (ie, patients who tolerated 500 μg OD and did not down-titrate).

However,  for  all  subgroup  pairs  with  sufficient  number  of  patients,  the  average  tPDE4i  in  'nontolerators'  is  slightly  higher  when  compared  with  'tolerators'  at  the  same  dose.  For  example,  when considering the subgroup of patients who dropped out due to any reason, the median tPDE4i after 500 μg OD is 1.16 and 1.23 (+6%) in 'tolerators' and 'non-tolerators', respectively.

Nevertheless, comparing 'tolerators' of roflumilast 500 μg OD (median tPDE4i of 1.16 at 500 μg OD) with 'non-tolerators' of roflumilast 500 μg OD (median tPDE4i of 0.60 at 250 μg OD, ie, during the Down-Titration Period), the latter have still a markedly lower tPDE4i systemic exposure (-48.3%).

Table 5 shows summary statistics of observed individual tPDE4i activity after roflumilast 250 μg OD or 500 μg OD.

## Table 3. Summary statistics of observed tPDE4i after roflumilast 250 μg OD or 500 μg OD

<div style=\"page-break-after: always\"></div>

| Subgroup definition      | Subgroup definition   | tPDE4i   | tPDE4i   | tPDE4i        | tPDE4i   | tPDE4i   | tPDE4i         |
|--------------------------|-----------------------|----------|----------|---------------|----------|----------|----------------|
|                          |                       | N        | Med      | (5%, 95%)     | N        | Med      | (5%, 95%)      |
| All patients             |                       | 1114     | 1.17     | (0.352, 2.03) | 76       | 0.611    | (0.197, 1.243) |
| DO due to AE of interest | Yes                   | 67       | 1.28     | (0.427, 2.22) | 62       | 0.647    | (0.201, 1.239) |
| DO due to AE of interest | No                    | 1047     | 1.16     | (0.339, 2.02) | 14       | 0.436    | (0.212, 1.069) |
| DO due to any AE         | Yes                   | 77       | 1.29     | (0.464, 2.10) | 64       | 0.647    | (0.204, 1.237) |
| DO due to any AE         | No                    | 1037     | 1.16     | (0.337,2.02)  | 12       | 0.408    | (0.209, 1.006) |
| Do due to any reason     | Yes                   | 106      | 1.23     | (0.416, 2.06) | 75       | 0.600    | (0.197, 1.243) |
| Do due to any reason     | No                    | 1008     | 1.16     | (0.332, 2.02) | 1        | 0.626    | (0.626, 0.626) |
| Atleast1AE ofinterest    | Yes                   | 536      | 1.23     | (0.453, 2.09) | 75       | 0.600    | (0.197, 1.243) |
| Atleast1AE ofinterest    | No                    | 578      | 1.12     | (0.297, 1.98) | 1        | 0.929    | (0.929, 0.929) |
| At least 1 AE of any PT  | Yes                   | 693      | 1.22     | (0.416, 2.07) | 76       | 0.611    | (0.197, 1.243) |
| At least 1 AE of any PT  | No                    | 421      | 1.08     | (0.294, 1.97) | 0        |          | (-,-)          |

AE adverse event; DO dropout:; OD once daily; PT preferred term; tPDE4i: total phosphodiesterase 4 inhibition.

Only patients who received the roflumilast 500 μg OD treatment are used. These patients were split into 'toleratorsor ^non-tolerators*based on 5 different definitions (see OPTIMIZE CSR, Section 9.7.1.7.1) Summary statistics (median and 5th to 95t percentiles) were derived for each of the 5 x 2 subgroups and tPDE4i. The same statistics are shown for all patients as a reference.

Subgroup: overall population treated with roflumilast 500 μg OD and roflumilast 250 μg OD and subpopulations defined according to dropout and AE: discontinuation due to AE of interest; discontinuation due to AE of any PT; discontinuation due to any reason; at least one AE of interest; at least one AE of any PT

DO: dropout (discontinuation from the Main Period irrespective of starting the Down-Titration Period)

## Comparison of population PK results

The population PK analyses from the original submission described the PK of roflumilast parent and metabolite in 2 independent models.

The  current  OPTIMIZE  model  simultaneously  describes  parent  and  metabolite.  Benefits  of  this approach are that correlations, e.g., between the clearance of parent and metabolite are captured by the model, which should result in more reliable tPDE4i simulations. Also sparse data can be described with  more  certainty,  because  parent  and  metabolite  data  simultaneously  inform  all  individual  PK parameters.

The  covariate  analysis  in  the  original  models  was  built  on  PK  data  collected  in  healthy  volunteers, whereas the covariate analysis of the current OPTIMIZE population PK model is based on patient data only.

Comparison  of  covariate  findings  between  the  original  and  the  OPTIMIZE  population  PK model: A  high  level  overview  of  the  original  covariate  findings  is  described  here.  In  the  original submission,  the  impact  of  individual  covariates  was  determined  as  relative  change  in  tPDE4i  values from a reference subject, which was defined as male, non-smoking, non-black/non-Hispanic, healthy, aged  40-years  old.  In  OPTIMIZE,  the  reference  patient  was  a  male,  60-year  old,  former  smoker, baseline body weight of 70 kg.

In the original analysis, of the single covariates, black (race) had the greatest impact on tPDE4i, with a 42%  higher  mean  tPDE4i  than  non-black/non-Hispanic  patients.  Similarly,  but  to  a  lesser  extent, Hispanic  patients  were  estimated  to  have  a  28%  higher  mean  tPDE4i  than  non-black/non-Hispanic patients. Female patients were estimated to have a 19% higher mean tPDE4i than male patients. To the contrary, smokers were estimated to have a 19% lower mean tPDE4i than non-smokers/former smokers.

Using the population PK model with REACT and OPTIMIZE combined data, the assessment of the single covariate effect, assuming the 500 μg OD treatment, showed that tPDE4i ranges between 1.012 and 0.681 according to range of body weight observed in the studied population (ie, 33.5 to 160 kg) (no

<div style=\"page-break-after: always\"></div>

effect of weight was seen in the original analysis). Race was not identified as a covariate (due to the low numbers of black patients). As in the original analysis, higher tPDE4i values were estimated for females (+12% as compared to males) and lower tPDE4i values were obtained for current smokers (13% as compared to former/never  smokers).  For the  age  range  between  40  and  92  years,  tPDE4i ranged between 0.675 and 1.055.

## 2.8.3. Pharmacodynamics

Roflumilast is a PDE4 inhibitor, a non-steroid, anti-inflammatory active substance designed to target both the systemic and pulmonary inflammation associated with COPD. The mechanism of action is the inhibition  of  PDE4,  a  major  cyclic  adenosine  monophosphate  (cAMP)-metabolizing  enzyme  found  in structural and inflammatory cells important to the pathogenesis of COPD (Daxas SmPC).

Roflumilast  targets  the  PDE4A,  4B  and  4D  splicing  variants  with  similar  potency  in  the  nanomolar range. The affinity to the PDE4C splicing variants is 5 to 10-fold lower. This mechanism of action and the  selectivity  also  apply  to  roflumilast  N-oxide,  which  is  the  major  active  metabolite  of  roflumilast (Daxas SmPC).

## PK-PD relationship

Three types of analyses were performed to characterize the relationship of systemic exposure with

- a) post-BD FEV1 observations (PK/FEV1 models),
- b) the percentage of patients with at least one AE (PK/AE models), and
- c) the time to treatment discontinuation due to AEs (PK/TTE models).

## Methods

## a) PK/FEV1 dataset

In  the  OPTIMIZE  study,  out  of  1238  patients  with  valid  PK  samples,  all  had  FEV1  measurements. Therefore,  all  1238  patients  were  also  included  in  the  PK/FEV1  analysis.  In  total,  the  OPTIMIZE PK/FEV1 dataset consists of 6093 FEV1 observations: 1991 observations from the 500 μg OD subset, 2053 observations from the 500 μg EOB subset, and 2049 observations from the 250 μg OD subset.

The  PK/FEV1  dataset  was  created  from  the OPTIMIZE  data  with  minor  modifications; postbronchodilator observations and FEV1 observations at screening were removed.

Treatment phases and Visit numbers were assigned to allow differentiation between treatment phases (up-titration,  maintenance,  and  down-titration),  for  graphical  evaluation  and  modelling  purposes. Empirical Bayesian Estimates of PK parameters for individual patients using the final PK model were used to compute tPDE4i values for each of the treatment phases. These were added to the PK/FEV1 dataset to be used as PK input.

Additional  columns  were  added  to  identify  patients  in  potential  special  interest  categories,  such  as COPD severity, body weight, and age. In addition, new columns were created for the percentage of the study  period  during  which  there  was  concomitant  LABA/ICS  use  and  a  flag  to  indicate  concomitant LABA/ICS use at each observation.

The PK/FEV1 model was developed using the following stepwise approach:

1. First, the previously developed base and final REACT models  were applied to the OPTIMIZE data according to a Bayesian Feedback procedure (i.e. MAXEVAL = 0 in the NONMEM code, meaning that estimation is not performed but parameters already available are used to provide predictions for the new OPTIMIZE dataset);

2. Description of FEV1 was then optimized on the OPTIMIZE dataset using the REACT covariate model as a starting point.

Due to the absence of placebo group data in the OPTIMIZE data, all disease progression and placeborelated fixed-effect parameters were fixed at REACT values. Covariate effect parameters on BSL and SLP4 were re-estimated, but not those on E0, because of the shorter time period over which FEV1

<div style=\"page-break-after: always\"></div>

observations were available. This is due to the different duration of the OPTIMIZE study as compared to the REACT one, being 12 weeks (plus 8 weeks if the patients started the down-titration period) and 52 weeks, respectively.

All  random  effect  parameters  (BSV  on  BSL  and  E0,  and  WSV)  were  re-estimated.  Differences  in  PK between  up-titration  dose  regimens  were  evaluated  by  estimating  separate  treatment  parameters (SLP4 and ThalfP4) for 500 μg EOD and 250 μg OD versus 500 μg OD dose regimens; 3. A formal covariate  analysis  was  performed  on  BSL  (the  only  parameter  for  which  a  BSV  was  estimated  on OPTIMIZE data). A forward inclusion/backward elimination procedure was followed. Forward inclusion was done on top of the covariates already present in the REACT model. During backward elimination, all covariates were removed one-by-one (including those already present in the REACT model).

## b) PK/AE dataset

There were 1238 patients in the PK/AE dataset. The binary response variable AE was set to 'yes' for patients with at least 1 AE with Medical Dictionary for Regulatory Activities preferred term (PT) in 'Any AE (all PTs)' during the Main Period of the study. Systemic exposure in the model was defined as the predicted tPDE4i with the 500 μg OD treatment. In total, 797 (64.4%) of patients reported at least 1 AE.  Patient  counts  (and  percent)  for  each  arm  of  the  study  were:  257  (62.1%)  in  the  250  μg  OD treatment  arm,  269  (65.0%)  in  the  500  μg  EOD  treatment  arm,  271  (66.1%)  in  the  500  μg  OD treatment arm.

To assess the incidence and timing of AEs of interest, a list of 'AEs of interest' was compiled consisting of 6 groups of related PTs: headache, diarrhoea, nausea, decreased appetite, insomnia, and abdominal pain. For the analysis that explored the relationship between PK and AEs of interest, an additional 5 groups of related PTs were included in a list referred to as 'AEs of interest' (extended list) to ensure consistency with previous PK/AE analyses, consisting of 11 groups of related PTs: headache, diarrhoea, nausea, abdominal pain, appetite disorders, sleep disorders, vomiting, angioedema, anxiety, depression, weight loss. In total, 633 (51.1%) patients reported at least 1 of these AEs. The 'AEs of interest' category was used in the safety statistics analysis of OPTIMIZE and the 'Any AE' category was used for sensitivity analyses.

## c) PK/TTE dataset

There were 1238 patients in the PK/TTE dataset. The PK/TTE analysis was based on all discontinuation events due to 'AEs of Interest (extended list)' during the Main Period from all patients. Any AE that led to discontinuation from the Main Period was recorded with event time defined as days after treatment start  until  last  Main  Period  study  medication  intake  (days  on  MP),  excluding  potential  later  study medication intakes during the Down-Titration Period. For each patient i and every AE group X , the time to  discontinuation TTE\\_Xi was  defined  as  'censored'  if  no  AE  in  group X lead  to  treatment discontinuation of patient i from the Main Period. In case patient i had an AE in group X which lead to discontinuation  from  the  Main  Period, TTE\\_Xi was  set  to  the  number  of  days  that  the  patient  was treated during the Main Period.

For each subject, the tPDE4i predicted for the treatment phase at which this patient discontinued was chosen  as  systemic  exposure  variable.  If  discontinuation  happened  during  up-titration  phase  of  the Main  Period,  tPDE4i  predicted  for  the  respective  up-titration  treatment  was  used  (tPDE4i\\_250OD, tPDE4i\\_500EOD, or tPDE4i\\_500OD), if discontinuation happened during the maintenance phase of the Main  Period,  tPDE4i\\_500OD  was  used.  In  case  a  patient  either  completed  the  Main  Period  or discontinued due to another reason, the respective tPDE4i predicted for the last day of the patient's Main Period was used.

## Results

## a) Exposure-response model for FEV1

The previous exposure-response model for FEV1 was developed based on data from the REACT study, and described the relative change from baseline in FEV1, as a function of roflumilast systemic exposure expressed as tPDE4i. The REACT model has now been applied to PK and FEV1 data from the OPTIMIZE study to further characterize the exposure FEV1 response of roflumilast and roflumilast N-oxide.

## The final OPTIMIZE model

The final OPTIMIZE FEV1 model contains the following covariate effects:

<div style=\"page-break-after: always\"></div>

- COPD status, concomitant long acting muscarinic antagonist (LAMA) use, percent reversibility (for short-acting bronchodilators), age, weight, sex and race on baseline FEV1
- Weight on placebo effect
- Smoking status on treatment effect slope.

All parameters could be estimated with good precision (CV&lt;50%). The final model described OPTIMIZE data well (Figure 4).

Figure 4 . Visual Predictive Checks for FEV1 change from baseline (a and b) and mean change from baseline (c and d), during up-titration and maintenance phases of the Main Period (a and c) and the Down-Titration Period (b and d) using the current final FEV1 model

## (a) All observations, Main Period

(b) All observations, Down-Titration Period

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

(c) Mean, Main Period

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

(a) and (b): Solid line and grey area: median prediction and 90% prediction interval, respectively; blue and red dotted  lines:  median  observation  and  5th  and  95th  percentiles  of  observations,  respectively;  grey  dots: observations.

(c) and (d): Solid line and grey area: median prediction and 90% prediction interval, respectively; dots: mean FEV1 values. Vertical dashed line (c) indicates the time point between the Up-Titration phase and the Maintenance phase. (b) and (d): For the Down-Titration Period, data were plotted at Visit Day assuming start of down-titration at Day 84.

Source: see Module 5.3.4.2, PK and PK/PD analysis of exposure and efficacy report (OPTIMIZE), Figure 8.

The observed FEV1 changes in the OPTIMIZE study are well described by the FEV1 model developed for  the  REACT  study  in  the  treatment  phases  (up-titration,  maintenance,  and  down-titration)  and across the different treatment arms. Model simulations showed that change of FEV1 from baseline is lower  at  the  end  of  the  4-week  up-titration  treatment  phase  with  roflumilast  250  μg  OD  than roflumilast 500 μg OD (Figure 4, [c]), and is predicted to decrease after down-titration from roflumilast 500 μg OD to roflumilast 250 μg OD (Figure 4, [d]).

## Covariate Effects:

To evaluate the influence of covariates in the PD model, FEV1 and FEV1 change from baseline (ΔFEV1) estimates  for  a  500  μg  OD  dose  regimen  at  steady  state,  after  4  weeks  and  after  12  weeks  of treatment, were calculated assuming a typical tPDE4i value, accounting for patient covariates.

Covariates weight, COPD severity, and percent reversibility for short-acting bronchodilators resulted in the largest change in FEV1 at baseline parameter, followed by the effect of age, sex, race and the use of LAMA at baseline, while smoking affected the proportionality coefficient for roflumilast tPDE4i. The range of predicted FEV1 change from baseline at week 4 and week 12 (resulting from covariates in the PK/FEV1 model) was largest for weight and smoking.

For example, ΔFEV1 after 12 weeks ranged from 32.0 to 157 mL for a 33.5 to 160 kg weight range, and  was  dependent  on  smoking  status  (96.5  versus  56.0  mL  for  current  versus  former/never smokers).

## b) Results of the PK/AE analysis

## b1. AEs of interest

The final model quantifies a significant increase in the percentage of subjects with AEs of Interest with increased exposure (see Figure 5). The plot show the mean model response (thick line) together with a shaded ribbon indicating the 95% confidence intervals around the mean response. The erratic thin line represents the local fit (local fit is a locally averaged percentage of subjects with adverse events and

<div style=\"page-break-after: always\"></div>

it's  variability  is  not  directly  related  to  the  shaded  95%  CIs,  i.e.  it  is  not  expected  to  have approximately 95% of the local fits within the shaded area, as it would be with standard VPC plots).

Figure 5. Model response from the logistic regression model for the percentage of subjects with AEs of Interest (extended list) as a function of tPDE4i (500μg OD).

<!-- image -->

In  addition  covariates LAMAC and SMOK indicated that percentages of subjects with AEs of Interest were

- Higher in subjects concomitantly treated with LAMAs when compared with subjects not taking LAMAs.
- Higher in former smokers when compared with current smokers.

Total PDE4i was a significant predictor of the percentage of patients with AEs in 7 out of 9 tested PT groups.  Logistic  regression  analysis  indicates  that  the  percentage  of  patients  with  AEs  of  interest (extended  list),  Any  AE  (all  PTs),  diarrhoea,  appetite  disorders,  insomnia,  nausea,  and  weight  loss, according to the model, depends on tPDE4i. The percentage of patients with headache and abdominal pain  was  not  found  to  depend  on  tPDE4i,  according  to  the  model.  Smoking  habit  was  a  significant predictor in 5 models.

In  addition,  covariates  Asian  and  concomitant use of LAMA or LABA/ICS  were significant for one PT group each (RO-2455-302-RD: Expert Report to Characterize PK/AE).

Moreover,  variable  treatment  arm  (250  μg  OD/500  μg  EOD)  was  not  found  as  a  covariate  in  any model, ie, the percentages of patients with AEs are not affected by treatment arm but were sufficiently characterized by tPDE4i as a descriptor of systemic exposure.

Simulations of the PK/AE models were performed to assess the probability of a patient to develop AEs in  dependence of their characteristics and roflumilast systemic exposure. Relative risks over placebo were derived from these simulations. Placebo effects were predicted since there was no placebo arm included in OPTIMIZE.

Among all simulated scenarios for the 'AEs of interest (extended list)', the median predicted RR (to placebo)  for  a  reference  patient  (male,  age  64  years,  former  smoker,  body  weight  74  kg,  and concomitant treatment with LAMA) when treated with 500 μg OD is1.31 with a 90% prediction interval of [0.43, 4.67].

The lowest average RR of 1.27 [0.41, 4.56] was predicted for young patients (age=51 years) and the highest average RR of 1.38 [0.38, 5.66] was predicted for patients concomitantly treated with LAMAs. Relative differences of both extremes when compared with the reference were -3% and +5% and not considered clinically relevant.

<div style=\"page-break-after: always\"></div>

Table 4. Simulated tPDE4i, percentages of subjects with AEs of Interest (extended list), and relative risk to placebo in subgroups defined by PK and PD covariates for typical subjects.

| Scenario                                                                      | tPDE4io                                               | AEo                                                      | tPDE4i250                                                  | AE250                                                    | RR250                                                 | tPDE4i500                                             | AE500                                                          | RR500                                                      |
|-------------------------------------------------------------------------------|-------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|----------------------------------------------------------------|------------------------------------------------------------|
| WT=48 (PK-Covariate) WT=74 (PK-Covariate) WT=105 (PK-Covariate) Former Smoker | 0.00 [0.00, 0.00] 0.00 [0.00, 0.00] 0.00 [0.00, 0.00] | 44.5% [13.4, 80.7] 44.5% [13.3, 80.7] 44.5% [13.4, 80.6] | 0.72 [0.69, 0.76] 0.65 [0.62, 0.68] 0.60 [0.57, 0.63] 0.65 | 53.2% [18.0, 85.5] 52.3% [17.4, 85.1] 51.7% [17.1, 84.8] | 1.17 [0.35, 4.27] 1.16 [0.34, 4.22] 1.14 [0.34, 4.18] | 1.45 [1.38, 1.53] 1.30 [1.25, 1.36] 1.19 [1.14, 1.26] | 61.8% [23.8, 89.4] 60.1% [22.4, 88.7] 58.8% [21.6, 88.1]       | 1.34 [0.46, 4.76] 1.31 [0.43, 4.67] 1.28 [0.42, 4.58] 1.31 |
| (PK&PD-Covariate) CurrentSmoker (PK&PD-Covariate) Males (PK-Covariate)        | 0.00 [0.00, 0.00] 0.00 [0.00, 0.00] 0.00 [0.00, 0.00] | 44.5% [13.4, 80.7] 35.9% [9.7, 74.5] 44.5% [13.4, 80.7]  | [0.62, 0.68] 0.56 [0.54, 0.60]                             | 52.3% [17.4, 85.0] 42.5% [12.4, 79.3]                    | 1.15 [0.34, 4.22] 1.17 [0.29, 4.96] 1.15              | 1.30 [1.25, 1.36] 1.13 [1.07, 1.20] 1.30 [1.25, 1.36] | 60.1% [22.5, 88.7] 49.2% [15.7, 83.5]                          | [0.44, 4.66] 1.33 [0.36, 5.51]                             |
| Females (PK-Covariate) AGE=51 AGE=64 AGE=77                                   | 0.00 [0.00, 0.00] 0.00 [0.00,0.00] 0.00               | 44.5% [13.3, 80.7] 44.5% [13.4, 80.7]                    | 0.65 [0.62, 0.68] 0.72 [0.69, 0.77]                        | 52.3% [17.4, 85.0] 53.2% [18.0, 85.5]                    | [0.34, 4.22] 1.17 [0.35, 4.27] 1.14                   | 1.45 [1.38, 1.53] 1.15 1.30                           | 60.1% [22.5, 88.7] 61.8% [23.7, 89.4]                          | 1.31 [0.44, 4.66] 1.34 [0.46, 4.76]                        |
| (PK-Covariate) (PK-Covariate) (PK-Covariate) (PD-Covariate)                   | [0.00, 0.00] 0.00 [0.00, 0.00]                        | 44.5% [13.3, 80.7] 44.5% [13.4, 80.6]                    | 0.58 [0.55, 0.60] 0.65 [0.62, 0.68] 0.72 [0.68, 0.76]      | 51.4% [16.9, 84.6] 52.3% [17.4, 85.1] 53.2% [17.9, 85.5] | [0.33, 4.17] 1.16 [0.34, 4.22] 1.17 [0.35, 4.26] 1.15 | [1.10, 1.21] [1.25, 1.36] 1.44 [1.37, 1.52] 1.30      | 58.4% [21.3, 87.9] 60.1% [22.4, 88.7] 61.7% [23.7, 89.3] 60.1% | 1.27 [0.41, 4.56] 1.31 [0.43, 4.67] 1.34 [0.46, 4.74]      |
| WithConc.LAMA                                                                 | 0.00 [0.00, 0.00] 0.00                                | 44.5% [13.4, 80.7]                                       | 0.65 [0.62, 0.68] 0.65                                     | [17.4, 85.0] 43.5%                                       | [0.34, 4.22] 1.19                                     | [1.25, 1.36] 1.30                                     | [22.5, 88.7] 51.4%                                             | 1.31 1.38                                                  |
| W/o Conc.LAMA (PD-Covariate)                                                  | [0.00, 0.00]                                          | 36.0% [9.7, 74.5]                                        | [0.62, 0.68]                                               | 52.3% [12.9, 80.0]                                       | [0.30, 5.04]                                          | [1.25, 1.36]                                          | [16.9, 84.6]                                                   | [0.44, 4.66] [0.38, 5.66]                                  |

tPDE4idose is the simulated total PDE4 inhibitory activity in subjects treated with dose (Oμg,250μg,500μg) OD. AEaoss is the simulated percentage of subjects with AEs of Interest as median and 90% prediction interval (5tt to 95th percentile of all predictions).

## b.2 Any AE:

For any AE, the logit of probability depended on tPDE4i and race (Asian versus non-Asian). As with AEs of interest, LAMA use and smoking were also found to be covariates. In addition, covariates of the PK model  result  in  different  tPDE4i  levels  and  hence  translate  into  differences  in  RR  when  comparing simulations stratified by these variables. Nevertheless, these differences are small in all cases and do not indicate clinically relevant differences across all investigated subgroups.

For 'Any AEs', the predicted RR (to placebo) for a reference patient when treated with 500 μg OD is 1.31 [0.48, 4.43]. The lowest and highest predicted RRs in all scenarios were 1.15 [0.65, 2.64] for Asian patients and 1.34 [0.51, 4.52] for patients with a body weight of 48 kg. This corresponds to a 12% and +2% difference from the reference. Numerically the same highest RRs were also predicted for females and patients aged 77 years. The high variability in AEs translated into the prediction of RRs causing  largely  overlapping  prediction  intervals  in  all  cases  that  included  1  (no  effect).  Given  this variability, RRs were very similar among all simulated scenarios.

Table 5. Simulated tPDE4i, percentages of subjects with Any AE (all PTs), and relative risk to placebo in subgroups defined by PK and PD covariates for typical subjects.

<div style=\"page-break-after: always\"></div>

| Scenario                 | tPDE4io                                               | AEo                                         | tPDE4i250                        | AE250              | RR250                  | tPDE4i500                           | AE500                    | RR500                  |
|--------------------------|-------------------------------------------------------|---------------------------------------------|----------------------------------|--------------------|------------------------|-------------------------------------|--------------------------|------------------------|
| WT=48                    | 0.00 [0.00, 0.00] 0.00 [0.00, 0.00] 0.00 [0.00, 0.00] | 47.8% [14.9, 82.7] 47.8% [14.9, 82.7] 47.8% | 0.72 0.65 0.60 [0.57, 0.63] 0.65 | 57.5% 56.5%        | 1.18 [0.38, 4.05] 1.16 | 1.45 [1.38, 1.53] 1.30              | 66.7% [27.8, 91.3] 64.9% | 1.34 [0.51, 4.52] 1.31 |
| (PK-Covariate)           |                                                       |                                             | [0.69, 0.76]                     | [20.6, 87.5]       | 1.15 [0.36, 3.96] 1.16 | 1.19 [1.14, 1.26] 1.30 [1.25, 1.36] |                          |                        |
| WT=74                    |                                                       |                                             |                                  |                    |                        |                                     |                          |                        |
| (PK-Covariate)           |                                                       |                                             | [0.62,0.68]                      | [20.0, 87.1]       | [0.37, 4.00]           | [1.25, 1.36]                        | [26.2, 90.6]             | [0.48, 4.43]           |
| WT=105                   |                                                       |                                             |                                  | 55.8%              |                        |                                     | 63.6%                    | 1.29                   |
| (PK-Covariate)           |                                                       | [14.9, 82.7]                                |                                  | [19.5, 86.8]       |                        |                                     | [25.1, 90.1]             | [0.46, 4.35]           |
| FormerSmoker             | 0.00                                                  | 47.8%                                       |                                  | 56.5%              |                        |                                     | 64.9%                    | 1.31                   |
| (PK-Covariate)           | [0.00, 0.00]                                          | [14.9, 82.7]                                | [0.62, 0.68]                     | [20.0, 87.1]       | [0.37, 4.00]           |                                     | [26.2, 90.6]             | [0.48, 4.43]           |
| Current Smoker           | 0.00                                                  | 47.8%                                       | 0.56                             | 55.4%              | 1.14                   | 1.13                                | 62.8%                    | 1.27                   |
| (PK-Covariate)           | [0.00,0.00]                                           | [14.9, 82.7]                                | [0.54, 0.60]                     | [19.3, 86.6]       | [0.36, 3.94]           | [1.07, 1.20]                        | [24.4, 89.8]             | [0.45, 4.32]           |
| Males (PK-Covariate)     | 0.00 [0.00, 0.00]                                     | 47.8% [14.9, 82.7]                          | 0.65 [0.62, 0.68]                | 56.5% [20.0, 87.1] | 1.16 [0.37, 4.00]      | 1.30 [1.25, 1.36]                   | 64.9% [26.2, 90.6]       | 1.31 [0.48, 4.43]      |
| Females AGE=51           | 0.00                                                  | 47.8%                                       | 0.72 [0.69, 0.77]                | 57.5% [20.6, 87.6] | 1.18                   | 1.45                                | 66.7%                    | 1.34                   |
| (PK-Covariate)           | [0.00,0.00]                                           | [14.9, 82.7]                                |                                  |                    | [0.38, 4.05]           | [1.38, 1.53]                        | [27.7, 91.3]             | [0.50, 4.52]           |
|                          | 0.00                                                  | 47.8%                                       | 0.58 [0.55, 0.60]                | 55.5%              | 1.14                   | 1.15 [1.10, 1.21]                   | 63.1%                    |                        |
|                          |                                                       |                                             |                                  | [19.3, 86.6]       |                        |                                     |                          | 1.28                   |
| (PK-Covariate)           | [0.00, 0.00]                                          | [14.9, 82.7]                                |                                  |                    | [0.36, 3.95]           |                                     | [24.7, 89.9]             | [0.45, 4.33]           |
| AGE=64                   | 0.00                                                  | 47.8%                                       | 0.65                             | 56.5%              | 1.16                   | 1.30                                | 64.9%                    | 1.31                   |
| (PK-Covariate)           | [0.00, 0.00]                                          | [14.9, 82.7] 47.8%                          | [0.62, 0.68] 0.72                | [20.0, 87.1] 57.4% | [0.37, 4.00] 1.18      | [1.25, 1.36] 1.44                   | [26.2, 90.6] 66.6%       | [0.48, 4.43] 1.34      |
| AGE=77                   | 0.00                                                  |                                             |                                  |                    |                        |                                     |                          |                        |
| (PK-Covariate)           | [0.00,0.00]                                           | [14.9, 82.7] 47.8%                          | [0.68, 0.76]                     | [20.6, 87.5] 56.5% | [0.38, 4.04] 1.16      | [1.37, 1.52] 1.30                   | [27.7, 91.2] 64.9%       | [0.50, 4.50] 1.31      |
| Non-Asian (PD-Covariate) | 0.00 [0.00, 0.00]                                     | [14.9, 82.7]                                | 0.65 [0.62, 0.68]                | [20.0, 87.1]       | [0.37, 4.00]           | [1.25, 1.36]                        | [26.2, 90.6]             | [0.48, 4.43]           |
| Asian                    | 0.00                                                  | 69.9%                                       | 0.65                             | 76.7%              | 1.08                   |                                     | 82.4%                    |                        |
|                          |                                                       |                                             |                                  |                    |                        | 1.30                                |                          | 1.15                   |
| (PD-Covariate)           | [0.00, 0.00]                                          | [30.7, 92.4]                                | [0.62, 0.68]                     | [38.8, 94.5]       | [0.54, 2.48]           | [1.25, 1.36]                        | [47.3, 96.1]             | [0.65, 2.64]           |

tPDE4idos is the simulated total PDE4 inhibitory activity in subjects treated with dose (Oμg,250μg,500μg) OD. AEaoss is the simulated percentage of subjects with Any AE (all PTs), treated with dose. RRaose is the simulated risk relative to placebo of subjects with Any AE (all PTs), treated with dose.

## c) Results of the PK/TTE analysis

Time-to-event models with a log-normal hazard adequately described discontinuation times from the Main Period (up-titration and maintenance phases) and from the up-titration phase of the Main Period only due to AEs of interest (extended list) and due to Any AEs.

The  variable  'treatment  arm  250  μg  OD'  was  a  significant  covariate  in  all  models,  indicating  that patients treated with roflumilast 250 μg OD for 4 weeks before increasing the dose to roflumilast 500 μg OD had significantly lower discontinuation rates due to AEs of interest (extended list) and due to Any AEs during the Main Period compared to patients in  the  500  μg  EOD  or  500  μg  OD  treatment arms.

In  addition,  variables  Asian,  sex,  and  age  were  found  as  significant  covariates  when  characterizing discontinuation events during the Main Period; discontinuation rates due to AEs were higher for Asians, females, and with increasing age. However, when characterizing discontinuation events during the uptitration phase of the Main Period only, only body weight was found beside 'treatment arm 250 μg OD' as a covariate; early treatment discontinuation due to AEs in OPTIMIZE (within the up-titration phase) was found to be co-dependent on other patient characteristics rather than late discontinuation events.

Despite up-titration with 250 μg OD, systemic exposure (as characterized by tPDE4i) was not found to significantly affect discontinuation rates.

## Discussion about the PK-response models:

## a) Comparison of findings between the original and OPTIMIZE PK/FEV1 analyses:

The originally developed exposure-response models for FEV1 were based on data from 4 Phase II/III studies testing roflumilast compared with placebo without PK sampling. These models were developed as  dose/response  models  and  then  extended  using  simulated  typical  systemic  exposure  as  a  PK variable.  In  contrast,  the  OPTIMIZE  PK/FEV1  analyses  is  an  individual  exposure  response  model describing  the  change  in  FEV1  over  time  as  a  function  of  tPDE4i  and  therefore  cannot  be  directly compared  with  the  original  model.  In  addition,  there  were  differences  in  treatment  duration  and background therapy between OPTIMIZE and the originally reported studies.

## b) Comparison of findings between the original and OPTIMIZE PK/AE analyses:

In  the  PK/AE  analyses  in  the  original  submission,  a  significant  exposure-response  relationship  was identified for diarrhoea, nausea, and headache. In OPTIMIZE PK/AE analyses, systemic exposure, as measured by tPDE4i, was a significant predictor of the percentage of patients with AEs in 7 out of 9

<div style=\"page-break-after: always\"></div>

tested  PT  groups;  AEs  of  interest  (extended  list),  Any  AE  (all  PTs),  diarrhoea,  appetite  disorders, insomnia, nausea, and weight loss depends on tPDE4i. The percentages of patients with headache and abdominal pain were not found to depend on tPDE4i.

However, the originally reported and OPTIMIZE PK/AE models cannot be directly compared in detail due to the difference in the dosing regimen compared to that currently approved for roflumilast.

## 2.8.4. Discussion on clinical pharmacology

This  application  is  based  on  the  study  RO-2455-302-RD  (OPTIMIZE),  'a  multicenter,  randomized, double-blind, Phase 3 study to evaluate tolerability and pharmacokinetics of 500 μg roflumilast once daily with an up-titration regimen in COPD, including an open-label Down-Titration Period evaluating tolerability and PK of 250 μg roflumilast once daily in patients not tolerating 500 μg roflumilast oncedaily'.

The OPTIMIZE population pharmacokinetic (PK) analyses used OPTIMIZE data combined with PK data from the REACT study (Study RO 2455-404-RD). Parameters of the final population PK model were estimated with good precision (coefficient of variation of the estimates less than 25%) and estimates were  consistent  with  previous  findings.  The  model  was  able  to  adequately  describe  average  PK concentrations as well as the BSV across all treatment phases (up-titration, maintenance, and downtitration) and dosing schemes.

Reducing the dose of roflumilast to 250 μg OD in patients who did not tolerate roflumilast 500 μg OD markedly  reduced  tPDE4i  to  below  those  typically  observed  in  patients  who  tolerated  500  μg  OD. Therefore, administration of roflumilast 250 μg OD may not induce sufficient PDE4 inhibition to exert clinical efficacy.

Although the applicant states that dose adjustment for patient covariates (such as gender, age and smoking status) is not warranted, it does not prevent from updating section 5.2 of the SmPC. In addition, the need for dose adjustment should be further discussed for some special populations.

The Applicant has submitted the requested pre-study validation report ACTC2 including two addendum (Analyte Stability in Frozen Matrix Sodium Heparin and Stability of Standards in Solution).

In  general,  the  pre-study  or  method  validation  of  the  bioanalytical  method  was  consistent  and demonstrated  an  adequate  linearity,  precision  and  accuracy  (both  intra-  and  inter-day)  within  the calibrated  range,  which  showed  also  an  adequate  selectivity,  absence  of  significant  carry-over  and matrix  effect  and  adequate  dilution  linearity.  In  addition,  the  analyte  long-term  stability  was demonstrated for 716 days at -20 ºC and -70 ºC.

New PK data generated from OPTIMIZE in almost 19.000 samples from 1238 COPD patients are robust and may be of interest for prescribers. In this respect, section 5.2 of the SmPC must be updated with respect  to:  a)  PK  data  of  the  250  microgram  dose.  It  should  be  stated  that  these  levels  are  subtherapeutic  and  therefore  not  recommended  for  maintenance  treatment,  with  cross  reference  to section 5.1 and 4.2;

b) The influence of intrinsic/extrinsic factors on PDE4 inhibitory activity (i.e.: age, weight, race, gender and smoking status) (subsection of special populations).

Upon request,  adiscussion  about  potential  need  for  dose  adjustments  was  provided    (e.g.:  whether obese patients may require maintenance doses &gt; 500 micrograms or if Asian patients and/or patients with low body weight may require maintenance doses &lt; 500 micrograms.

The company provided a new population PK model on the combined REACT and OPTIMIZE dataset and identified no clinically relevant changes of systemic exposure levels in populations of particular interest (eg, elderly patients, female patients, or patients with high [&gt;80 kg] or low [&lt;60 kg] baseline body weight).

With  respect  to  race, Asian  patients  tend  to  have  a  lower  body  weight  than  patients  from  Western countries.  Asian race was not a significant covariate in population PK analysis, whereas in subgroup analyses of pivotal studies (Study M2-124 and Study M2-125), the effect of roflumilast versus placebo on  the  rate  of  moderate  or  severe  exacerbations  showed  no  heterogeneity  depending  on  race. Therefore, is was concluded that the approved maintenance dose of roflumilast 500 μg OD does not need to be adjusted in these populations.

<div style=\"page-break-after: always\"></div>

The mechanism of action, primary and secondary pharmacology of roflumilast are well established and were already assessed in the roflumilast 500 microg MAA. The new line extension application is based on a single pivotal study (OPTIMIZE study) that included combined PK, PD, efficacy and safety data. Only the new PD data pertaining to the OPTIMIZE PK-PD model have been described and assessed in this section.

Three  types  of  analyses  were  performed  to  characterize  the  relationship  of  systemic  exposure  of  3 roflumilast  starting  regimes  (250  microg  OD  or  500  microg  EOD  for  4  weeks  followed by  500  for 8 additional weeks versus standard regime of roflumilast 500 microg OD for 12 weeks) with a) post-BD FEV1 observations (PK/FEV1 models); b) the percentage of patients with at least one AE (PK/AE models), and c) the time to treatment discontinuation due to AEs (PK/TTE models).

The population PK/FEV1 model predicted a reduced improvement in FEV1 at roflumilast 250 μg OD compared to roflumilast 500 μg OD during the 4-week up-titration phase of the Main Period. The model also predicted a decrease of FEV1 change from baseline in subjects down-titrating from 500 μg OD to 250 μg OD in the Down-Titration Period. In accordance with reducing the dose of roflumilast to 250 μg once daily in patients who did not tolerate roflumilast 500 μg once daily, total PDE4 inhibition (tPDE4i) was  markedly  reduced  by  approximately  50%  to  below  that  typically  observed  in  patients  who tolerated 500 μg once daily, and this led to a smaller change in forced expiratory volume in the first second  (FEV1)  from  baseline.  Therefore,  administration  of  roflumilast  250  μg  once  daily  may  not induce  sufficient  phosphodiesterase  4  (PDE4)  inhibition  to  exert  clinical  efficacy.  This  is  further discussed in the efficacy section.

PK/PD models of incidence of adverse events (AEs) and time-to event models for discontinuation from the  study  were  also  developed.  Covariate  analyses  using  these  models  found  weighted  plasma exposure of roflumilast and its metabolite to be a significant predictor of AE incidence, and dose in the up-titration phase to be a significant predictor of discontinuations. The models were based on average concentrations and were unable to explain the differences in discontinuation rates between the two uptitration regimes (250 microg OD vs. 500 microg EOD), despite average concentrations were similar. Other  PK  characteristics  (e.g.  Cmax)  might  be  required  in  addition  to  characterize  the  PK/safety relationship. The sparse data used to build the population PK model did not allow a robust prediction of Cmax.  and therefore cannot analyze a potential relationship between Cmax and discontinuation rates. It was concluded that,  even  if  further  analyses  of  PK/safety  data  based  on  Cmax  were  possible,  these would not change the position regarding the benefit of introducing a starting dose of roflumilast 250 μg OD.

On  the  other  hand,  time  to  event  models  attempt  to  characterize  the  (discontinuation)  time (dependent variable) as a function of so called predictor or independent variables.

These data provided supporting evidence that starting roflumilast treatment with 250 μg once daily for 4 weeks followed by up-titration to the 500 μg once daily dose results in lower discontinuation rates and AEs of interest, compared to starting with roflumilast 500 μg once daily. This is applicable for the 12 week study period. No assumptions can be made beyond this period.

Nevertheless, in previous roflumilast clinical trials, Kaplan-Meier plots of time to onset of AEs show that the majority of events in the roflumilast treated-patients occur early, and that there is a plateau after 4 weeks. Therefore, the first 4 weeks of treatment represents the dosing period most relevant to the  aims  of  the  study  (ie,  to  improve  tolerability  of  roflumilast  through  use  of  alternative  dosing regimens).  After this time, there is no evidence to support a need for further improvements, as the frequency of AEs with roflumilast is not higher than with placebo, and the rate of withdrawals from study treatment are low.

## 2.8.5. Conclusions on clinical pharmacology

New  PK  data  generated  from  OPTIMIZE  in  almost  19.000  samples  from  1238  COPD  patients  are robust.  Results  from  the  new  population  PK  model  on  the  combined  REACT  and  OPTIMIZE  dataset identified no clinically relevant changes of systemic exposure levels in populations of particular interest (eg, elderly patients, female patients, or patients with high [&gt;80 kg] or low [&lt;60 kg] baseline body weight).  With respect to race, Asian patients tend to have a lower body weight than patients from Western countries.  Asian race was not a significant covariate in population PK analysis, whereas in subgroup  analyses  of  pivotal  studies  (Study M2-124  and  Study  M2-125),  the  effect  of  roflumilast versus placebo on the rate of moderate or severe exacerbations showed no heterogeneity depending

<div style=\"page-break-after: always\"></div>

on race.  Therefore, the approved maintenance dose of roflumilast 500 μg OD does not need to be adjusted in these populations.

With  respect  to  PK-PD  relationship,  three  types  of  analyses  were  performed  to  characterize  the relationship of systemic exposure of 3 roflumilast starting regimes (250 microg OD or 500 microg EOD for  4  weeks  followed  by  500  for  8  additional  weeks  versus  standard  regime  of  roflumilast  500 micrograms  OD  for  12  weeks)  with:  a)  post-BD  FEV1  observations  (PK/FEV1  models);  b)  the percentage  of  patients  with  at  least  one  AE  (PK/AE  models),  and  c)  the  time  to  treatment discontinuation due to AEs (PK/TTE models).

Results from the new population PK model and PK-PD model of pre-BD FEV1 also indicates that 250 micrograms roflumilast is associated to sub-therapeutic levels and therefore should not be used for maintenance treatment. The SmPC has been ammended accordingly in secctions 4.2 and 5.1 to warn against the use of the 250 microgram dose as maintenance dose. The applicant has been requested to discuss about what are considered therapeutic and subtherapeutic levels (e.g. levels of PDE4 inhibitory activity)  and  make  a  revised  proposal  to  include  these  levels  in  the  SmPC  for  the  250  microg (subtherapeutic) and 500 microg (therapeutic) (see LoI).

PK/PD models of incidence of adverse events (AEs) and time-to event models for discontinuation from the study were also developed. The models were based on average concentrations. Covariate analyses using  these  models  found  weighted  plasma  exposure  of  roflumilast  and  its  metabolite  to  be  a significant predictor of AE incidence, and dose in the up-titration phase to be a significant predictor of discontinuations.

## 2.9. Clinical efficacy

## 2.9.1. Dose-response studies and main clinical studies

This submission is based on data from a single study (Study RO 2455 302-RD [OPTIMIZE]) conducted to  fulfil  a  Committee  for  Medicinal  Products  for  Human  Use  (CHMP)  post-authorization  measure (FUM004) to explore alternative doses of roflumilast to minimise the risk of  drug interactions, poor tolerability, and the influence of factors such as gender, age, and smoking status on the bioavailability of the product in patients with chronic obstructive pulmonary disease (COPD).

The single pivotal OPTIMIZE study was a multicenter, randomized, double-blind, Phase III study that comprised  a  12-week  Main  Period,  including  an  initial  4-week  up-titration  regimen  to  assess  if alternative dosing strategies (roflumilast 250 μg once daily or 500 μg every other day) could minimise the risk of poor tolerability of the approved dose of 500 μg once daily (primary safety objective).

The primary endpoint was the percentage of patients prematurely discontinuing study treatment due to any reason during the Main Period (see Module 2.7.4). The study also included an 8-week DownTitration Period in patients not tolerating the approved dose of roflumilast 500 μg once daily during the Main Period, to assess if a lower maintenance dose of 250 μg once daily could be proposed to minimise the risk of poor tolerability (secondary safety objective).

## CLINICAL STUDY REPORT RO-2455-302-RD

Study  Title: A  Multicenter,  Randomized,  Double-Blind  Phase  3  Study  to  Evaluate  Tolerability  and Pharmacokinetics of 500 μg Roflumilast Once Daily With an Up-Titration Regimen in COPD, including an Open-Label Down-Titration Period Evaluating Tolerability and Pharmacokinetics of 250 μg Roflumilast Once Daily in Subjects Not Tolerating 500 μg Roflumilast Once-Daily.

## Methods:

Study  Sites: 161  ex-US  sites  in  15  countries  had  subjects  enrolled  in  the  double-blind  treatment period

<div style=\"page-break-after: always\"></div>

Study Periods: Double-blind  treatment  period  (4  weeks),  single-blind  treatment  period  (8  weeks), open-label Down-Titration Period (8 weeks), safety follow-up (30 days).

## Study Dates:

- Date first subject signed informed consent form: 30 April 2014.
- Date of last subject's last visit/contact (from the Clinical database): 21 October 2015.
- Date of last subject's last procedure for collection of data for primary endpoint: 18 September 2015

Study Duration: A maximum of 20 weeks plus a 30-day safety follow-up period.

## Methods

OPTIMIZE was a multicenter, randomized, double-blind, 3-arm, parallel group, phase 3 study with an open-label Down-Titration Period for subjects who withdrew from the Main Period of the study. During the Main Period, subjects were randomized receive 1 of the 3 treatments consisting of 2 up-titration treatment groups: 250 μg OD or 500 μg EOD for the first 4 weeks followed by 500 μg OD for 8 weeks, and the currently approved roflumilast regimen of 500 μg OD administered for 12 weeks.

During the Main Period, the first 4 weeks (up-titration) was double-blinded, and the following 8 weeks (maintenance  period)  was  single-blinded.  All  subjects  discontinuing  from  the  Main  Period  were permitted to enter an 8-week open-label Down-Titration Period where they received roflumilast 250 μg OD.

Spirometry  and  subject-assessed  treatment  satisfaction  for  efficacy  assessments  were  performed  at Screening (V0, Days -21 to -7), Randomization (V1, Day 1), and at Weeks 2, 4, 8, and 12 (Visits V2, V3, V4, and Vend) of the Main Period, and at Baseline (V0DT=Vend of Main Period) and at Weeks 2, 4 and 8 (Visits V1DT, V2DT and VendDT) of the Down-Titration Period. Six milliliter blood samples for PK analysis were drawn at Visits V2, V4, Vend/V0DT, V1DT, V2DT and VendDT.

Figure 6. Schematic of RO-2455-302-RD (OPTIMIZE) study design

<!-- image -->

D

day, DDT  day of the down-titration period, DT  down-titration, EOD  every other day, FU  safety follow-up phone

<div style=\"page-break-after: always\"></div>

call;  OD  once daily, R  randomisation, Rof  roflumilast, V  Visit, VDT  visit of the down-titration period, Vend  last visit.

## · Study participants

## Number of Subjects:

Planned: 1323 subjects planned for randomization

Enrolled in the Main Period: 1323 subjects

Enrolled  in  Down-Titration  Period:  104  subjects  including  80  subjects  who  withdrew  from  the  Main Period while receiving roflumilast 500 μg OD (the analysis of main interest for Down-Titration Period).

## Analyzed:

Safety analysis set (SAS) for Main Period: 1321 subjects,

Full analysis set (FAS): 1323 subjects,

SAS for Down-Titration Period: 104 subjects including 80 subjects who withdrew from the Main Period while receiving roflumilast 500 μg OD (the analysis of main interest for Down-Titration Period);

Valid case set (VCS) for Main Period: 1156 subjects, PK set: 1238 subjects.

## Diagnosis and Main Criteria for Inclusion:

This study included patients aged ≥40 years with a history of chronic obstructive pulmonary disease (COPD) (at least 12 months prior to Screening Visit [V0] with post-bronchodilator forced expiratory volume in the first second [FEV1]/forced vital capacity [FVC] ratio &lt;70% and FEV1 ≤50% of predicted) associated  with  chronic  productive  cough  (for  3  months  in  each  of  the  2  years  prior  to  V0)  and  a history of exacerbations (at least 1 documented COPD exacerbations within 1 year prior to V0), and were concomitantly treated with a fixed combination of long-acting β2-agonist and inhaled corticosteroid. Patients also were former or current smokers.

## Exclusion criteria:

## a) Criteria affecting the read-out parameters of the study:

1. The subject had a COPD exacerbation ongoing at Screening (Visit V0), or has a COPD exacerbation between V0 and V1.

2. The subject had a lower respiratory tract infection not resolved 4 weeks prior to Screening (Visit V0).
3. The subject had a diagnosis of asthma and/or other relevant lung disease (eg, history of primary bronchiectases, cystic fibrosis, bronchiolitis, lung resection, lung cancer, interstitial lung disease [eg, fibrosis, silicosis, sarcoidosis], or active tuberculosis).
4. The subject had a known α1-antitrypsin deficiency.
5. The subject had taken roflumilast within 6 months of Screening (Visit V0).

## b) Criteria within ethical considerations in terms of general health:

6. The subject had clinically relevant abnormal laboratory values suggesting an undiagnosed disease requiring further clinical evaluation (as assessed by the investigator).

7. The subject had a history of severe psychiatric or neurological disorders.

## · Treatments

During the Main Period, subjects were randomized receive 1 of the 3 treatments consisting of 2 uptitration treatment groups: 250 μg OD or 500 μg EOD for the first 4 weeks followed by 500 μg OD for 8 weeks, and the currently approved roflumilast regimen of 500 μg OD administered for 12 weeks. All subjects  discontinuing  from  the  Main  Period  were  permitted  to  enter  an  8-week  open-label  DownTitration Period where they received roflumilast 250 μg OD.

<div style=\"page-break-after: always\"></div>

## Table 6. Study treatments in OPTIMIZE clinical trial.

TestProduct,Dose and Mode of Administration,and Lot Nunber:

| Study Medication   | Product Dose Strength and Form   | Study Dosage   | Mode of Administration   | DrugProduct Lot Number   |
|--------------------|----------------------------------|----------------|--------------------------|--------------------------|
| Roflumilast        | 250 μg, tablet                   | 250 μg OD      | Oral                     | 10883205and11056250      |
| Roflumilast        | 500 μg, tablet                   | 500 μg OD      | Oral                     | 10883213and11056242      |
| Roflumilast        | 500 μg, tablet                   | 500 μg EOD     | Oral                     | 10883213and11056242      |

Reference Therapy, Dose and Mode of Administration, and Lot Number:

| Study Medication   | Product Dose Strength   | Study Dosage   | Mode of Administration   | Drug Product Lot Number   |
|--------------------|-------------------------|----------------|--------------------------|---------------------------|
| Placebo            | O μg, tablet            | 0 μg EOD       |                          | 10883221 and 11056253     |

## · Objectives

## Primary:

- To  evaluate  discontinuation  rates  of  roflumilast  500  μg  once  daily  (OD)  using  an  up-titration regimen with either 250 μg OD or 500 μg every other day (EOD) for the first 4 weeks of treatment followed by 500 μg OD for 8 weeks compared with continuous treatment of 500 μg OD during the entire 12-week Main Period.
- To evaluate if subjects who do not tolerate roflumilast 500 μg OD have a drug exposure with 250 μg roflumilast OD similar to that observed in other subjects with the 500 μg OD dose.

## Secondary:

- To evaluate the gastrointestinal tolerability of roflumilast 500 μg OD with an up-titration regimen compared with continuous treatment of 500 μg OD.
- To evaluate the safety, discontinuations and tolerability especially the gastrointestinal tolerability of roflumilast 250 μg OD in subjects not tolerating the 500 μg OD dose.
- To  evaluate  the  safety  of  roflumilast  500  μg  OD  with  an  up-titration  regimen  compared  with continuous treatment of 500 μg OD.
- To evaluate the efficacy of roflumilast 500 μg OD with an up-titration regimen on lung function compared with continuous treatment of 500 μg OD.
- To  characterize  the  efficacy  of  roflumilast  250  μg  OD  on  pulmonary  function  during  a  DownTitration Period, in subjects who do not tolerate roflumilast 500 μg OD.
- To evaluate subject-assessed treatment satisfaction with an up-titration regimen compared with continuous treatment of roflumilast 500 μg OD.
- To characterize subject-assessed treatment satisfaction of roflumilast 250 μg OD during a DownTitration Period, in subjects who do not tolerate roflumilast 500 μg OD.
- To  characterize  the  pharmacokinetics  (PK)  of  roflumilast  and  roflumilast  N-oxide  with  an  uptitration regimen.
- To  characterize  the  PK  of  roflumilast  and  roflumilast  N-oxide  with  roflumilast  250  μg  OD  in subjects not tolerating the 500 μg OD dose.
- To characterize the PK/pharmacodynamic (PD) relation with respect to relevant safety and efficacy parameters

## · Outcomes/endpoints

## Primary Endpoint

- The primary endpoint was the percentage of subjects prematurely discontinuing study treatment due to any reason (during Main Period, [Visit V1 to Vend]).

Key Secondary Endpoints

<div style=\"page-break-after: always\"></div>

- Percentage of subjects with adverse events (AEs) of interest to evaluate tolerability during Main Period (V1 to Vend). For the purposes of safety analysis, the treatment-emergent adverse events (TEAEs) of interest were defined as diarrhea, nausea, headache, decreased  appetite, insomnia, and abdominal pain.
- Change in prebronchodilator FEV1 during Down-Titration Period (V0DT to VendDT).
- Percentage  of  subjects  prematurely  discontinuing  study  treatment  due  to  any  reason  during Down-Titration Period (V0DT to VendDT).

Other secondary endpoints were:

- Change in prebronchodilator FEV1 from V1 to V2, V3, V4, and Vend (during Main Period of the study) and also from V1 to VendDT (including Down-Titration Period).
- Change in prebronchodilator  FVC  from  V1  to  V2,  V3,  V4,  and  Vend  (during  Main  Period  of  the study) and also from V0DT to VendDT and V1 to VendDT (including Down-Titration Period).

•

- Change in subject-assessed treatment satisfaction scores from V1 to V2, V3, V4, and Vend (during Main  Period  of  the  study)  and  also  from  V0DT  to  VendDT  and  V1  to  VendDT  (including  DownTitration Period).

Pharmacokinetic secondary endpoints:

- PK profiles of roflumilast and roflumilast N-oxide.
- Individual  and  population  PK  parameters  for  roflumilast  and  roflumilast  N-oxide  (the  active metabolite)  and  total  phosphodiesterase  4  (PDE4)  inhibitory  activity  (tPDE4i)  of  both  active moieties including covariate effects on these parameters (where 'tPDE4i' activity includes the PDE inhibitory activity of roflumilast itself as well as roflumilast N-oxide).
- Relationship  between  PK  and  relevant  safety  (AEs  of  interest  [extended  list]  to  evaluate tolerability,  ie,  diarrhea,  nausea,  headache,  decreased  appetite,  insomnia,  abdominal  pain, vomiting, angioedema, anxiety,and weight loss) and efficacy (FEV1) parameters.

Safety:

- Safety  was  assessed  by  evaluation  of  AEs,  changes  in  laboratory  values,  vital  signs,  physical examination  findings,  body  weight  and  body  mass  index  (BMI),  as  well  as  changes  on  the Columbia Suicide Severity Rating Scale (C-SSRS).

## · Sample size

The sample size for the Main Period was based on the primary endpoint of the percentage of subjects discontinuing study treatment due to any reason, during the Main Period of the study, up to Week 12. Discontinuation rates for the sample size calculation were estimated from data of the roflumilast COPD pivotal  studies  pool  (M2-124  and  M2-125),  which  included  a  very  similar  subject  population  as  the OPTIMIZE study. The discontinuation rates after the initial 12 weeks of treatment were used to reflect the treatment duration of the OPTIMIZE study (total treatment duration of the pivotal studies was 1 year).

With these assumptions, Kaplan-Meier estimates revealed discontinuation rates of 20% with roflumilast and 13% with placebo.

Based on these data, a total of 441 subjects per treatment arm, 1323 overall, will provide 80% power to declare superiority of each of:

- Roflumilast 250 μg OD/500 μg OD vs. reference.
- Roflumilast 500 μg EOD/500 μg OD vs. reference.

Where the reference is  defined  as  roflumilast  500  μg  OD  for  12  weeks.  It  refers  to  a  2-group  chisquare test of equal proportions (OR =1), assuming discontinuation rates of 13% on each of the uptitration arms and 20% on the reference arm, and a 2-sided significance level of 5.0% using a closed testing  procedure  with  hierarchical  evaluation  (roflumilast  250  μg  OD/500  μg  OD  being  tested  first followed by roflumilast 500 μg EOD/500 μg OD).

The expected sample size for the Down-Titration Period was based on the above assumption that 13% to  20% of subjects prematurely discontinue roflumilast treatment. Including about 1323 subjects in the Main Period will thus lead to approximately 150 subjects in the Down-Titration Period assuming that  75%  of  subjects  who  discontinue  from  the  Main  Period  will  continue  into  the  Down-Titration Period.

<div style=\"page-break-after: always\"></div>

## · Randomisation

In this  study, a 1:1:1 randomization was employed. Eligible subjects were randomized by means of interactive voice response system/interactive web response system (IVRS/IWRS). At each dispensing visit, the system assigned an appropriate investigational medicinal product (IMP) kit(s) from the stock available at the study center for each subject.

## · Blinding (masking)

The first 4 weeks of the main treatment period was double-blind. The following 8 weeks of the main treatment period was single-blinded with the sponsor and investigators aware that all subjects were receiving  roflumilast  500  μg  OD.  All  subjects  discontinuing  from  the  main  treatment  period  were permitted to enter an 8-week, Down-Titration Period where subjects received open-label roflumilast 250 μg OD. In all cases, the original randomized treatment regimen remained blinded to all parties for the duration of the study.

Roflumilast 250 μg and 500 μg tablets as well as the placebo tablets were identical in appearance, shape  and  color,  and  had  identical  labeling  and  packaging.  The  investigational  drug  blind  was maintained  using  the  IVRS/IWRS,  and  was  not  to  be  broken  unless  information  concerning  the investigational drug was necessary for the medical treatment of a subject, or in the event of a medical emergency (Section 8.5 of the protocol).

## · Statistical methods

In this study, all confirmatory decisions were taken to assess superiority. For this purpose, the primary and key secondary endpoints in safety were based on the SAS, where as the key secondary endpoint in efficacy was based on the FAS (Intention-to-treat analysis). To analyze robustness of results, analyses based  on  the  VCS  (Per-protocol  analysis)  was  generally  performed  in  addition  and  interpreted  as supportive analysis.

For hypothesis testing, a hierarchical testing procedure was prespecified to control the overall type I error rate of 5% for the primary and key secondary endpoints as described in above is as follows: The null hypotheses to be tested in a fixed order at the 2-sided 0.05 significance level were:

- H01: the percentage of discontinuations by Week 12 on roflumilast 250 μg OD/500 μg OD was not lower than or equal to that on roflumilast 500 μg OD.
- H02: the percentage of discontinuations by Week 12 on roflumilast 500 μg EOD/500 μg OD was not lower than or equal to that on roflumilast 500 μg OD.
- H03: the percentage of AEs of interest by Week 12 on roflumilast 250 μg/500 μg OD was not lower than or equal to that on roflumilast 500 μg OD.
- H04: the percentage of AEs of interest by Week 12 on roflumilast 500 μg EOD/500 μg OD was not lower than or equal to that on roflumilast 500 μg OD.
- In  addition,  the  change  from  Baseline  (V0DT)  in  pre-bronchodilator  FEV1  during  the open-label down-titration period was estimated.

The  above  testing  procedure  controlled  the  5%  error  rate;  each  subsequent  hypothesis  would  be tested for confirmatory basis only if all previously tested hypotheses had been rejected. As a result, the  principle  of  closed  testing  implied  that  the  overall  2-sided  false-rejection  rate  of  the  study  was maintained at 5%. If any test could not be performed on a confirmatory basis, because a previous test had failed, the test was performed in an exploratory manner.

For statistical interpretation, the default significance level was 5%, CIs for point estimates were 95% and all tests were interpreted as 2-sided.

The  analyses  of  'main  interest'  for  the  Down-Titration  Period  were  those  conducted  in  only  those subjects who were taking roflumilast 500 μg OD during the Main Period at the time of discontinuation (thus excluding subjects who discontinued whilst taking roflumilast 250 μg OD or 500 μg EOD during the Main Period for the Down-Titration Period).

## Safety:

<div style=\"page-break-after: always\"></div>

The  primary  endpoint  (percentage  of  subjects  prematurely  discontinuing  study  treatment  for  any reason during the Main Period from V1 to Vend) was analyzed using a logistic regression model, with study  treatment,  country  and  baseline  FEV1  as  explanatory  variables.  Superiority  analyses  were performed using a hierarchical testing procedure.

Comparisons were made at the 2-sided 5% significance level.  As  a  supportive  analysis,  the  hazard ratio for each up-titration arm compared with the roflumilast 500 μg OD arm and the associated 95% CI were estimated using a Cox proportional hazards model with study treatment and country as class effects and baseline FEV1 as a continuous covariate. Subjects who did not discontinue study treatment during the Main Period were censored at Vend (final visit of Main Period). A sensitivity analysis was performed for the primary and key secondary endpoints.

The  percentage  of  subjects  with  AEs  of  interest  (diarrhea,  nausea,  headache,  decreased  appetite, insomnia,  and  abdominal  pain)  was  analyzed  using  a  logistic  regression  analysis  as  part  of  the hierarchical  approach  as  described  for  the  primary  safety  endpoint.  Time  to  onset,  duration  and intensity of AEs of interest to evaluate tolerability was summarized descriptively. Descriptive statistics were  used  to  analyze  the  endpoint  of  percentage  of  subjects  prematurely  discontinuing  study treatment due to any reason (from V0DT to VendDT).

Analyses of AEs, clinical laboratory values, vital signs, body weight and BMI, as well as C-SSRS were performed descriptively.

## Efficacy:

The key secondary endpoint (change in pre-bronchodilator FEV1 from V0DT to VendDT) was assessed with an analysis of variance (ANCOVA) model using the last observation carried forward (LOCF) value, as described by Ebutt and Frith. The robustness of the primary method for the key-secondary endpoint was assessed using another ANCOVA model for repeated measurements, as described by Verbeke and Molenberghs. These analyses were repeated for change in pre-bronchodilator FEV1 from Baseline (V1) to  the  end  of  the  Main  Period  (Vend),  as  well  as  for  the  endpoints  of  change  from  Baseline  in  prebronchodilator FVC and subject-assessed treatment satisfaction.

Also,  as  a  sensitivity  analysis,  change  in  pre-bronchodilator  FEV1  from  baseline  (V0DT)  to  the  last scheduled  post-randomization  visit  was  analyzed  with  a  pattern  mixture  model  implemented  by multiple imputation replacing LOCF in accounting for missing data.

## · Changes in study conduct or in the planned analyses

There was 1 protocol amendment: Protocol Amendment 1 with the following changes:

- All procedures outlined in the Vend visit were to be performed at V0DT for subjects continuing into the open-label Down-Titration Period of the study.
- Clarified that the 'Liver Function Test Abnormalities' were not be a separate subject discontinuation/withdrawal category.
- Clarified  that  an  additional  dose  of  study  drug  was  not  to  be  provided  at  Vend  for  subjects discontinuing prematurely from the Main Period without continuing into the Down-Titration Period, and that only 1 PK sample was to be taken at this visit.

## Results

## · Participant flow

The disposition of randomized subjects is summarized in Table 9. Of the 1323 subjects who went on to be randomized, 2 subjects (0.2%) were never treated. In total, 1043 subjects (79%) completed the Main  Period.  Of  the  278  subjects  (21.0%)  who  discontinued  during  the  Main  Period,  146  subjects (11.1%) discontinued during the first 4 weeks of the Main Period (up to Visit 3).

A total of 104 subjects (7.9%) who withdrew from the Main Period entered the Down-Titration Period (where they received roflumilast 250 μg OD). Approximately one-quarter of these subjects went on to discontinue from this Down-Titration Period, with the most common reason for discontinuation from this  period  due  to  an  AE.  Of  the  104  subjects  who  entered  the  Down-Titration  Period,  80  subjects

<div style=\"page-break-after: always\"></div>

(comprising of 20, 22 and 38 subjects from the 250 μg OD/500 μg OD, 500 μg EOD/500 μg OD, and 500 μg OD treatment groups, respectively) entered after not tolerating at least 1 dose of roflumilast 500 μg OD during the Main Period. The remaining 24 subjects (104-80=24) who entered the Down Titration Period did not receive roflumilast 500 μg OD in the Main Period but received either 250 μg OD or 500 μg EOD, during the first 4 weeks of low dose roflumilast.

Table 7. Disposition of Subjects (All Randomized Subjects)

|                                                              | Roflumilast 250 μg OD/ 500 μg OD (N=441)   | Roflumilast 500 μgEOD/ 500 g OD (N=439)   | Roflumilast 500 μg OD (N=443)   | Total (N=1323)         |
|--------------------------------------------------------------|--------------------------------------------|-------------------------------------------|---------------------------------|------------------------|
|                                                              | Number of Subjects (%)                     | Number of Subjects (%)                    | Number of Subjects (%)          | Number of Subjects (%) |
| Randomizedand treated                                        | 441 (100.0)                                | 437 (99.5)                                | 443 (100.0)                     | 1321 (99.8)            |
| Randomized but not treated                                   | 0                                          | 2 (0.5)                                   | 0                               | 2 (0.2)                |
| Completed study drug (a)(c)(d)                               | 360 (81.6)                                 | 349 (79.9)                                | 334 (75.4)                      | 1043 (79.0)            |
| Prematurely discontinued study drug (b)(c)(d)                | 82 (18.6)                                  | 88 (20.1)                                 | 109 (24.6)                      | 279 (21.1)             |
| SubjectsintheSASforMainPeriod                                | 441 (100.0)                                | 437 (99.5)                                | 443 (100.0)                     | 1321 (99.8)            |
| Subjects discontinuing Main Period (c)                       | 81 (18.4)                                  | 88 (20.1)                                 | 109 (24.6)                      | 278 (21.0)             |
| Discontinued during first 4 weeks of Main Period (V1-V3) (c) | 34 (7.7)                                   | 42 (9.6)                                  | 70 (15.8)                       | 146 (11.1)             |
| Reason for Main Period discontinuation (e)                   |                                            |                                           |                                 |                        |
| PTE/AE                                                       | 44 (54.3)                                  | 57 (64.8)                                 | 68 (62.4)                       | 169 (60.8)             |
| Major/significant protocol deviation                         | 0                                          | 1(1.1)                                    | 3 (2.8)                         | 4 (1.4)                |
| Lost to follow-up                                            | 4 (4.9)                                    | 2 (2.3)                                   | 1 (0.9)                         | 7 (2.5)                |
| Voluntary withdrawal                                         | 23 (28.4)                                  | 23 (26.1)                                 | 21 (19.3)                       | 67 (24.1)              |
| Study termination                                            | 0                                          | 0                                         | 0                               | 0                      |
| Pregnancy                                                    | 0                                          | 0                                         | 0                               | 0                      |
| Lack of efficacy                                             | 2 (2.5)                                    | 0                                         | 0                               | 2 (0.7)                |
| Other                                                        | 8 (9.9)                                    | 5 (5.7)                                   | 16 (14.7)                       | 29 (10.4)              |
| Subjects in theSAS forDown-TitrationPeriod (c)               | 27 (6.1)                                   | 39 (8.9)                                  | 38 (8.0)                        | 104 (7.9)              |
| Subjects discontinuing Down-Titration Period (e)             | 7 (25.9)                                   | 11 (28.2)                                 | 7 (18.4)                        | 25 (24.0)              |
| Reason for Down-TitrationPeriod discontinuation (f) AE       | 4 (57.1)                                   | 10 (90.9)                                 | 3 (42.9)                        | 17 (68.0)              |
| Major/significant protocol deviation                         | 0                                          | 0                                         | 0                               | 0                      |
| Lost to follow-up                                            | 0                                          | 0                                         | 0                               | 0                      |
| Voluntary withdrawal                                         | 2 (28.6)                                   | 1 (9.1)                                   | 2 (28.6)                        | 5 (20.0)               |
| Study termination                                            | 0                                          | 0                                         | 0                               | 0                      |
| Pregnancy                                                    | 0                                          | 0                                         | 0                               | 0                      |
| Lack of efficacy                                             | 0                                          | 0                                         | 0                               | 0                      |
| Other                                                        | 1 (14.3)                                   | 0                                         | 2 (28.6)                        | 3 (12.0)               |

Source:Table 15.1.5.

(a) Subjects are defined as having completed study drug if they did not discontinue from the Main Period.

(b) Subjects are defined as having prematurely discontinued study drug if they discontinued from either the Main Period or the Down-Titration Period.

(c) Percentages are based on SAS for the Main Period.

(d) One subject who completed the Main Period and therefore was not eligible to enter the Down-Titration Period was mistakenly enrolled in this period. This subject was then prematurely discontinued from the Down-TitrationPeriod, and is thus counted as having completed and discontinued study drug.

(e) Percentages are based on SAS for the Down-Titration Period

(f). Percentages for reason for discontinuation of study drug are based on the total number of subjects who prematurely discontinued the study drug during the associated period.

## · Recruitment and study conduct

In total, 1585 subjects were screened, of which 1323 subjects (83.5%) from 161 sites in 15 countries were eligible for randomization and included in the FAS. The most common reason for exclusion was not meeting inclusion criteria (in 162 of 262 subjects [61.8%]).

<div style=\"page-break-after: always\"></div>

Subjects were randomized into the double-blind main treatment period at a total of 161 sites in 15 countries:  Bulgaria  (11  sites),  Germany  (9),  Greece  (5),  Hungary  (21),  Republic  of  Korea  (9), Philippines (4), Poland (15), Romania (19), Russia (17), Slovakia (12), South Africa (14), Spain (2), Thailand (3), Ukraine (14), and United Kingdom (6).

For statistical analyses, countries were divided into 4 regions as follows: Western Europe (Germany, Spain,  United  Kingdom),  North-Eastern  Europe  (Poland,  Russia,  Ukraine),  South-Eastern  Europe (Bulgaria, Greece, Hungary, Romania, Slovakia), and Non-European (South Korea, Philippines, South Africa, Thailand).

During the study, persistent noncompliance was noted at site 6002, which was based in South Africa. Following  routine  monitoring  of  the  site  a  number  of  significant  noncompliance  issues  were  noted including inadequate source documentation confirming the eligibility of 3 subjects, a subinvestigator who was not a listed delegate obtaining informed consent, and the incorrect storing of PK samples. Study recruitment at the site was paused while corrective action, including the retraining of staff was undertaken. The recruitment hold was subsequently lifted, and the site was permitted to recruit one subject. Three days later, the site monitor reported persistent noncompliance at the site, resulting in Takeda conducting an audit at the study site. At the time of the investigation, the site had screened 5 subjects; 1 subject was a screen failure, and 4 subjects had completed the study. The audit was rated as  'unsatisfactory'  due  to  significant  noncompliance  issues,  and  the  site  was  closed  from  further participation in the study protocol.

The noncompliance issues/site closure had been reported to the Ethics Committee and the Regulatory Authority  (Medicines  Control  Council)  of  South  Africa.  At  the  time  of  the  investigation,  the  site  had screened 5 subjects; 1 subject was a screen failure, and 4 subjects had completed the study. Although subject data was included in the primary intention-to-treat (ITT) analysis, to account for any impact on data integrity, a sensitivity analysis excluding subject data from South African Site 6002, which was suspected of scientific misconduct, was carried out.

## · Baseline data

## Main Period

Demographic and baseline characteristics  are  summarized  in  Table  10  for  the  Main  Period.  Overall, demographic characteristics were similar across the 3 treatment groups. The majority of subjects in each  treatment  group  were  White  (405  subjects  [91.8%]  in  the  roflumilast  250  μg  OD/500  μg  OD group,  399  subjects  [91.3%]  in  the  roflumilast  500  μg  EOD/500  μg  OD  group  and  405  subjects [91.4%] in the roflumilast 500 μg OD group). The mean (SD) age of subjects was 64.2 (7.81), 65.0 (8.21), and 64.6 (8.36) years in the roflumilast 250 μg OD/500 μg OD, 500 μg EOD/500 μg OD, and 500  μg  OD  groups,  respectively.  The  250  μg  OD/  500  μg  OD  dose  group  was  comprised  of  more subjects aged 40 to 64 years (54.9% of subjects) than the other 2 dose groups (46.2% and 50.6% for 500 μg EOD/ 500 μg OD and 500 μg OD, respectively). The majority of subjects in each treatment group  were  male  (72.6%  in  roflumilast  250  μg  OD/500  μg  OD  group,74.4%  in  roflumilast  500  μg EOD/500 μg OD group, and 76.3% in roflumilast 500 μg OD group).

## Table 8. Demographic and Baseline Characteristics (SAS, Main Period)

<div style=\"page-break-after: always\"></div>

|                              |                                       | Roflumilast 250μg OD/ 500 μg OD (N=441)                                    | Roflumilast 500μgEOD/ 500 μg OD (N=437)   | Roflumilast 500 μg OD (N=443)   | Total (N=1321)      |
|------------------------------|---------------------------------------|----------------------------------------------------------------------------|-------------------------------------------|---------------------------------|---------------------|
| Age (years)                  | Mean (SD)                             | 64.2 (7.81)                                                                | 65.0 (8.21)                               | 64.6 (8.36)                     | 64.6 (8.13)         |
| Age (years)                  | Median (min, max)                     | 64.0 (43, 84)                                                              | 65.0 (40, 83)                             | 64.0 (40, 90)                   | 64.0 (40, 90)       |
| Age group, n (%) 40-64 years |                                       | 242 (54.9)                                                                 | 202 (46.2)                                | 224 (50.6)                      | 668 (50.6)          |
| Age group, n (%) 40-64 years | 65-84 years                           | 199 (45.1)                                                                 | 235 (53.8)                                | 217 (49.0)                      | 651 (49.3)          |
| Age group, n (%) 40-64 years | ≥85 years                             | 0                                                                          | 0                                         | 2 (0.5)                         | 2 (0.2)             |
| Sex, n (%)                   | Male                                  | 320 (72.6)                                                                 | 325 (74.4)                                | 338 (76.3)                      | 983 (74.4)          |
| Sex, n (%)                   | Female                                | 121 (27.4)                                                                 | 112 (25.6)                                | 105 (23.7)                      | 338 (25.6)          |
| Ethnicity, n (%)             | Hispanic or Latino                    | 1 (0.2)                                                                    | 2 (0.5)                                   | 5 (1.1)                         | 8 (0.6)             |
| Ethnicity, n (%)             | Not Hispanic and Latino               | 428 (97.1)                                                                 | 423 (96.8)                                | 426 (96.2)                      | 1277 (96.7)         |
| Ethnicity, n (%)             | Missing                               | 12 (2.7)                                                                   | 12 (2.7)                                  | 12 (2.7)                        | 36 (2.7)            |
| Race, n (%)                  | American Indian or Alaskan Native     | 0                                                                          | 1 (0.2)                                   | 0                               | 1 (0.1)             |
| Race, n (%)                  | Asian                                 | 32 (7.3)                                                                   | 30 (6.9)                                  | 32 (7.2)                        | 94 (7.1)            |
| Race, n (%)                  | Black or African American             | 3 (0.7)                                                                    | 3 (0.7)                                   | 3 (0.7)                         | 9 (0.7)             |
| Race, n (%)                  | NativeHawaiian/Other Pacific Islander | 1 (0.2)                                                                    | 4 (0.9)                                   | 3 (0.7)                         | 8 (0.6)             |
| Race, n (%)                  | White                                 | 405 (91.8)                                                                 | 399 (91.3)                                | 405 (91.4)                      | 1209 (91.5)         |
| Height (cm)                  | Mean (SD)                             | 169.1 (8.73)                                                               | 168.8 (8.66)                              | 169.1 (8.55)                    | 169.0 (8.64)        |
| Height (cm)                  | Median (min, max)                     | 170.0 (140, 198)                                                           | 170.0 (146, 194)                          | 170.0 (120, 191)                | 170.0 (120, 198)    |
| Weight (kg)                  | Mean (SD)                             | 75.68 (18.686)                                                             | 74.40 (17.804)                            | 75.74 (16.900)                  | 75.28 (17.808)      |
| Weight (kg)                  | Median (min, max)                     | 74.00 (38.0, 160.0)                                                        | 74.00 (33.5, 134.0)                       | 74.00 (38.9, 131.0)             | 74.00 (33.5, 160.0) |
| BMI (kg/m²) (a)              | Mean (SD)                             | 26.39 (5.987)                                                              | 26.01 (5.618)                             | 26.46 (5.880)                   | 26.29 (5.830)       |
| BMI (kg/m²) (a)              | Median (min, max)                     | 25.30 (13.6, 58.8) 25.70 (14.1, 49.7) 25.90 (14.9, 83.8)25.60 (13.6, 83.8) |                                           |                                 |                     |

Source:Table 15.1.8.1.

(a) Subject with a BMI of 83.5 kg/m² had a baseline weight of 120 kg and height of 120 cm.

Baseline is the assessment taken on the reference start date (Randomization Visit V1 for the Main Period and final visit of Main Period Vead/Vopr for the Down-Titration Period) or the last assessment taken prior to the start of study dnug intake in the study period.

Other baseline characteristics are summarized in Table 11 for the Main Period. With the exception of 3 subjects whose information is missing, all subjects had a history of COPD exacerbation, although the majority  of  subjects  had  experienced  ≤2  episodes  within  the  1  year  prior  to  Screening.  A  small proportion of subjects (6.5%-6.9% across the 3 treatment groups) had previously received roflumilast treatment,  though  none  of  these  had  stopped  due  to  intolerability.  Baseline  lung  function  results (FEV1, FVC, FEV1/FVC, and %FEV1 reversibility) were broadly similar across the 3 treatment groups.

Table 9. Other Baseline Characteristics (SAS, Main Period)

<div style=\"page-break-after: always\"></div>

|                                      |                                              | Roflumilast 250 μg OD/ 500 μg OD (N=441)   | Roflumilast 500 μg EOD/500 μg OD (N=437)   | Roflumilast 500 μg OD (N=443)         | Total (N=1321)    |
|--------------------------------------|----------------------------------------------|--------------------------------------------|--------------------------------------------|---------------------------------------|-------------------|
| Smoking                              | Never smoked                                 | 0                                          | 0                                          | 0                                     | 0                 |
| classification, n (%)                | Current smoker                               | 213 (48.3)                                 | 198 (45.3)                                 | 196 (44.2)                            | 607 (46.0)        |
| classification, n (%)                | Ex smoker                                    | 228 (51.7)                                 | 239 (54.7)                                 | 247 (55.8)                            | 714 (54.0)        |
| Cigarette pack years                 | Mean (SD)                                    | 38.1 (17.49)                               | 40.2 (19.22)                               | 37.6 (17.70)                          | 38.6 (18.17)      |
| (amount) (a)                         | Median (min, max)                            | 37.0 (10, 113)                             | 39.0 (10, 160)                             | 35.0 (10, 142)                        | 37.0 (10, 160)    |
|                                      | Interpretation of chest Within normal limits | 188 (42.6)                                 | 176 (40.3)                                 | 185 (41.8)                            | 549 (41.6)        |
| x-ray, n (%)                         | Abnormal, not clinically significant         | 223 (50.6)                                 | 230 (52.6)                                 | 236 (53.3)                            | 689 (52.2)        |
| x-ray, n (%)                         | Abnormal, clinically significant             | 8 (1.8)                                    | 6 (1.4)                                    | 5 (1.1)                               | 19 (1.4)          |
| x-ray, n (%)                         | Not done                                     | 21 (4.8)                                   | 25 (5.7)                                   | 17 (3.8)                              | 63 (4.8)          |
| x-ray, n (%)                         | Missing                                      | 1 (0.2)                                    | 0                                          | 0                                     | 1 (0.1)           |
| COPD exacerbation history, n (%)     | Yes                                          | 441 (100.0)                                | 436 (99.8)                                 | 441 (99.5)                            | 1318 (99.8)       |
| COPD exacerbation history, n (%)     | No                                           | 0                                          | 0                                          | 0                                     | 0                 |
| COPD exacerbation history, n (%)     | Missing                                      | 0                                          | 1 (0.2)                                    | 2 (0.5)                               | 3 (0.2)           |
| >2 exacerbation episodes, n (%)      | Yes                                          | 6 (1.4)                                    | 9 (2.1)                                    | 9 (2.0)                               | 24 (1.8)          |
| >2 exacerbation episodes, n (%)      | No                                           | 435 (98.6)                                 | 427 (97.7)                                 | 432 (97.5)                            | 1294 (98.0)       |
| Previous roflumilast                 | Yes                                          | 29 (6.6)                                   | 30 (6.9)                                   | 29 (6.5)                              | 88 (6.7)          |
| treatment, n (%)                     | No                                           | 411 (93.2)                                 | 407 (93.1)                                 | 414 (93.5)                            | 1232 (93.3)       |
| treatment, n (%)                     | Missing                                      | 1 (0.2)                                    | 0                                          | 0                                     | 1 (0.1)           |
| Stopped due to intolerability, n (%) | Yes                                          | 0                                          | 0                                          | 0                                     | 0                 |
| Stopped due to intolerability, n (%) | No                                           | 440 (99.8)                                 | 437 (100.0)                                | 443 (100.0)                           | 1320 (99.9)       |
| Stopped due to intolerability, n (%) | Missing                                      | 1 (0.2)                                    | 0                                          | 0                                     | 1 (0.1)           |
| Prebronchodilator FEV1. (L)          | n                                            | 440                                        | 436                                        | 443                                   | 1319              |
| Prebronchodilator FEV1. (L)          | Mean (SD)                                    | 1.022 (0.3177)                             | 1.028 (0.3173)                             | 1.018 (0.3289)                        | 1.023 (0.3211)    |
| Prebronchodilator FEV1. (L)          | Median (min, max)                            | 0.980 (0.32, 2.27)                         | 1.000 (0.28, 1.90)                         | 0.990 (0.26, 1.98) 0.990 (0.26, 2.27) |                   |
| Predicted FEV (%) (b)                | n                                            | 440                                        | 436                                        | 443                                   | 1319              |
| Predicted FEV (%) (b)                | Mean (SD)                                    | 35.94 (8.823)                              | 36.66 (8.803)                              | 36.03 (9.533)                         | 36.21 (9.060)     |
| Predicted FEV (%) (b)                | Median (min, max)                            | 36.45 (10.0, 69.0)                         | 37.55 (10.3, 75.9)                         | 37.00 (3.3, 75.3)                     | 37.00 (3.3, 75.9) |
| Prebronchodilator FVC (L)            | n                                            | 440                                        | 436                                        | 443                                   | 1319              |
| Prebronchodilator FVC (L)            | Mean (SD)                                    | 2.304 (0.7418)                             | 2.303 (0.7091)                             | 2.314 (0.6822)                        | 2.307 (0.7109)    |
| Prebronchodilator FVC (L)            | Median (min, max)                            | 2.210 (0.65, 4.76)                         |                                            |                                       |                   |
| Postbronchodilator FEV/FVC ratio     |                                              | 438                                        | 433                                        | 440                                   | 1311              |
| Postbronchodilator FEV/FVC ratio     | Mean (SD)                                    | 0.460 (0.1362)                             | 0.465 (0.1078)                             | 0.456 (0.1096)                        | 0.460 (0.1186)    |
| (derived) % FEV reversibility        | Median (min, max) 11                         | 0.450 (0.17, 2.26) 440                     | 436                                        | 443                                   | 1319              |
| (derived) % FEV reversibility        | Mean (SD)                                    | 7.108 (12.0016)                            | 6.452 (14.4437)                            | 7.390 (11.4071)                       | 6.986 (12.6737)   |
| (derived) % FEV reversibility        | Median (min, max)                            | 5.485 (-27.27,                             | 4.310 (-28.05,                             | 5.380 (-24.14,                        | 5.130 (-28.05,    |
| (derived) % FEV reversibility        |                                              | 90.59)                                     | 147.06)                                    | 59.55)                                | 147.06)           |

Source:Table15.1.8.1.

(a) Number of pack-years = (number of cigarettes smoked per day/20) x number of years smoked.

(b) According to the study database, 1 subject reported a predicted FEV of 3.3%, which appears to have been miscalculated and incorrectly entered by the study site. This data point should read 33%.

## Concomitant medications

Nearly all subjects in the Main Period (1320 subjects, 99.9%) were receiving an ongoing concomitant medication at Baseline. Overall, the type and frequency of concomitant medication was broadly similar across treatment groups (Table 12).

Table 10. Summary of Relevant COPD Medications Used Before, During the Main Period, or After Treatment in ≥10% of Subjects in Any Treatment Group (SAS, Main Period)

<div style=\"page-break-after: always\"></div>

| Extended ATC Code                                                                              | Pretreatment           | Main Period            | Posttreatment          |
|------------------------------------------------------------------------------------------------|------------------------|------------------------|------------------------|
| (Medication Group)                                                                             | Number of Subjects (%) | Number of Subjects (%) | Number of Subjects (%) |
| Roflumilast 250 μg 0D/ 500 μg OD (N=441)                                                       |                        |                        |                        |
| Subjects with any relevant COPD medications                                                    | 430 (97.5)             | 430 (97.5)             | 428 (97.1)             |
| R03AC (Inhaled short-acting beta-2-agonists)                                                   | 314 (71.2)             | 314 (71.2)             | 293 (66.4)             |
| R03BAL (Inhaled combination of corticosteroids and long-acting beta-2-agonists)                | 301 (68.3)             | 299 (67.8)             | 296 (67.1)             |
| R03BD (Inhaled long-acting anticholinergics)                                                   | 277 (62.8)             | 277 (62.8)             | 274 (62.1)             |
| R03ACL (Inhaled 1ong-acting beta-2-agonists)                                                   | 116 (26.3)             | 115 (26.1)             | 114 (25.9)             |
| R03DA (Xanthines)                                                                              | 111 (25.2)             | 85 (19.3)              | 80 (18.1)              |
| R03BA (Inhaled Corticosteroids)                                                                | 71 (16.1)              | 71 (16.1)              | 70 (15.9)              |
| R03ACC (Inhaled combination of short acting beta-2-agonists and short-acting anticholinergics) | 76 (17.2)              | 67 (15.2)              | 67 (15.2)              |
| H02 (Corticosteroids [excluding inhaled and nasal applications])                               | 77 (17.5)              | 26 (5.9)               | 5 (1.1)                |
| Roflumilast 500 μg EOD/500 μg 0D (N=437)                                                       |                        |                        |                        |
| Subjects with any relevant COPD medications                                                    | 429 (98.2)             | 428 (97.9)             | 427 (97.7)             |
| R03AC (Inhaled short-acting beta-2-agonists)                                                   | 310 (70.9)             | 310 (70.9)             | 284 (65.0)             |
| R03BAL (Inhaled combination of corticosteroids and long-acting beta-2-agonists)                | 297 (68.0)             | 296 (67.7)             | 296 (67.7)             |
| R03BD (Inhaled long-acting anticholinergics)                                                   | 257 (58.8)             | 259 (59.3)             | 259 (59.3)             |
| R03ACL (Inhaled 1ong-acting beta-2-agonists)                                                   | 97 (22.2)              | 96 (22.0)              | 97 (22.2)              |
| R03DA (Xanthines)                                                                              | 110 (25.2)             | 89 (20.4)              | 86 (19.7)              |
| R03BA (Inhaled Corticosteroids)                                                                | 76 (17.4)              | 77 (17.6)              | 75 (17.2)              |
| R03ACC (Inhaled combination of short acting beta-2-agonists and short-acting anticholinergics) | 78 (17.8)              | 73 (16.7)              | 71 (16.2)              |
| H02 (Corticosteroids [excluding inhaled and nasal applications])                               | 86 (19.7)              | 31 (7.1)               | 9 (2.1)                |
| Roflumilast 500 μg OD (N=443)                                                                  |                        |                        |                        |
| Subjects with any relevant COPD medications                                                    | 436 (98.4)             | 436 (98.4)             | 434 (98.0)             |
| R03BAL (Inhaled combination of corticosteroids and long-acting beta-2-agonists)                | 298 (67.3)             | 299 (67.5)             | 298 (67.3)             |
| R03AC (Inhaled short-acting beta-2-agonists)                                                   | 302 (68.2)             | 295 (66.6)             | 278 (62.8)             |
| R03BD (Inhaled long-acting anticholinergics)                                                   | 254 (57.3)             | 254 (57.3)             | 253 (57.1)             |
| R03ACL (Inhaled 1ong-acting beta-2-agonists)                                                   | 99 (22.3)              | 98 (22.1)              | 97 (21.9)              |
| R03DA (Xanthines)                                                                              | 107 (24.2)             | 89 (20.1)              | 85 (19.2)              |
| R03ACC (Inhaled combination of short acting beta-2-agonists and short-acting anticholinergics) | 90 (20.3)              | 83 (18.7)              | 80 (18.1)              |
| R03BA (Inhaled Corticosteroids)                                                                | 84 (19.0)              | 81 (18.3)              | 77 (17.4)              |
| H02 (Corticosteroids [excluding inhaled and nasal applications])                               | 84 (19.0)              | 39 (8.8)               | 12 (2.7)               |

Source: Table 15.1.12.5.1.

Subjects receiving a particular medication during more than 1 period were counted in all relevant periods.

The posttreatment period includes concomitant medications taken posttreatment for all subjects, including those who entered the down-titration period, who had a follow-up assessment.

ATC=Anatomical Therapeutic Chemical.

## Down-Titration Period

Demographic and baseline characteristics are summarized in Table 13 for subjects who did not tolerate roflumilast  500  μg  OD  during  the  Main  Period  and  subsequently  entered  the  Down-Titration  Period (N=80).

Overall, demographic characteristics were similar across the 3 treatment groups in the Down-Titration Period.  As  shown  in  Table  13,  the  majority  of  subjects  in  each  treatment  group  were  White  (18 subjects  [90.0%]  in  the  roflumilast  250  μg  OD/500  μg  OD  group,  21  subjects  [95.5%]  in  the roflumilast  500  μg  EOD/500  μg  OD  group,  and  34  subjects  [89.5%]  in  the  roflumilast  500  μg  OD group). The mean (SD) age of subjects was 65.6 (8.82), 63.5 (5.93), and 66.0 (7.78) years in the roflumilast 250 μg OD/500 μg OD, 500 μg EOD/500 μg OD, and 500 μg OD groups, respectively. The

<div style=\"page-break-after: always\"></div>

500 μg EOD/500 μg OD and 500μg OD treatment groups were comprised of more subjects aged 40 to 64 years (50.0% and 52.6% of subjects, respectively) than the 250 μg OD/ 500 μg OD dose group (40.0%). The majority of subjects in each treatment group were male (60.0% in roflumilast 250 μg OD/500 μg OD group, 54.5% in roflumilast 500 μg EOD/500 μg OD group, and 63.2% in roflumilast 500 μg OD group).

Table 11 . Demographic and Baseline Characteristics of Subjects in the DownTitration Period Who Did Not Tolerate Roflumilast 500 μg OD in the Main Period (SAS, Down-Titration Period)

|                  |                             | Roflumilast 250μgOD/ 500 g OD (N=20)                                | Roflumilast 500μgEOD/ 500 g OD (N=22)   | Roflumilast 500 μg OD (N=38)   | Total (N=80)                |
|------------------|-----------------------------|---------------------------------------------------------------------|-----------------------------------------|--------------------------------|-----------------------------|
| Age (years)      | Mean (SD)                   | 65.6 (8.82)                                                         | 63.5 (5.93)                             | 66.0 (7.78)                    | 65.2 (7.58)                 |
|                  | Median (min, max)           | 65.5 (50, 77)                                                       | 64.0 (54, 76)                           | 63.5 (50, 82)                  | 65.0 (50, 82)               |
| Age group, n (%) | 40-64 years                 | 8 (40.0)                                                            | 11 (50.0)                               | 20 (52.6)                      | 39 (48.8)                   |
|                  | 65-84 years                 | 12 (60.0)                                                           | 11 (50.0)                               | 18 (47.4)                      | 41 (51.3)                   |
|                  | ≥85 years                   | 0                                                                   | 0                                       | 0                              | 0                           |
| Sex, n (%)       | Male                        | 12 (60.0)                                                           | 12 (54.5)                               | 24 (63.2)                      | 48 (60.0)                   |
|                  | Female                      | 8 (40.0)                                                            | 10 (45.5)                               | 14 (36.8)                      | 32 (40.0)                   |
| Ethnicity, n (%) | Hispanic or Latino          | 0                                                                   | 0                                       | 0                              | 0                           |
|                  | Not Hispanic and Latino     | 20 (100.0)                                                          | 22 (100.0)                              | 37 (97.4)                      | 79 (98.8)                   |
|                  | Missing                     | 0                                                                   | 0                                       | 1 (2.6)                        | 1 (1.3)                     |
| Race, n (%)      | Asian                       | 2 (10.0)                                                            | 1 (4.5)                                 | 3 (7.9)                        | 6 (7.5)                     |
|                  | Black or African American   | 0                                                                   | 0                                       | 1 (2.6)                        | 1 (1.3)                     |
|                  | White                       | 18 (90.0)                                                           | 21 (95.5)                               | 34 (89.5)                      | 73 (91.3)                   |
| Height (cm)      | Mean (SD)                   | 166.5 (7.42)                                                        | 167.0 (8.85)                            | 166.7 (8.79)                   | 166.8 (8.39)                |
|                  | Median (min, max)           | 167.5 (148, 180) 168.0 (150, 185) 167.5 (149, 185) 168.0 (148, 185) |                                         |                                |                             |
| Weight (kg)      | Mean (SD) Median (min, max) | 76.74 (24.321) 83.50 (38.0,                                         | 80.08 (21.280) 74.85 (46.6,             | 74.45 (15.423) 74.30 (38.9,    | 76.57 (19.485) 75.85 (38.0, |
|                  |                             | 129.0)                                                              | 134.0)                                  | 102.0)                         | 134.0)                      |
| BMI (kg/m)       | Mean (SD)                   | 27.41 (7.540)28.64 (7.037)                                          |                                         | 26.72 (5.145)                  | 27.42 (6.315)               |
|                  | Median (min, max)           | 26.70 (13.6, 44.6)                                                  | 27.45 (17.5, 44.3)                      | 26.60 (15.8, 39.3)             | 27.05 (13.6, 44.6)          |

Source:Table 15.1.8.2A.

Baseline is the assessment taken on the reference start date (Randomization Visit V1 for the Main Period and final visit of Main Period Vend/Vopr for the Down-Titration Period) or the last assessment taken prior to the start of study drug intake in the study period.

As  shown  in  Table  14,  all  subjects  had  a  history  of  COPD  exacerbation,  although  no  subject  had experienced &gt;2 episodes within the 1 year prior to Screening. In total, 5.0%, 9.1%, and 13.2% of subjects in the roflumilast 250 μg OD/500 μg OD, 500 μg EOD/500 μg OD, and 500 μg OD treatment groups, respectively, had previously received roflumilast treatment, though none of these had stopped due  to  intolerability.  There  was  an  imbalance  between  treatment  groups  in  baseline  %FEV1 reversibility, probably due to the small sample size (N=80).

Table 12 . Other Baseline Characteristics (SAS, Down-titration Period)

<div style=\"page-break-after: always\"></div>

|                                            |                                              | Roflumilast 250 μgOD/ 500 μgOD (N=20)                     | Roflumilast 500μgEOD/ 500 μg OD (N=22)   | Roflumilast 500 μg OD (N=38)                            | Total (N=80)         |
|--------------------------------------------|----------------------------------------------|-----------------------------------------------------------|------------------------------------------|---------------------------------------------------------|----------------------|
| Smoking classification, n (%)              | Never smoked                                 | 0                                                         | 0                                        | 0                                                       | 0                    |
| Smoking classification, n (%)              | Current smoker                               | 9 (45.0)                                                  | 14 (63.6)                                | 18 (47.4)                                               | 41 (51.3)            |
| Smoking classification, n (%)              | Ex smoker                                    | 11 (55.0)                                                 | 8 (36.4)                                 | 20 (52.6)                                               | 39 (48.8)            |
| Cigarette pack years (amount) (a)          | Mean (SD)                                    | 44.4 (24.44)                                              | 35.9 (10.32)                             | 36.4 (12.91)                                            | 38.3 (16.20)         |
| Cigarette pack years (amount) (a)          | Median (min, max)                            | 40.0 (18, 113)                                            | 35.0 (20, 57)                            | 40.0 (13, 80)                                           | 40.0 (13, 113)       |
| x-ray, n (%)                               | Interpretation of chest Within normal limits | 7 (35.0)                                                  | 7 (31.8)                                 | 16 (42.1)                                               | 30 (35.7)            |
| x-ray, n (%)                               | Abnormal, not clinically significant         | 13 (65.0)                                                 | 13 (59.1)                                | 19 (50.0)                                               | 45 (56.3)            |
| x-ray, n (%)                               | Abnormal, clinically significant             | 0                                                         | 1 (4.5)                                  | 1 (2.6)                                                 | 2 (2.5)              |
| x-ray, n (%)                               | Not done                                     | 0                                                         | 1 (4.5)                                  | 2 (5.3)                                                 | 3 (3.8)              |
| COPD exacerbation history, n (%)           | Yes                                          | 20 (100.0)                                                | 22 (100.0)                               | 38 (100.0)                                              | 80 (100.0)           |
| COPD exacerbation history, n (%)           | No                                           | 0                                                         | 0                                        | 0                                                       | 0                    |
| >2 exacerbation episodes, n (%)            | Yes                                          | 0                                                         | 0                                        | 0                                                       | 0                    |
| >2 exacerbation episodes, n (%)            | No                                           | 20 (100.0)                                                | 22 (100.0)                               | 38 (100.0)                                              | 80 (100.0)           |
| Previous roflumilast treatment, n (%)      | Yes                                          | 1 (5.0)                                                   | 2 (9.1)                                  | 5 (13.2)                                                | 8 (10.0)             |
| Previous roflumilast treatment, n (%)      | No                                           | 19 (95.0)                                                 | 20 (90.9)                                | 33 (86.8)                                               | 72 (90.0)            |
| Stopped due to intolerability, n (%)       | Yes                                          | 0                                                         | 0                                        | 0                                                       | 0                    |
| Stopped due to intolerability, n (%)       | No                                           | 20 (100.0)                                                | 22 (100.0)                               | 38 (100.0)                                              | 80 (100.0)           |
| Prebronchodilator FEV1. (L)                | Mean (SD)                                    | 0.886 (0.2675)                                            | 1.019 (0.2787)                           | 0.930 (0.3236)                                          | 0.944 (0.2990)       |
| Prebronchodilator FEV1. (L)                | Median (min, max)                            | (711 600) 0060 (711 000 0680 (91 9900) 9101 (901 90) 0180 |                                          |                                                         |                      |
| Predicted FEV1 (%)(b) Mean (SD)            |                                              | 33.51 (8.974)                                             | 37.07 (7.690)                            | 34.71 (10.977)                                          | 35.06 (9.660)        |
| Predicted FEV1 (%)(b) Mean (SD)            | Median (min, max)                            |                                                           |                                          | 30.90 (13.9, 49.0) 37.70 (24.0, 50.0) 33.50 (3.3, 59.0) | 33.60 (3.3, 59.0)    |
| Prebronchodilator FVC (L)                  | Mean (SD)                                    | 1.860 (0.5609)                                            | 2.206 (0.6266)                           | 2.078 (0.5652)                                          | 2.059 (0.5881)       |
| Prebronchodilator FVC (L)                  | Median (min, max)                            |                                                           |                                          |                                                         |                      |
| Postbronchodilator FEV/FVC ratio (derived) | Mean (SD)                                    | 0.470 (0.1019)                                            | 0.481 (0.1256)                           | 0.471 (0.1287)                                          | 0.473 (0.1202)       |
| Postbronchodilator FEV/FVC ratio (derived) | Median (min, max)                            |                                                           |                                          |                                                         |                      |
| % FEV reversibility                        | Mean (SD)                                    | 5.113 (11.8264)                                           | 3.470 (16.0616)                          | 5.486 (9.8107)                                          | 4.838 (12.1670)      |
| % FEV reversibility                        | Median (min, max)                            | 4.135 (-25.20, 26.60)                                     | 0.380 (-24.14, 37.23)                    | 5.100 (-24.14, 31.58)                                   | 4.220(-25.20, 37.23) |

## Source:Table15.1.8.2A

(a) Number of pack-years = (number of cigarettes smoked per day/20) x number of years smoked.

incorrectly entered by the study site. This data point should read 33%.

## · Numbers analysed

The number of subjects in each analysis set is shown in Table below.

## Table 13 . Number of Subjects

<div style=\"page-break-after: always\"></div>

|                                      | Roflumilast 250 μg OD/ 500 μg OD n (%)   | Roflumilast 500μgEOD/ 500 μg OD n (%)   | Roflumilast 500 μg OD (%) I   | Total n (%)   |
|--------------------------------------|------------------------------------------|-----------------------------------------|-------------------------------|---------------|
| FAS                                  | 441                                      | 439                                     | 443                           | 1323          |
| SAS for Main Period (a)              | 441 (100.0)                              | 437 (99.5)                              | 443 (100.0)                   | 1321 (99.8)   |
| SAS for Down-Titration Period (b)(c) | 27 (6.1)                                 | 39 (8.9)                                | 38 (8.6)                      | 104 (7.9)     |
| VCS (a)                              | 386 (87.5)                               | 383 (87.2)                              | 387 (87.4)                    | 1156 (87.4)   |
| PK dataset (d)                       | 409                                      | 408                                     | 392                           | 1238          |

Source: Table 15.1.7 and Appendix 16.1.10.3 Table 2.

Note: Definitions of analysis sets are provided in Section 9.7.1.1.

(a) Percentages are based on FAS.

(b) Percentages are based on SAS for the Main Period.

- (c) 80 subjects were included in the SAS for the Down-Titration Period for subjects who entered the period after not tolerating at least 1 dose of roflumilast (comprising of 20, 22 and 38 subjects from the 250 μg OD/500 μg OD, 500 μg EOD/500 μg OD, and 500 μg OD treatment groups, respectively).
- (d) There were 29 subjects who discontinued the Main Period before first visit for PK blood draws, but entered into the Down-Titration Phase.

## Protocol Deviations

The number of subjects with ≥1 protocol deviation was broadly similar across treatment groups, and did not have any clinically significant impact on the interpretation of the study data or subject safety. In all treatment groups, the most common protocol deviation was 'selection criteria not met'.

Table 14 . Significant Protocol Deviations (FAS)

|                                                           | Roflumilast 250 μg OD/ 500μg OD (N=441)   | Roflumilast 500μgEOD/ 500 μg OD (N=439)   | Roflumilast 500 μg OD (N=443)   | Total (N=1323)         |
|-----------------------------------------------------------|-------------------------------------------|-------------------------------------------|---------------------------------|------------------------|
|                                                           | Number of Subjects (%)                    | Number of Subjects (%)                    | Number of Subjects (%)          | Number of Subjects (%) |
| Subjects with at least 1 protocol deviation               | 55 (12.5)                                 | 56 (12.8)                                 | 56 (12.6)                       | 167 (12.6)             |
| Excluded concomitant medication                           | 3 (0.7)                                   | 5 (1.1)                                   | 4 (0.9)                         | 12 (0.9)               |
| Procedure not performed as per protocol                   | 18 (4.1)                                  | 13 (3.0)                                  | 7 (1.6)                         | 38 (2.9)               |
| Selection criteria not met                                | 22 (5.0)                                  | 27 (6.2)                                  | 28 (6.3)                        | 77 (5.8)               |
| Subject not withdrawn as per protocol                     | 0                                         | 1 (0.2)                                   | 0                               | 1 (0.1)                |
| Treatment deviation                                       | 1 (0.2)                                   | 1 (0.2)                                   | 1 (0.2)                         | 3 (0.2)                |
| Overall Main Period compliance is <75% or >125%           | 15 (3.4)                                  | 14 (3.2)                                  | 23 (5.2)                        | 52 (3.9)               |
| Overall Down-Titration Period compliance is <75% 0r >125% | 0                                         | 2 (0.5)                                   | 1 (0.2)                         | 3 (0.2)                |

Source: Table 15.1.6

Subjects may have more than 1 protocol deviation, but are counted only once per category and in the total.

## Measurements of Treatment Compliance

Compliance to study medication was similarly high across treatment groups during the Main Period and Down-Titration Period. During the Main Period, at least 95% of subjects in all treatment groups having compliance between ≥75% and ≤125% of study medication: mean (SD) treatment compliance was 104.42% (91.623%), 100.92% (14.138%), and 102.36% (20.549%) in roflumilast 250 μg OD/500 μg OD,  500  μg  EOD/500  μg  OD,  and  500  μg  OD  treatment  groups,  respectively.  During  the  DownTitration Period, mean (SD) treatment compliance was 99.21% (4.177%), 107.75% (26.381%), and 102.91% (33.432%) in roflumilast 250 μg OD/500 μg OD, 500 μg EOD/500 μg OD, and 500 μg OD

<div style=\"page-break-after: always\"></div>

treatment groups, respectively, with at least 90.9% of subjects in all treatment groups taking between ≥75% and ≤125% of study medication.

A significant protocol deviation of treatment compliance &lt;75% or &gt;125% was reported in 52 of 1323 subjects  (3.9%) during the Main Period and in 3 of 1323 (0.2%) during the Down-Titration Period. Treatment  noncompliance  led  to  discontinuation  in  2  subjects  (both  in  the  250  μg  OD/500  μg  OD treatment group).

## · Outcomes and estimation

The primary endpoint of this study was the percentage of subjects prematurely discontinuing study treatment  due  to  any  reason  (during  Main  Period,  ie,  Visit  V1  to  Vend).  Although  this  is  a  safety endpoint, it is described first in this assessment report to follow the same hierarchy as in the clinical study.

Efficacy was assessed as a 'key secondary endpoint', and 'other secondary endpoint' in this study. The key  secondary  efficacy  endpoints  were  assessed  using  hierarchical  statistical  testing  procedures. However, as a result of the failure to reach statistical significance for the second hierarchical test, all efficacy endpoints tested using this procedure were performed in an exploratory manner.

## Primary endpoint

## Primary Analysis of the Primary Endpoint: Percentage of Subjects Prematurely Discontinuing Study Treatment Due to Any Reason During the Main Period

A logistic  regression  model was used with terms for study treatment, country and baseline FEV1 as explanatory variables. Treatment comparisons were made at a 5% significance level, 2-sided, following hierarchical testing procedure. As a supportive analysis for the primary results, results based on Cox proportional hazards model were also presented.

The result of the statistical analyses for the primary endpoint is shown in Table 17. Compared with roflumilast 500 μg OD [H01] the odds of discontinuing the Main Period were statistically significantly lower in the roflumilast 250 μg OD/500 μg OD treatment group at the 5% significance level (24.6% vs. 18.4%  of  subjects,  OR=0.66,  95%  CI:  0.47,  0.93;  p-value  0.017,  primary  endpoint).  At  the  5% significance level, there was no statistically significant difference between roflumilast 500 μg OD and roflumilast 500 μg EOD/500 μg OD treatment groups [H02] (OR 0.76, 95% CI: 0.55, 1.07; p-value 0.114). Supportive analysis Cox proportional hazards model found a similar result for roflumilast 250 μg OD/500 μg OD (HR=0.68, 95 % CI: 0.51, 0.92) and roflumilast 500 μg EOD/500 μg OD (HR=0.77, 95% CI: 0.58, 1.02) versus roflumilast 500 μg OD.

Table 15. Statistical Analysis and Hierarchical Testing of the Primary Safety Endpoint: Percentage of Subjects Prematurely Discontinuing Study Treatment Due to Any Reason During the Main Period (SAS, Main Period)

|                                                        | Roflumilast 250 μg OD/500 μg OD (N=441)   | Roflumilast 500 μg E0D/500 μg OD (N=437)   | Roflumilast 500 μg OD (N=443)   |
|--------------------------------------------------------|-------------------------------------------|--------------------------------------------|---------------------------------|
| Subjects prematurely discontinuing Main Period, n (%)  | 81 (18.4)                                 | 88 (20.1)                                  | 109 (24.6)                      |
| p-value for comparison against Reference 500 μg OD (a) | 0.017 (H01)                               | 0.114 (H02)                                |                                 |
| OR (95% CI) for comparison against Reference (a)       | 0.66 (0.47, 0.93)                         | 0.76 (0.55, 1.07)                          |                                 |
| HR (95% CI) for comparison against Reference (b)       | 0.68 (0.51,0.92)                          | 0.77 (0.58, 1.02)                          |                                 |

Source: Table 15.2.1.1.

H01, H02 = Order of hierarchical testing

(a) Logistic regression model with study treatment, country and baseline FEV as explanatory variables.

(b) Cox proportional hazards model with study treatment and country as class effects, and baseline FEV as a continuous variable.

<div style=\"page-break-after: always\"></div>

A summary of the time to discontinuation during the Main Period is displayed in Figure 7.

Compared  with  either  up-titration  treatment  group,  the  frequency  of  discontinuation  in  the  500  μg treatment group was greater and started to occur earlier. The Kaplan-Meier plot is based on the Main Period data only and, as indicated by the plot, some subjects had 150 days for their Main Period and were censored at that time point.

Figure 7. Kaplan-Meier Plot for Prematurely Discontinuing Study Treatment Due to Any Reason During the Main Period (SAS, Main Period)

<!-- image -->

Source: Figure 15.2.1.1.1.

Time to discontinuation is calculated from date of first dose in the Main Period until the date of last dose in the Main Period. Subjects who did not discontinue from the Main Period will be censored at the time of their last Main Period dose date. The plot is based on the Main Period data only and, as indicated by the plot, some subjects had 150 days for their Main Period and were censored at that time point.

500 μg OD.

## Sensitivity analyses of the primary endpoint:

The results based on the logistic regression model with region as a covariate, instead of country, were consistent  with  the  primary  analysis  results;  compared  with  roflumilast  500  μg  OD,  the  odds  of discontinuing  from  the  Main  Period  were  lower  in  the  roflumilast  250  μg  OD/500  μg  OD  treatment group (OR=0.70, 95% CI: 0.50, 0.97; p-value 0.032).

The results of the sensitivity analyses by excluding the South African site (Site 6002) for the primary endpoint supported the results of the primary analysis. Compared with roflumilast 500 μg OD, the odds of discontinuing from the Main Period were lower in the roflumilast 250 μg OD/500 μg OD treatment group (OR=0.66, 95% CI: 0.47, 0.93; p-value 0.017).

This is not unexpected, as this site only included 5 patients and only 2 of them had a primary event (one in group 2 and one in group 3)

## Subgroup Analyses of the Primary Endpoint

Subgroup  analysis  of  the  primary  endpoint  is  displayed  in  Figure  8.  In  the  majority,  analyses  of subgroups tended to support the primary finding, such that the odds of premature discontinuation from the Main Period were lower in the up-titration groups compared with the reference treatment.

The subgroups that trended towards favoring reference treatment (roflumilast 500 μg OD) were nonEuropean region and Asian race (versus roflumilast 250 μg OD/500 μg OD), and north-Eastern Europe

Time since first dose

(days)

<div style=\"page-break-after: always\"></div>

region  and  current  smoking  status  (versus  roflumilast  500  μg  EOD/500  μg  OD).  Logistic  regression could  not  be  performed  for  the  subgroup  body  weight  &lt;60  kg  as  complete  convergence  was  not obtained, or for Black and Other race subgroups due to the low number of subjects in these subgroups.

CIs were wide for some subgroups, predominantly due to the small number of subjects in each of the subgroups. In particular, Asian race (32, 30, 32 subjects in the roflumilast 250 μg OD/500 μg OD, 500 μg EOD/500 μg OD, and 500 μg OD treatment groups, respectively), and Western Europe (20, 33, and 19 subjects, respectively).

Figure 8. Forest Plot of ORs (95% CI) for Subjects Prematurely Discontinuing Study Treatment Due to Any Reason in the Main Period, by Subgroup and Overall (SAS, Main Period)

Roflumilast 250 μg OD/500 μg OD vs. Roflumilast 500 μg OD:

<!-- image -->

Source: Figure 15.2.2.1.1.

An OR of&lt;1 favors the up-titration treatment 250 μg OD/500 μg OD or 500 μg EOD/500 μg OD. An OR &gt;1 favors 500 μg OD.

A logistic regression model with study treatment, country and baseline FEV; as explanatory variables has been used. The 'Black' and ^Other' race subgroup categories were not considered for the logistic regression because of their significantlylow counts.

*=Used Firth Logistic Regression, ∧=Results not used as complete convergence not obtained.

## Key Secondary Safety Endpoint: TEAEs of Interest during the Main Period

The  results  of  the  statistical  analysis  of  TEAEs  of  Interest  (diarrhea,  nausea,  headache,  reduced appetite,  insomnia,  or  abdominal  pain)  during  the  Main  Period  are  considered  exploratory  based  on insufficient evidence to reject the null hypothesis for the primary endpoint at the 5% significance level  [H02] in the framework of hierarchical testing (i.e.: no statistically significant differences were found  for  the  comparison  between  groups  2  and  3  for  the  primary  endpoint  of  premature discontinuations).

<div style=\"page-break-after: always\"></div>

Compared with roflumilast 500 μg OD, the odds of experiencing a 'TEAE of interest' was significantly lower at the 5% significance level in the roflumilast 250 μg OD/500 μg OD treatment group (54.2% versus 45.4% of subjects, OR=0.63, 95% CI: 0.47, 0.83; p-value = 0.001). This difference was not observed between roflumilast 500 μg EOD/500 μg OD (48.3% of subjects) and the roflumilast 500 μg OD (54.2%) treatment groups in the analysis of AEs of interest.

The more frequent TEAEs of interest were diarrhea, decreased appetite, nausea and headache, all of them occurring more frequently and starting soon in the control group than in the roflumilast 250 μg OD/500 μg OD experimental group (Table 18).

Table 16 . Statistical Analysis of the Key Secondary Endpoint: TEAEs of Interest to Evaluate Tolerability During the Main Period (SAS, Main Period)

|                                                          | Roflumilast 250 μg OD/ 500 μg OD (N=441)   | Roflumilast 500 μgE0D/ 500 μg OD (N=437)   | Roflumilast 500μg OD (N=443)   | Total (N=1321)   |
|----------------------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------|------------------|
| Subjects with TEAEs of interest to evaluate tolerability | 200 (45.4)                                 | 211 (48.3)                                 | 240 (54.2)                     | 651 (49.3)       |
| Diarrhea                                                 |                                            |                                            |                                |                  |
| Subjects with ≥1 TEAE, n (%)                             | 108 (24.5)                                 | 114 (26.1)                                 | 134 (30.2)                     | 356 (26.9)       |
| Subjects with severe TEAE, n (%)                         | 1 (0.2)                                    | 6 (1.4)                                    | 5 (1.1)                        | 12 (0.9)         |
| Median time to onset of first TEAE, days (min, max)      | 8.0 (0, 81)                                | 10.0 (0, 90)                               | 5.5 (0, 73)                    | 8.0 (0, 90)      |
| Median duration of TEAE, days (min, max)                 | 3.0 (1, 88)                                | 3.0 (1, 90)                                | 3.0 (1, 95)                    | 3.0 (1, 95)      |
| Nausea                                                   |                                            |                                            |                                |                  |
| Subjects with ≥1 TEAE, n (%)                             | 87 (19.7)                                  | 92 (21.1)                                  | 110 (24.8)                     | 289 (21.9)       |
| Subjects with severe TEAE, n (%)                         | 1 (0.2)                                    | 2 (0.5)                                    | 3 (0.7)                        | 6 (0.5)          |
| Median time to onset of first TEAE, days (min, max)      | 10.0 (0, 84)                               | 14.0 (0, 74)                               | 6.5 (0. 66)                    | 9.0 (0, 84)      |
| Median duration of TEAE, days (min, max)                 | 2.0 (1, 84)                                | 2.0 (1, 90)                                | 3.5 (1, 90)                    | 3.0 (1, 90)      |
| Headache                                                 |                                            |                                            |                                |                  |
| Subjects with ≥1 TEAE, n (%)                             | 107 (24.3)                                 | 115 (26.3)                                 | 115 (26.0)                     | 337 (25.5)       |
| Subjects with severe TEAE, n (%)                         | 3 (0.7)                                    | 0                                          | 3 (0.7)                        | 6 (0.5)          |
| Median time to onset of first TEAE, days (min, max)      | 9.0 (0, 84)                                | 10.0 (0,84)                                | 5.0 (0, 79)                    | 9.0 (0, 84)      |
| Median duration of TEAE, days (min, max)                 | 2.0 (1, 97)                                | 2.0 (1, 90)                                | 3.0 (1, 93)                    | 2.0 (1, 97)      |
| Decreased appetite                                       |                                            |                                            |                                |                  |
| Subjects with ≥1 TEAE, n (%)                             | 100 (22.7)                                 | 105 (24.0)                                 | 129 (29.1)                     | 334 (25.3)       |
| Subjects with severe TEAE, n (%)                         | 2 (0.5)                                    | 1 (0.2)                                    | 5 (1.1)                        | 8 (0.6)          |
| Median time to onset of first TEAE, days (min, max)      | 10.0 (0, 84)                               | 15.0 (0, 76)                               | 7.0 (0, 65)                    | 9.0 (0, 84)      |
| Median duration of TEAE, days (min, max)                 | 4.0 (1,98)                                 | 3.5 (1, 124)                               | 4.0 (1, 117)                   | 4.0 (1, 124)     |
| Insomnia                                                 |                                            |                                            |                                |                  |
| Subjects with ≥1 TEAE, n (%)                             | 98 (22.2)                                  | 106 (24.3)                                 | 110 (24.8)                     | 314 (23.8)       |
| Subjects with severe TEAE, n (%)                         | 3 (0.7)                                    | 4 (0.9)                                    | 2 (0.5)                        | 9 (0.7)          |
| Median time to onset of first TEAE, days (min, max)      | 10.0 (0, 73)                               | 7.0 (0, 74)                                | 7.0 (0, 73)                    | 8.0 (0, 74)      |
| Median duration of TEAE, days (min, max)                 | 2.0 (1, 137)                               | 3.0 (1, 80)                                | 4.0 (1, 117)                   | 3.0 (1, 137)     |
| Abdominal pain                                           |                                            |                                            |                                |                  |
| Subjects with ≥1 TEAE, n (%)                             | 85 (19.3)                                  | 72 (16.5)                                  | 89 (20.1)                      | 246 (18.6)       |
| Subjects with severe TEAE, n (%)                         | 2 (0.5)                                    | 7 (1.6)                                    | 4 (0.9)                        | 13 (1.0)         |
| Median time to onset of first TEAE, days (min, max)      | 10.0 (0, 84)                               | 16.0 (0, 81)                               | 7.0 (0, 76)                    | 10.0 (0, 84)     |
| Median duration of TEAE, days (min, max)                 | 3.0 (1, 96)                                | 3.0 (1, 80)                                | 3.0 (1, 87)                    | 3.0 (1, 96)      |

Source: Table 15.3.1.16.1.

A TEAE in the Main Period is defined as any AE, regardless of relationship to study medication that occurs after the first dose of of study medication in the Down-Titration Period.

The PTs included under each AE of interest is listed in Section 16.2 of the SAP (Appendix 16.1.9).

## Secondary endpoints

<div style=\"page-break-after: always\"></div>

## Change From Baseline in Prebronchodilator FEV1

## Main period:

Improvements in prebronchodilator FEV1 from V1 to each Main Period postrandomization visit were clinically  relevant  (approximately  100  mL)  and  showed  minimal  differences  across  the  3  treatment groups (LS means of 0.09 L, 0.13 L, and 0.11 L for roflumilast 250 μg OD/500 μg OD, 500 μg EOD/500 μg OD, and roflumilast 500 μg OD treatment groups, respectively; Table 19 FAS). Similar results were shown when subjects for both Main Period and Down-Titration Period were evaluated (LS means of 0.07  L,  0.14  L,  and  0.10  L  for  roflumilast  250  μg  OD/500  μg  OD,  500  μg  EOD/500  μg  OD,  and roflumilast 500 μg OD treatment groups, respectively; Table 19 FAS).

Table 17 . Statistical Analysis of the change in FEV1 during the study.

|                                                                                                          |                                                                                                          | Roflumilast 250 μg OD/500 μg OD                                                                          | Roflumilast500 μg EOD/500 μg OD                                                                          | Roflumilast 500 μg OD                                                                                    |
|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| Change in Prebronchodilator FEV, (L) From Baseline (Vl) to Each Main Period Postrandomization Visit. FAS | Change in Prebronchodilator FEV, (L) From Baseline (Vl) to Each Main Period Postrandomization Visit. FAS | Change in Prebronchodilator FEV, (L) From Baseline (Vl) to Each Main Period Postrandomization Visit. FAS | Change in Prebronchodilator FEV, (L) From Baseline (Vl) to Each Main Period Postrandomization Visit. FAS | Change in Prebronchodilator FEV, (L) From Baseline (Vl) to Each Main Period Postrandomization Visit. FAS |
| Subjects in the FAS, N                                                                                   |                                                                                                          | 441                                                                                                      | 439                                                                                                      | 443                                                                                                      |
| LS means (a)                                                                                             |                                                                                                          | 0.09                                                                                                     | 0.13                                                                                                     | 0.11                                                                                                     |
| Treatment difference vs reference arm (a)                                                                | LS mean (SE)                                                                                             | -0.03 (0.017)                                                                                            | 0.02 (0.017)                                                                                             | 0.11                                                                                                     |
| Treatment difference vs reference arm (a)                                                                | D%56                                                                                                     | (-0.06, 0.00)                                                                                            | (-0.01, 0.05)                                                                                            | 0.11                                                                                                     |
| Treatment difference vs reference arm (a)                                                                | p-value                                                                                                  | 0.093                                                                                                    | 0.252                                                                                                    | 0.11                                                                                                     |
| Change in Prebronchodilator FEV (L) From Baseline (Vl) to Each Main Period Postrandomization Visit VCS   | Change in Prebronchodilator FEV (L) From Baseline (Vl) to Each Main Period Postrandomization Visit VCS   | Change in Prebronchodilator FEV (L) From Baseline (Vl) to Each Main Period Postrandomization Visit VCS   | Change in Prebronchodilator FEV (L) From Baseline (Vl) to Each Main Period Postrandomization Visit VCS   | Change in Prebronchodilator FEV (L) From Baseline (Vl) to Each Main Period Postrandomization Visit VCS   |
| Subjects in the VCS, N                                                                                   |                                                                                                          | 386                                                                                                      | 383                                                                                                      | 387                                                                                                      |
| LS means (b)                                                                                             |                                                                                                          | 0.08                                                                                                     | 0.13                                                                                                     | 0.11                                                                                                     |
| Treatment difference vs reference arm (a)                                                                | LS mean (SE)                                                                                             | -0.03 (0.018)                                                                                            | 0.02 (0.017)                                                                                             | 0.11                                                                                                     |
| Treatment difference vs reference arm (a)                                                                | N %56                                                                                                    | (-0.06, 0.00)                                                                                            | (-0.02, 0.05)                                                                                            | 0.11                                                                                                     |
| Treatment difference vs reference arm (a)                                                                | p-value                                                                                                  | 0.090                                                                                                    | 0.306                                                                                                    | 0.11                                                                                                     |
| Change in Prebronchodilator FEV (L) From Baseline (Vl) to Each PostrandomizationVisit,FAS                | Change in Prebronchodilator FEV (L) From Baseline (Vl) to Each PostrandomizationVisit,FAS                | Change in Prebronchodilator FEV (L) From Baseline (Vl) to Each PostrandomizationVisit,FAS                | Change in Prebronchodilator FEV (L) From Baseline (Vl) to Each PostrandomizationVisit,FAS                | Change in Prebronchodilator FEV (L) From Baseline (Vl) to Each PostrandomizationVisit,FAS                |
| Subjects in the FAS, N                                                                                   |                                                                                                          | 441                                                                                                      | 439                                                                                                      | 443                                                                                                      |
| LS means (a)                                                                                             |                                                                                                          | 0.07                                                                                                     | 0.14                                                                                                     | 0.10                                                                                                     |
| Treatment difference vs reference arm (a)                                                                | LS mean (SE)                                                                                             | -0.03 (0.021)                                                                                            | 0.04 (0.021)                                                                                             | 0.10                                                                                                     |
| Treatment difference vs reference arm (a)                                                                | ID%56                                                                                                    | (-0.07, 0.01)                                                                                            | (0.00, 0.08)                                                                                             | 0.10                                                                                                     |
| Treatment difference vs reference arm (a)                                                                | p-value                                                                                                  | 0.133                                                                                                    | 0.068                                                                                                    | 0.10                                                                                                     |
| Change in Prebronchodilator FEV (L) From Baseline (Vl) toEach PostrandomizationVisit,VCS                 | Change in Prebronchodilator FEV (L) From Baseline (Vl) toEach PostrandomizationVisit,VCS                 | Change in Prebronchodilator FEV (L) From Baseline (Vl) toEach PostrandomizationVisit,VCS                 | Change in Prebronchodilator FEV (L) From Baseline (Vl) toEach PostrandomizationVisit,VCS                 | Change in Prebronchodilator FEV (L) From Baseline (Vl) toEach PostrandomizationVisit,VCS                 |
| Subjects in the VCS, N                                                                                   |                                                                                                          | 386                                                                                                      | 383                                                                                                      | 387                                                                                                      |
| LS means (a)                                                                                             |                                                                                                          | 0.06                                                                                                     | 0.14                                                                                                     | 0.10                                                                                                     |
| Treatment difference vs reference arm (a)                                                                | LS mean (SE)                                                                                             | -0.04 (0.022)                                                                                            | 0.04 (0.021)                                                                                             |                                                                                                          |
| Treatment difference vs reference arm (a)                                                                | ID %56                                                                                                   | (-0.08, 0.01)                                                                                            | (0.00, 0.08)                                                                                             |                                                                                                          |
| Treatment difference vs reference arm (a)                                                                | p-value                                                                                                  | 0.092                                                                                                    | 0.074                                                                                                    |                                                                                                          |

Source:Table 15.2.1.1A

SAS  and  FAS  Down-Titration  Period  analyses  are  based  on  a  subgroup  of  80  subjects  (250  μg  OD/500  μg  OD [n=20], 500 μg EOD/500 μg OD [n= 22], 500 μg OD [n= 38]), who received 500 μg OD and discontinued during the Main Period. VCS Down-Titration Period analyses are based on a subgroup of 69 subjects (250 μg OD/500 μg OD [n=16], 500 μg EOD/500 μg OD [n= 18], 500 μg OD [n=35]), who received 500 μg OD and discontinued during the Main Period.

(a) ANCOVA model (Verbeke and Molenberghs) including study treatment, baseline value, time and treatment-bytime interaction as fixed factors and covariates.

Down-Titration Period: the  analysis  of  main  interest  was  for  those  patients  who  did  not  tolerate roflumilast  500  μg  OD  during  the  Main  Period  and  subsequently  entered  the  down-Titration  period (n=80), in order to ascertain whether a the 250 microgram dose, administered to all of them, could be

<div style=\"page-break-after: always\"></div>

effective (i.e.: whether it could produce improvements in pre-BD FEV1 from the start of down-titration to  end  of  down-titration).  Eighty  subjects  (of  1321  subjects,  6.0%)  who  did  not  tolerate  roflumilast 500 μg OD in the Main Period were treated with roflumilast 250 μg OD for 8 weeks (n=20 for the roflumilast  250  μg  OD/500  μg  OD  group,  n=22  for  roflumilast  500  μg  EOD/500  μg  OD  group,  and n=38 for the roflumilast 500 μg OD group at Baseline, V0DT). The analyses indicated no effect of the 250 microgram low-dose roflumilast in pre-BD FEV1 (Table 20).

Table 18 . Change in pre-BD FEV1 (L) from baseline down-titration to last scheduled down-titration period visit (FAS and VCS).

|                                                                                                                       |                                                                                                                       | Roflumilast 250 μg OD/500 μg OD                                                                                       | Roflumilast 500 μg EOD/500 pg OD                                                                                      | Roflumilast 500 μg OD                                                                                                 |
|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| Change in Prebronchodilator FEV (L) From Baseline (VOpr) to Last Scheduled Down-Titration Period Visit (Vendpr), FAS  | Change in Prebronchodilator FEV (L) From Baseline (VOpr) to Last Scheduled Down-Titration Period Visit (Vendpr), FAS  | Change in Prebronchodilator FEV (L) From Baseline (VOpr) to Last Scheduled Down-Titration Period Visit (Vendpr), FAS  | Change in Prebronchodilator FEV (L) From Baseline (VOpr) to Last Scheduled Down-Titration Period Visit (Vendpr), FAS  | Change in Prebronchodilator FEV (L) From Baseline (VOpr) to Last Scheduled Down-Titration Period Visit (Vendpr), FAS  |
| Subjects in the FAS, N                                                                                                |                                                                                                                       | 441                                                                                                                   | 439                                                                                                                   | 443                                                                                                                   |
| Subjects in the FAS analyzed, n                                                                                       |                                                                                                                       | 20                                                                                                                    | 22                                                                                                                    | 38                                                                                                                    |
| LS means (a)                                                                                                          |                                                                                                                       | 0.01                                                                                                                  | 0.13                                                                                                                  | 0.00                                                                                                                  |
| Treatment difference vs reference arm (a)                                                                             | LS mean (SE)                                                                                                          | 0.02 (0.095)                                                                                                          | 0.13 (0.093)                                                                                                          |                                                                                                                       |
| Treatment difference vs reference arm (a)                                                                             | 95% CI                                                                                                                | (-0.17, 0.20)                                                                                                         | (-0.05, 0.32)                                                                                                         |                                                                                                                       |
| Treatment difference vs reference arm (a)                                                                             | p-value                                                                                                               | 0.871                                                                                                                 | 0.162                                                                                                                 |                                                                                                                       |
| Change in Prebronchodilator FEV1 (L) From Baseline (VOpr) to Last Scheduled Down-Titration Period Visit (Vendpr), VCS | Change in Prebronchodilator FEV1 (L) From Baseline (VOpr) to Last Scheduled Down-Titration Period Visit (Vendpr), VCS | Change in Prebronchodilator FEV1 (L) From Baseline (VOpr) to Last Scheduled Down-Titration Period Visit (Vendpr), VCS | Change in Prebronchodilator FEV1 (L) From Baseline (VOpr) to Last Scheduled Down-Titration Period Visit (Vendpr), VCS | Change in Prebronchodilator FEV1 (L) From Baseline (VOpr) to Last Scheduled Down-Titration Period Visit (Vendpr), VCS |
| Subjects in the VCS, N                                                                                                |                                                                                                                       | 386                                                                                                                   | 383                                                                                                                   | 387                                                                                                                   |
| Subjects in the VCS analyzed, n                                                                                       |                                                                                                                       | 16                                                                                                                    | 18                                                                                                                    | 35                                                                                                                    |
| LS means (a)                                                                                                          |                                                                                                                       | 0.05                                                                                                                  | 0.09                                                                                                                  | 0.02                                                                                                                  |
| Treatment difference vs reference arm (a)                                                                             | LS mean (SE)                                                                                                          | 0.03 (0.094)                                                                                                          | 0.07 (0.092)                                                                                                          |                                                                                                                       |
| Treatment difference vs reference arm (a)                                                                             | 95% CI                                                                                                                | (-0.16, 0.22)                                                                                                         | (-0.11, 0.26)                                                                                                         |                                                                                                                       |
| Treatment difference vs reference arm (a)                                                                             | p-value                                                                                                               | 0.747                                                                                                                 | 0.428                                                                                                                 |                                                                                                                       |

Source:Table15.2.1.1A

SAS and FAS Down-Titration Period analyses are based on a subgroup of 80 subjects (250 μg OD/500 μg OD [n=20], 500 μg EOD/500 μg OD [n= 22],. 500 μg OD [n= 38], who received 500 μg OD and discontinued during the Main Period. VCS Down-Titration Period analyses are based on a subgroup of 69 subjects (250 μg OD/500 μg OD [n=16], 500 μg EOD/500 μg OD [n= 18], 500 μg OD [n=35]), who received 500 μg OD and discontinued during the Main Period.

(a) ANCOVA model (Ebbutt and Frith [1o]) using LOCF with study treatment as fixed factor and baseline value as covariate.

The lack of effect on pre-BD FEV1 of a lower roflumilast maintenance dose was consistent in the perprotocol analysis based on the VCS and in several sensitivity analyses.

## Other efficacy endpoints:

FVC: In all treatment groups, mean FVC increased from V1 to Vend. Improvements in mean FVC from V1 to each Main Period post-randomization visit showed minimal differences across the 3 treatment groups (LS Means of 0.09L, 0.15L, and 0.15L for roflumilast 250 μg OD/ 500 μg OD, 500 μg EOD/500 μg OD, and roflumilast 500 μg OD treatment groups, respectively). Similar results were shown when subjects for both Main Period and Down-Titration Period were evaluated (LS means of 0.09 L, 0.17 L, and 0.14 L for roflumilast 250 μg OD/500 μg OD, 500 μg EOD/500 μg OD, and roflumilast 500 μg OD treatment groups, respectively.

Patients'  satisfaction  with  treatment: Subject  treatment  satisfaction  was  assessed  by  asking subjects to assess their satisfaction with their COPD therapy at each visit on a 7-point scale ranging from  0  indicating  very  satisfied  to  6  indicating  very  dissatisfied.  Therefore,  a  within  group  negative change  from  baseline  indicates  increased  satisfaction  with  study  treatment  compared  with  previous treatment  at  baseline,  while  a  between  group  negative  difference  indicates  an  increased  change  in satisfaction with experimental treatment versus baseline compared with the corresponding change in the control treatment.

<div style=\"page-break-after: always\"></div>

At  baseline,  patients  had  a  mean  1.8  score,  which  indicates  that  the  majority  were  between  1 (Satisfied) and 2 (Somewhat satisfied), but closer to 2.

Analyses  without  adjustment  for  multiplicity  found  a  statistically  significant  difference  at  the  5% significance  level  for  the  change  in  subject-assessed  treatment  satisfaction  scores  from  V1  to  each post-randomization  visit  during  the  Main  Period  favoring  roflumilast  250  μg  OD/500  μg  OD  versus roflumilast 500 μg (LS mean for treatment difference -0.20, 95% CI: -0.33, -0.06; p-value 0.004; see Table  below).  Therefore,  patients  on  the  control  group  still  remained  closer  to  score  2  (somewhat satisfied) while patients on the group 1 became closer to score 1 (satisfied).

Table 19 . Statistical Analysis of the Change in Subject-Assessed Treatment Satisfaction

|                                                                                                               |                                                                                                               | Roflumilast250pg OD/500 μg OD                                                                                 | Roflumilast500pg E0D/500pg OD                                                                                 | Roflumilast 500 pg OD                                                                                         |
|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| Change in Subject Treatment Satisfaction From Baseline (Vl) to Each MIain Period Postrandomization Visit. FAS | Change in Subject Treatment Satisfaction From Baseline (Vl) to Each MIain Period Postrandomization Visit. FAS | Change in Subject Treatment Satisfaction From Baseline (Vl) to Each MIain Period Postrandomization Visit. FAS | Change in Subject Treatment Satisfaction From Baseline (Vl) to Each MIain Period Postrandomization Visit. FAS | Change in Subject Treatment Satisfaction From Baseline (Vl) to Each MIain Period Postrandomization Visit. FAS |
| Subjects in the FAS, N                                                                                        |                                                                                                               | 441                                                                                                           | 439                                                                                                           | 443                                                                                                           |
| LS means (b)                                                                                                  |                                                                                                               | -0.40                                                                                                         | -0.30                                                                                                         | -0.21                                                                                                         |
| Treatment differenice vs reference arm (b)                                                                    | LS mean (SE)                                                                                                  | -0.20 (0.067)                                                                                                 | -0.09 (0.065)                                                                                                 |                                                                                                               |
| Treatment differenice vs reference arm (b)                                                                    | 95% CI                                                                                                        | (-0.33,-0.06)                                                                                                 | (-0.22, 0.03)                                                                                                 |                                                                                                               |
| Treatment differenice vs reference arm (b)                                                                    | p-value                                                                                                       | 0.004                                                                                                         | 0.150                                                                                                         |                                                                                                               |

Looking at the descriptive data at D84, there are numerically more patients in up-titration group1 that are satisfied (score 0-2) (89.1%) than in the control group (85.7%). On the contrary, there are more patients dissatisfied (score 4-6) in the control group (7.5%) than in up-titration group 1 (3.7%) (Table 15.2.4.3)

Table 20 . Summary of Subject Treatment Satisfaction Assessment (FAS)

| Visit/Response                       | Roflumilast 250 μg OD/ 500 μg OD (N=441)   | Roflumilast 500 μg EoD/ 500 μg OD (N=439)   | Roflumilast 500 μg OD (N=443)   |
|--------------------------------------|--------------------------------------------|---------------------------------------------|---------------------------------|
| Baseline (V1) (n[&])                 | 441                                        | 438                                         | 443                             |
| 0. Very satisfied                    | 72 (16.3)                                  | 76 17.4)                                    | 79 17.8)                        |
| 1.Satisfied                          | 149 33.8)                                  | 143 32.6)                                   | 146 33.0)                       |
| 2. Somewhat satisfied                | 96 （ 21.8)                                 | 95 21.7)                                    | 107 24.2)                       |
| 3.Neither satisfied nor dissatisfied | 81 18.4)                                   | 72 16.4)                                    | 62 14.0)                        |
| 4.Somewhat dissatisfied              | 29 ( 6.6)                                  | 34 7.8)                                     | 29 6.5)                         |
| 5. Dissatisfied                      | 12 2.7)                                    | 14 3.2)                                     | 17 3.8)                         |
| 6.Very dissatisfied                  | 2 0.5)                                     | 4 0.9)                                      | 3 0.7)                          |
| Vend (Day 84)(n[&])                  | 407                                        | 416                                         | 412                             |
| 0. Very satisfied                    | 114 28.0)                                  | 109 26.2)                                   | 98 23.8)                        |
| 1.Satisfied                          | 167 （ 41.0)                                | 155 （ 37.3)                                 | 167 40.5)                       |
| 2. Somewhat satisfied                | 82 20.1)                                   | 93 22.4)                                    | 89 21.6)                        |
| 3.Neither Satisfied nor dissatisfied | 29 ( 7.1)                                  | 38 9.1)                                     | 27 ( 6.6)                       |
| 4.Somewhatdissatisfied               | 7 ( 1.7)                                   | 11 2.6)                                     | 10 2.4)                         |
| 5.Dissatisfied                       | 6 1.5)                                     | 6 ( 2.2)                                    | 19 4.6)                         |
| 6.Very dissatisfied                  | 2 ( 0.5)                                   | 1 0.2)                                      | 2 0.5)                          |

Source: Table 15.2.4.3 of the OPTIMIZE CSR

## · Ancillary analyses

See previous section for sensitivity analyses and subgroup analyses of the main endpoint. No other relevant ancillary analyses are available.

## · Summary of main efficacy results

<div style=\"page-break-after: always\"></div>

The following table summarises the efficacy/safety results from the main study supporting the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

## Table 21. Summary of efficacy for trial RO-2455-302-RD (OPTIMIZE)

| Title: A Multicenter, Randomized, Double-Blind Phase 3 Study to Evaluate Tolerability and Pharmacokinetics of 500 μg Roflumilast Once Daily With an Up-Titration Regimen in COPD, Including an Open-Label Down-Titration Period Evaluating Tolerability and Pharmacokinetics of 250 μg   | Title: A Multicenter, Randomized, Double-Blind Phase 3 Study to Evaluate Tolerability and Pharmacokinetics of 500 μg Roflumilast Once Daily With an Up-Titration Regimen in COPD, Including an Open-Label Down-Titration Period Evaluating Tolerability and Pharmacokinetics of 250 μg   | Title: A Multicenter, Randomized, Double-Blind Phase 3 Study to Evaluate Tolerability and Pharmacokinetics of 500 μg Roflumilast Once Daily With an Up-Titration Regimen in COPD, Including an Open-Label Down-Titration Period Evaluating Tolerability and Pharmacokinetics of 250 μg   | Title: A Multicenter, Randomized, Double-Blind Phase 3 Study to Evaluate Tolerability and Pharmacokinetics of 500 μg Roflumilast Once Daily With an Up-Titration Regimen in COPD, Including an Open-Label Down-Titration Period Evaluating Tolerability and Pharmacokinetics of 250 μg   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                         | in Subjects Not Tolerating 500 μg Roflumilast Once-Daily Study No. RO-2455-302-RD (OPTIMIZE)                                                                                                                                                                                             | in Subjects Not Tolerating 500 μg Roflumilast Once-Daily Study No. RO-2455-302-RD (OPTIMIZE)                                                                                                                                                                                             | in Subjects Not Tolerating 500 μg Roflumilast Once-Daily Study No. RO-2455-302-RD (OPTIMIZE)                                                                                                                                                                                             |
| Design                                                                                                                                                                                                                                                                                   | A Multicenter, Randomized, controlled, Double-Blind, Phase 3 Study                                                                                                                                                                                                                       | A Multicenter, Randomized, controlled, Double-Blind, Phase 3 Study                                                                                                                                                                                                                       | A Multicenter, Randomized, controlled, Double-Blind, Phase 3 Study                                                                                                                                                                                                                       |
| Design                                                                                                                                                                                                                                                                                   | Duration of main phase: Duration of Run-in phase:                                                                                                                                                                                                                                        | Duration of main phase: Duration of Run-in phase:                                                                                                                                                                                                                                        | 84 days (up-titration 28 days + maintenance 56 days) 21 days (prior to randomization)                                                                                                                                                                                                    |
| Design                                                                                                                                                                                                                                                                                   | Duration of Extension phase:                                                                                                                                                                                                                                                             | Duration of Extension phase:                                                                                                                                                                                                                                                             | 8-week down-titration period                                                                                                                                                                                                                                                             |
| Hypothesis                                                                                                                                                                                                                                                                               | Superiority (on discontinuation rates during the 12-week main period).                                                                                                                                                                                                                   | Superiority (on discontinuation rates during the 12-week main period).                                                                                                                                                                                                                   | Superiority (on discontinuation rates during the 12-week main period).                                                                                                                                                                                                                   |
| Treatments groups                                                                                                                                                                                                                                                                        | Group 1: 250 μg OD for 4 weeks followed by 500 μg OD for 8 weeks                                                                                                                                                                                                                         | Group 1: 250 μg OD for 4 weeks followed by 500 μg OD for 8 weeks                                                                                                                                                                                                                         | N= 441                                                                                                                                                                                                                                                                                   |
| Treatments groups                                                                                                                                                                                                                                                                        | Group 2: 500 μg every other day (EOD) followed by 500 μg OD for 8 weeks                                                                                                                                                                                                                  | Group 2: 500 μg every other day (EOD) followed by 500 μg OD for 8 weeks                                                                                                                                                                                                                  | N= 437                                                                                                                                                                                                                                                                                   |
| Treatments groups                                                                                                                                                                                                                                                                        | Group 3: 500 μg OD during the entire 12-week main period                                                                                                                                                                                                                                 | Group 3: 500 μg OD during the entire 12-week main period                                                                                                                                                                                                                                 | N= 443                                                                                                                                                                                                                                                                                   |
| Endpoints and definitions                                                                                                                                                                                                                                                                | Primary endpoint                                                                                                                                                                                                                                                                         | Percentage of subjects prematurely discontinuing study treatment for any reason during the Main Period (from V1 to Vend) (from baseline to end of treatment, D84)                                                                                                                        | OR between treatment groups was analyzed using a logistic regression model, with study treatment, country and baseline FEV1 as explanatory variables. Hierarchical approach: group 1 vs. group 3 followed by Group 2 vs. group 3.                                                        |
| Endpoints and definitions                                                                                                                                                                                                                                                                | Key secondary endpoint 1                                                                                                                                                                                                                                                                 | Percentage of subjects with adverse events (AEs) of interest to evaluate tolerability during Main Period (V1 to Vend). change in                                                                                                                                                         | The percentage of subjects with AEs of interest (diarrhea, nausea, headache, decreased appetite, insomnia, and abdominal pain) was analyzed using a logistic regression analysis as part of the hierarchical approach as described for the primary safety endpoint.                      |
| Endpoints and definitions                                                                                                                                                                                                                                                                | Key secondary endpoint 2                                                                                                                                                                                                                                                                 | prebronchodilator FEV1 during the 8- week down-titration period (V0DT to VendDT) Percentage of subjects prematurely discontinuing study treatment due to any reason during the 8-                                                                                                        | Difference between treatment groups was assessed with an analysis of variance (ANCOVA) model using the last observation carried forward (LOCF) value                                                                                                                                     |
| Endpoints and definitions                                                                                                                                                                                                                                                                | Key secondary endpoint 3                                                                                                                                                                                                                                                                 | week down-titration period (V0DT to VendDT)                                                                                                                                                                                                                                              | treatment during main period.                                                                                                                                                                                                                                                            |
| Database lock                                                                                                                                                                                                                                                                            | N/A. Last patient's last visit/contact on 18 October 2015                                                                                                                                                                                                                                | N/A. Last patient's last visit/contact on 18 October 2015                                                                                                                                                                                                                                | N/A. Last patient's last visit/contact on 18 October 2015                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          | Descriptive, disaggregated by prior                                                                                                                                                                                                                                                      |
| Results and Analysis                                                                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Analysis description                           | Primary Analysis                                                                                                  |
|------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| Analysis population and time point description | Subjects prematurely discontinuing main period. Intent to treat (Full analysis set: FAS), from baseline to day 84 |

H01, H02 = Order of hierarchical testing.

|                                                        | Roflumilast 250 μg OD/500 μg OD (N=441)   | Roflunilast 500 μg EOD/500 μg OD (N=437)   | Roflumilast 500 μg OD (N=443)   |
|--------------------------------------------------------|-------------------------------------------|--------------------------------------------|---------------------------------|
| Subjects prematurely discontinuing Main Period, n (%)  | 81 (18.4)                                 | 88 (20.1)                                  | 109 (24.6)                      |
| p-value for comparison against Reference 500 μg OD (a) | 0.017 (H01)                               | 0.114 (H02)                                |                                 |
| OR (95% CI) for comparison against Reference (a)       | 0.66 (0.47, 0.93)                         | 0.76 (0.55, 1.07)                          |                                 |
| HR (95% CI) for comparison against Reference (b)       | 0.68 (0.51, 0.92)                         | 0.77 (0.58,1.02)                           |                                 |

- (a) Logistic regression model with study treatment, country and baseline FEV as explanatory variables.
- (b) Cox proportional hazards model with study treatment and country as class effects, and baseline FEV as a continuous variable.

## Analysis description Key secondary endpoint 1

Analysis and

population time

description point

Subjects with AEs of interest

Intent to treat (Full analysis set: FAS), from baseline to day 84

|                                                        | Roflumilast 250 μg OD/500 μg OD (N=441)   | Roflumilast 500 μg EOD/500 μg OD (N=437)   | Roflumilast 500 μg OD (N=443)   |
|--------------------------------------------------------|-------------------------------------------|--------------------------------------------|---------------------------------|
| Subjects with AEs of interest, n (%)                   | 200 (45.4)                                | 211 (48.3)                                 | 240 (54.2)                      |
| p-value for comparison against Reference 500 μg OD (a) | 0.001                                     | 0.091                                      |                                 |
| OR(95% CI) for companison against Reference (a)        | 0.63 (0.47,0.83)                          | 0.78 (0.59, 1.04)                          |                                 |

(a) Logistic regression model with study treatment, country and baseline FEV as explanatory variables.

## Analysis description Key secondary endpoint 2

Analysis and

population time

description

Change in pre-BD FEV1 during down-titration period.

Intent to treat (Full analysis set: FAS), during the 8-week open-label down- titration period

point

|                                                                                                                       |                                                                                                                       | Roflumilast 250 μg OD/500μg OD                                                                                        | Roflumilast 500 μg EOD/500 μg OD                                                                                      | Roflumilast 500 pg OD                                                                                                 |
|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| Change in Prebronchodilator FEV1 (L) From Baseline (VOpr) to Last Scheduled Down-Titration Period Visit (Vendpr), FAS | Change in Prebronchodilator FEV1 (L) From Baseline (VOpr) to Last Scheduled Down-Titration Period Visit (Vendpr), FAS | Change in Prebronchodilator FEV1 (L) From Baseline (VOpr) to Last Scheduled Down-Titration Period Visit (Vendpr), FAS | Change in Prebronchodilator FEV1 (L) From Baseline (VOpr) to Last Scheduled Down-Titration Period Visit (Vendpr), FAS | Change in Prebronchodilator FEV1 (L) From Baseline (VOpr) to Last Scheduled Down-Titration Period Visit (Vendpr), FAS |
| Subjects in the FAS, N                                                                                                | Subjects in the FAS, N                                                                                                | 441                                                                                                                   | 439                                                                                                                   | 443                                                                                                                   |
| Subjects in the FAS analyzed, n                                                                                       | Subjects in the FAS analyzed, n                                                                                       | 20                                                                                                                    | 22                                                                                                                    | 38                                                                                                                    |
| LS means (a)                                                                                                          | LS means (a)                                                                                                          | 0.01                                                                                                                  | 0.13                                                                                                                  | 0.00                                                                                                                  |
| Treatment difference vs reference arm (a)                                                                             | LS mean (SE)                                                                                                          | 0.02 (0.095)                                                                                                          | 0.13 (0.093)                                                                                                          |                                                                                                                       |
| Treatment difference vs reference arm (a)                                                                             | 95% CI                                                                                                                | (-0.17, 0.20)                                                                                                         | (-0.05, 0.32)                                                                                                         |                                                                                                                       |
| Treatment difference vs reference arm (a)                                                                             | p-value                                                                                                               | 0.871                                                                                                                 | 0.162                                                                                                                 |                                                                                                                       |

## Analysis description

Key secondary endpoint 3

<div style=\"page-break-after: always\"></div>

<!-- image -->

## 2.9.2. Discussion on clinical efficacy

## Design and conduct of clinical studies

This submission is based on data from a single study (Study RO 2455 302-RD [OPTIMIZE]) conducted to  fulfil  a  Committee  for  Medicinal  Products  for  Human  Use  (CHMP)  postauthorisation  measure (FUM004) to explore alternative doses of roflumilast to minimise the risk of  drug interactions, poor tolerability, and the influence of factors such as gender, age, and smoking status on the bioavailability of the product in patients with chronic obstructive pulmonary disease (COPD).

OPTIMIZE was a multicenter, randomized, double-blind, 3-arm, parallel group, phase 3 study with an open-label Down-Titration Period for subjects who withdrew from the Main Period of the study. During the Main Period, subjects were randomized receive 1 of the 3 treatments consisting of 2 up-titration treatment groups: 250 μg OD or 500 μg EOD for the first 4 weeks followed by 500 μg OD for 8 weeks, and the currently approved roflumilast regimen of 500 μg OD administered for 12 weeks. During the Main  Period,  the  first  4  weeks  (up-titration)  was  double-blinded,  and  the  following  8  weeks (maintenance  period)  was  single-blinded.  All  subjects  discontinuing  from  the  Main  Period  were permitted to enter an 8-week open-label Down-Titration Period where they received roflumilast 250 μg OD.

Spirometry  and  subject-assessed  treatment  satisfaction  for  efficacy  assessments  were  performed  at Screening (V0, Days -21 to -7), Randomization (V1, Day 1), and at Weeks 2, 4, 8, and 12 (Visits V2, V3, V4, and Vend) of the Main Period, and at Baseline (V0DT=Vend of Main Period) and at Weeks 2, 4 and 8 (Visits V1DT, V2DT and VendDT) of the Down-Titration Period. Six milliliter blood samples for PK analysis were drawn at Visits V2, V4, Vend/V0DT, V1DT, V2DT and VendDT.

Inclusion and exclusion criteria in OPTIMIZE study are in line with the indication (severe COPD and a history  of  exacerbations)  and  contraindications/non-recommendation  of  use  detailed  in  the  Daxas SmPC. Study medications included  roflumilast 250 μg tablet, 500 μg tablet and placebo (roflumilast 0 μg  tablet).    Placebo  was  used  only  during  the  4-week  up-titration  period  (the  only  phase  that  was double-blinded)  (the  8  week  continuation  after  initial  4-week  up-titration  was  single  blinded,  as investigators knew that all patients were receiving the roflumilast 500 μg tablet, although they were unaware of the type of initial 4-week treatment that patients had received).

Primary Endpoint was the percentage of subjects prematurely discontinuing study treatment due to any  reason  during  Main  Period.  Key  Secondary  Endpoints  included  the  percentage  of  subjects  with adverse  events  (AEs)  of  interest  to  evaluate  tolerability  during  Main  Period,    the  change  in prebronchodilator FEV1 during Down-Titration Period (V0DT to VendDT) and the percentage of subjects prematurely discontinuing study treatment due to any reason during Down-Titration Period (V0DT to VendDT). Other secondary endpoints were:  change in prebronchodilator FEV1 during Main Period of the  study,  change  in  prebronchodilator  FVC  during  Main  Period  and  also  including  Down-Titration Period; change in subject-assessed treatment satisfaction scores during Main Period of the study and also including Down-Titration Period.

Randomisation and blinding/masking methods were appropriate.

<div style=\"page-break-after: always\"></div>

Subjects were randomized into the double-blind main treatment period at a total of 161 sites in 15 countries:  Bulgaria  (11  sites),  Germany  (9),  Greece  (5),  Hungary  (21),  Republic  of  Korea  (9), Philippines (4), Poland (15), Romania (19), Russia (17), Slovakia (12), South Africa (14), Spain (2), Thailand (3), Ukraine (14), and United Kingdom (6). During the study, persistent noncompliance was noted at site  6002,  which  was  based  in  South  Africa.  At  the  time  of  the  investigation,  the  site  had screened 5 subjects; 1 subject was a screen failure, and 4 subjects had completed the study. The site was closed from further participation in the study protocol. A request for triggered GCP inspection  was proposed  by  the  Rapporteur  for  the  following  clinical  study:  RO-2455-302-RD  (OPTIMIZE)  and  was discussed at CHMP.  It should be ruled out that the non compliance on GCP is an isolated finding in center  6002  in  South-Africa  or  if  it  is  systemic  to  the  whole  trial.  The  CHMP  did  not  find  sufficient reasons to trigger an inspection for this study.

## Efficacy data and additional analyses

A total of 1321 randomized patients received at least one dose of study drug (441 in 250/500 microg group  1;  437  in  500  microg  EOD  group  2;  443  in  the  500  microg  OD  control  group).  Overall, demographic characteristics were similar across the 3 treatment groups. The majority of subjects in each  treatment  group  were  White  (405  subjects  [91.8%]  in  the  roflumilast  250  μg  OD/500  μg  OD group,  399  subjects  [91.3%]  in  the  roflumilast  500  μg  EOD/500  μg  OD  group  and  405  subjects [91.4%] in the roflumilast 500 μg OD group). The mean (SD) age of subjects was 64.2 (7.81), 65.0 (8.21), and 64.6 (8.36) years in the roflumilast 250 μg OD/500 μg OD, 500 μg EOD/500 μg OD, and 500  μg  OD  groups,  respectively.  The  250  μg  OD/  500  μg  OD  dose  group  was  comprised  of  more subjects aged 40 to 64 years (54.9% of subjects) than the other 2 dose groups (46.2% and 50.6% for 500 μg EOD/ 500 μg OD and 500 μg OD, respectively). The majority of subjects in each treatment group  were  male  (72.6%  in  roflumilast  250  μg  OD/500  μg  OD  group,74.4%  in  roflumilast  500  μg EOD/500 μg OD group, and 76.3% in roflumilast 500 μg OD group).

Nearly all subjects in the Main Period (1320 subjects, 99.9%) were receiving an ongoing concomitant medication at Baseline. Overall, the type and frequency of concomitant medication was broadly similar across treatment groups. About 67% of patients was receiving a dual ICS+LABA combination during the main period, and 63% of patients were receiving a LAMA. However, no data about the aggregated number  of  patients  receiving  the  ICS+LAMA  combination  or  ICS+LABA+LAMA  combination  were reported. Tolerability may differ (be worse) at increasing number of concomitant medications. In fact, concomitant LAMA use was a covariate in the PK/PD model of adverse events.

During the procedure, the applicant was requested to analyse the main endpoint and key secondary safety endpoint in the target population included in the product labelling (i.e.: severe COPD patients treated with ICS plus LABA and/or LAMA), separately for dual combination (ICS+LABA or LAMA) and triple combination (ICS+LABA+LAMA) and to discuss the findings. The results were hampered by its post-hoc nature and lack of statistical power due to small sample sizes. Anyway, the analysis provided justify  for  all  of  the  subgroups  studied  to  take  advantage  of  the  250  µg  OD/500 µg  OD  up-titration regimen, regardless of concomitant LAMA or multiple concomitant medication use.

Percentage  of  Subjects  Prematurely  Discontinuing  Study  Treatment  Due  to  Any  Reason During the Main Period (main endpoint): Compared with roflumilast 500 μg OD [H01] the odds of discontinuing the Main Period using a logistic regression model were statistically significantly lower in the roflumilast 250 μg OD/500 μg OD treatment group at the 5% significance level (24.6% vs. 18.4% of subjects, OR=0.66, 95% CI: 0.47, 0.93; p-value 0.017, primary endpoint). At the 5% significance level,  there  was  no  statistically  significant  difference  between  roflumilast 500 μg  OD  and  roflumilast 500  μg  EOD/500  μg  OD  treatment  groups  [H02]  (OR  0.76,  95%  CI:  0.55,  1.07;  p-value  0.114). Supportive  analysis  Cox  proportional  hazards  model  found  a  similar  result  for  roflumilast  250  μg OD/500 μg OD (HR=0.68, 95 % CI: 0.51, 0.92) and roflumilast 500 μg EOD/500 μg OD (HR=0.77, 95% CI: 0.58, 1.02) versus roflumilast 500 μg OD.

The results based on the logistic regression model with region as a covariate, instead of country, were consistent with the primary analysis results. Compared with roflumilast 500 μg OD [H01The odds of discontinuing  from  the  Main  Period  were  lower  in  the  roflumilast  250  μg  OD/500  μg  OD  treatment group  (OR=0.70,  95%  CI:  0.50,  0.97;  p-value  0.032).  The  results  of  the  sensitivity  analyses  by

<div style=\"page-break-after: always\"></div>

excluding  the  South  African  site  (Site  6002)  for  the  primary  endpoint  supported  the  results  of  the primary analysis also yielded significant differences (OR=0.66, 95% CI: 0.47, 0.93; p-value 0.017).

Strictly  speaking,  the  single  pivotal  trial  supporting  this  application  does  not  fulfill  with  the  level  of statistical significance (considerably stronger than &lt;0.05) normally required for application based on a single  pivotal  trial  (Points  to  consider  on  application  with  1.  meta-analyses;  2.  one  pivotal  study; CHMP/EWP/2330/99).  However,  it  has  to  bear  in  mind  that,  on  the  one  hand,  the  results  on  the primary  (safety)  endpoint  were  quite  robust,  with  all  sensitivity  and  ancillary  analyses  of  the  main endpoint  showing  a  benefit,  and  with  all  secondary  endpoint  showing  also  a  benefit  in  safety  and patient's  satisfaction  and  no  detrimental  effect  on  efficacy  (pre-BD  FEV1).  On  the  other  hand,  the efficacy of roflumilast is out of question at this stage, and the line extension is restricted to improve the initial tolerability and decrease early withdrawal rates with treatment by starting with a lower dose. It  is  concluded  that  starting  with  a  halved  dose  for  the  first  4  weeks  followed  by  the  500  microg maintenance dose is safer than starting with 500 microg dose. In addition, no claims of efficacy are made for this starting dose.

Anyway,  while  recognizing  that  a  streamlined  posology  aimed  to  minimize  adverse  events  and treatment discontinuations is a positive goal, the applicant was requested to discuss about the clinical relevance and impact of decreasing the number of discontinuations by 6.2% in terms of preventing exacerbations.    With  a  6.2%  reduction  of  discontinuations  in  the  current  population  treated  with roflumilast would translate into a 12.9% reduction in exacerbations during the first year. According to market share of roflumilast in different regions, this would translate in the prevention of additional 340 exacerbations in Europe and 1031 exacerbations globally, compared with starting with the 500 microg dose. This benefit is added to the adverse events (mainly gastrointestinal) prevented.

During the procedure, the applicant was requested to discuss whether the results at 3 months would be sustained in the long term. In roflumilast clinical trials, Kaplan-Meier plots of time to onset of AEs show that the majority of events in the roflumilast treated-patients occur early, and that there is a plateau after  4  weeks.  Therefore,  the  first  4 weeks  of  treatment  represents  the  dosing  period  most relevant to the aims of the study (ie, to improve tolerability of roflumilast through use of alternative dosing regimens).  After this time, there is no evidence to support a need for further improvements, as the frequency of AEs with roflumilast is not higher than with placebo, and the rate of withdrawals from study treatment are low.

The results of the per protocol analysis provided during the procedure wer consistent with the results of  the  primary  analysis  and  supported  the  finding  that  protocol  deviations  had  no  impact  on  the interpretation of the study data.

Most  subgroups  trended  towards  favouring  the  250/500  microg  OD  up-titration  regimen  with  some exceptions. The subgroups that trended towards favoring reference treatment (roflumilast 500 μg OD) were  non-European  region  and  Asian  race  (versus  roflumilast  250  μg  OD/500  μg  OD),  and  northEastern Europe region and current smoking status (versus roflumilast 500 μg EOD/500 μg OD).

Race was not a significant covariate in population PK analysis, whereas in subgroup analyses of pivotal studies  (Study M2-124  and  Study  M2-125),  the  effect  of  roflumilast  versus  placebo  on  the  rate  of moderate or severe exacerbations showed no heterogeneity depending on race.  Results from the new population PK model on the combined REACT and OPTIMIZE dataset identified no clinically relevant changes of systemic exposure levels in other populations of particular interest (eg, elderly patients, female  patients,  smoking  status,  or  patients  with  high  [&gt;80 kg]  or  low  [&lt;60 kg]  baseline  body weight).  With respect to race, Therefore, the approved maintenance dose of roflumilast 500 μg OD does not need to be adjusted in these populations.

<div style=\"page-break-after: always\"></div>

Elderly patients seem under-represented in the OPTIMIZE study, and they are a special population at risk of adverse events and withdrawals. The applicant clarified that only 115 patients were between 75 to 84 years and only 2 patients were &gt;85 years old. With the limitations of small sample sizes, the subgroup analyses by age showed some small increases in adverse events with age with all dosing regimes, but the benefit of the new dosing regime in avoiding adverse events and discontinuations was consistently in favour of the new roflumilast regime regardless of age.

## TEAEs of Interest during the Main Period (Key Secondary Safety Endpoint):

The more frequent TEAEs of interest were diarrhea, decreased appetite, nausea and headache, all of them occurring more frequently and starting soon in the control group than in the roflumilast 250 μg OD/500 μg OD experimental group. Compared with roflumilast 500 μg OD, the odds of experiencing a 'TEAE of interest' was significantly lower at the 5% significance level in the roflumilast 250 μg OD/500 μg OD treatment group (54.2% versus 45.4% of subjects, OR=0.63, 95% CI: 0.47, 0.83; p-value = 0.001).  This  difference  was  not  observed  between  roflumilast  500  μg  EOD/500  μg  OD  (48.3%  of subjects) and the roflumilast 500 μg OD (54.2%) treatment groups in the analysis of AEs of interest.

The  results  of  the  statistical  analysis  of  TEAEs  of  Interest  (diarrhea,  nausea,  headache,  reduced appetite, insomnia, or abdominal pain) during the Main Period are supportive and consistent with the results  on  the  main  study  endpoint.  However, they are considered exploratory based on insufficient evidence to reject the null hypothesis for the primary endpoint at the 5% significance level [H02] in the  framework of hierarchical  testing  (i.e.:  no  statistically  significant  differences  were  found  for  the comparison between groups 2 and 3 for the primary endpoint of premature discontinuations).

## Change From Baseline in Prebronchodilator FEV1:

## a) Main treatment period:

Improvements in prebronchodilator FEV1 from V1 to each Main Period postrandomization visit were clinically  relevant  (approximately  100  mL)  and  showed  minimal  differences  across  the  3  treatment groups (LS means of 0.09 L, 0.13 L, and 0.11 L for roflumilast 250 μg OD/500 μg OD, 500 μg EOD/500 μg OD, and roflumilast 500 μg OD treatment groups, respectively). Similar results were shown when subjects for both Main Period and Down-Titration Period were evaluated (LS means of 0.07 L, 0.14 L, and 0.10 L for roflumilast 250 μg OD/500 μg OD, 500 μg EOD/500 μg OD, and roflumilast 500 μg OD treatment groups, respectively).

## b ) Down-Titration Period:

The analysis of main interest was for those patients who did not tolerate roflumilast 500 μg OD during the  Main  Period  and  subsequently  entered  the  down-Titration  period  (n=80),  in  order  to  ascertain whether a the 250 microgram dose, administered to all of them, could be effective (i.e.: whether it could produce improvements in pre-BD FEV1 from the start of downtitration to end of downtitration). Eighty subjects (of 1321 subjects, 6.0%) who did not tolerate roflumilast 500 μg OD in the Main Period were treated with roflumilast 250 μg OD for 8 weeks (n=20 for the roflumilast 250 μg OD/500 μg OD group, n=22 for roflumilast 500 μg EOD/500 μg OD group, and n=38 for the roflumilast 500 μg OD group at Baseline, V0DT). The analyses indicated no effect of the 250 microgram low-dose roflumilast in  pre-BD  FEV1.  The  lack  of  effect  on  pre-BD  FEV1  of  a  lower  roflumilast  maintenance  dose  was consistent in the per-protocol analysis based on the VCS and in several sensitivity analyses.

During the procedure, it was introduced in the product information that the 250 micrograms dose is subtherapeutic and should not be used for maintenance treatment.

<div style=\"page-break-after: always\"></div>

FVC: In  all  treatment groups, mean FVC increased from V1 to Vend with minimal differences across the 3 treatment groups. Similar results were shown when subjects for both Main Period and DownTitration Period were evaluated.

Patients'  satisfaction  with  treatment: The  secondary  outcome  of  mean  treatment  difference  in increased patient's satisfaction with treatment is difficult to interpret in terms of clinical relevance, as the  mean  values  at  study  time-point  compared  with  baseline  remain  between  1  (satisfied)  and  2 (somewhat satisfied) regardless of dosing schedule applied. Looking at the descriptive data at D84, there are numerically more patients in up-titration group1 that are very satisfied or satisfied (89.1%) than in the control group (85.7%). On the contrary, there are more patients dissatisfied (score 4-6) in the control group (7.5%) than in the up-titration group 1 (3.7%). Therefore, it seems that patient's satisfaction tended to be improved with the up-titration regime than with the standard regime. These results  are  consistent  with  the  primary  endpoint  of  treatment  withdrawals  and  the  key  secondary endpoint of AEs of interest (less risk of diarrhoea, insomnia, nausea). Patient's satisfaction with uptitration probably reflects a better tolerability (less adverse events with the 250 microg to 500 microg up-titration)  at  similar  efficacy  in  terms  of  lung  function  improvement  (i.e.:  similar  improvement  in pre-BD FEV1 regardless of dosing schedule, close to +100 ml).

## 2.9.3. Conclusions on clinical efficacy

This submission is based on data from a single study (Study RO 2455 302-RD [OPTIMIZE]) conducted to  fulfil  a  Committee  for  Medicinal  Products  for  Human  Use  (CHMP)  post-authorization  measure (FUM004) to explore alternative doses of roflumilast to minimize the risk of poor tolerability, and to investigate the influence of factors such as gender, age, and smoking status on the bioavailability of the product in patients with chronic obstructive pulmonary disease (COPD).

Compared with standard dosing (roflumilast 500 μg OD),  patients on the roflumilast 250 μg OD/500 μg  OD  up-titration  dosing  regimen  had  statistically  significant  lower  odds  of  discontinuing  the  Main Period using a logistic regression model (24.6% vs. 18.4% of subjects, OR=0.66, 95% CI: 0.47, 0.93; p-value 0.017, primary endpoint). Supportive analysis Cox proportional hazards model found a similar result  for  roflumilast  250  μg  OD/500  μg  OD  (HR=0.68,  95  %  CI:  0.51,  0.92).  The  results  were consistent  using  region  as  a  covariate,  instead  of  country.  In  addition,  the  results  of  the  sensitivity analyses  by  excluding  the  South  African  site  (Site  6002)  for  the  primary  endpoint  also  yielded significant differences (OR=0.66, 95% CI: 0.47, 0.93; p-value 0.017). On the contrary, the second uptitration regime tested (roflumilast 500 μg EOD/500 μg OD) was not superior to the standard dosing regime in reducing discontinuations (OR 0.76, 95% CI: 0.55, 1.07; p-value 0.114).

While  recognizing  that  a  streamlined  posology  aimed  to  minimize  adverse  events  and  treatment discontinuations is a positive goal, the applicant was requested to discuss about the clinical relevance and impact of decreasing the number  of discontinuations by 6.2%  in terms of preventing exacerbations.  The  applicant  considered  that,  6.2%  reduction  of  discontinuations  in  the  current population treated with roflumilast would translate into a 12.9% reduction in exacerbations during the first  year.  According  to  market  share  of  roflumilast  in  different  regions,  this  would  translate  in  the prevention of additional 340 exacerbations in Europe and 1031 exacerbations globally, compared with starting with the 500 microg dose. This benefit is added to the adverse events (mainly gastrointestinal) prevented.

Most subgroups trended towards favouring the 250/500 microgram OD up-titration regimen with some exceptions (non-European region and Asian race).   Race was not a significant covariate in population PK analysis, whereas in subgroup analyses of pivotal studies (Study M2-124 and Study M2-125), the effect  of  roflumilast  versus  placebo  on  the  rate  of  moderate  or  severe  exacerbations  showed  no heterogeneity depending on race.  Results from the new population PK model on the combined REACT and OPTIMIZE dataset identified  no  clinically  relevant  changes  of  systemic  exposure  levels  in  other populations  of  particular  interest  (eg,  elderly  patients,  female  patients,  smoking  status,  or  patients

<div style=\"page-break-after: always\"></div>

with  high  [&gt;80 kg]  or  low  [&lt;60 kg]  baseline  body  weight).    With  respect  to  race,  Therefore,  the approved  maintenance  dose  of  roflumilast  500 μg  OD  does  not  need  to  be  adjusted  in  these populations.

With respect to lung function, the three dosing regimens were associated to similar improvements in pre-BD FEV1 versus baseline, thus suggesting that all treatment approaches had similar efficacy. The analysis of FEV1 during down-titration period in patients who did not tolerate roflumilast in the main period indicated no effect of the 250 microgram low-dose roflumilast in pre-BD FEV1. The lack of effect on pre-BD FEV1 of a lower roflumilast maintenance dose was consistent in the per-protocol analysis based on the VCS and in several sensitivity analyses. In the product information it has been reinforced the message that the 250 micrograms dose is sub-therapeutic and should not be used for maintenance treatment.

## 2.9.4. Clinical safety

## Patient exposure

A summary of the duration of exposure to study drug (in weeks) during the Main Period is described in Table 24. The mean and median duration of exposure was broadly similar across treatment groups. The roflumilast 500 μg OD treatment group tended to have a greater number of subjects (72 of 443 subjects,  16.3%)  who  received  treatment  for  ≤4  weeks  compared  with  the  up-titration  treatment groups. More than 80% of subjects in each treatment group had exposure to roflumilast for more than 8 weeks during the Main Period (Table 24).

Table 22 . Main Period Study Medication Exposure (SAS, Main Period)

|                                                       | Roflumilast 250 μg OD/500 μg OD (N=441)   | Roflumilast500μg EOD/500 μg OD (N=437)   | Roflumilast 500 μg OD (N=443)   |
|-------------------------------------------------------|-------------------------------------------|------------------------------------------|---------------------------------|
| Duration of Exposure in Main Period (weeks)           |                                           |                                          |                                 |
| Mean (SD)                                             | 10.836 (3.0715)                           | 10.647 (3.1956)                          | 10.040 (3.8944)                 |
| Median (minimum,maximum)                              | 12.000 (0.14, 21.14)                      | 11.857 (0.14, 16.43)                     | 11.857 (0.14, 15.00)            |
| Duration of Exposure Categories in Main Period, n (%) |                                           |                                          |                                 |
| ≤4 weeks                                              | 35 (7.9)                                  | 42 (9.6)                                 | 72 (16.3)                       |
| >4 weeks - ≤8 weeks                                   | 28 (6.3)                                  | 20 (4.6)                                 | 16 (3.6)                        |
| >8 weeks                                              | 378 (85.7)                                | 375 (85.8)                               | 355 (80.1)                      |

Source: Table 15.1.14.1.

Study drug exposure is calculated as (the date of last dose - date of first dose + 1)/7).

## Down-Titration Period

Patients  were  exposed  to  roflumilast  250  micrograms  for  a  mean  between  6.7  to  7.2  weeks  in subgroups by prior treatment. At least 80% of subjects were exposed to roflumilast 250 micrograms for  more  than  4  weeks  during  the  Down-Titration  Period  in  subgroups  by  prior  treatment.  Only  12 patients were exposed for less than 4 weeks.

## Adverse events

## Summary of AEs by relatedness and severity

Main  Period: An  overview  of  TEAEs  occurring  during  the  Main  Period  is  summarized  in  Table  25. Overall, 61.2%, 64.3%, and 65.7% of subjects receiving 250 μg OD/500 μg OD, 500 μg EOD/ 500 μg OD, and 500 μg OD, respectively, experienced at least 1 TEAE during the Main Period (Table 25). The

<div style=\"page-break-after: always\"></div>

majority of TEAEs were investigator-assessed as unrelated to study treatment, and were rated mild-tomoderate intensity. In 15.3% of subjects, the TEAE led to study drug discontinuation.

Serious  TEAEs  occurred  in  a  similar  proportion  of  subjects  across  treatment  groups  (4.3%-5.0%  of subjects); the majority of SAEs were investigator-assessed as unrelated to study treatment.

Overall, 6 subjects (0.5%) died (1 further subject died ≥30 days after the last dose of roflumilast and is not included in Table 25, but is discussed in next section about SAES and death.

Table 23 . Overview of TEAEs Occurring in the Main Period (SAS, Main Period)

|                                           | Roflumilast 250 μg OD/500 g OD (N=441)   | Roflumilast 250 μg OD/500 g OD (N=441)   | Roflumilast 500 μg EOD/500 μg OD (N=437)   | Roflumilast 500 μg EOD/500 μg OD (N=437)   | Roflumilast 500 μg OD (N=443)   | Roflumilast 500 μg OD (N=443)   | Total (N=1321)   | Total (N=1321)   |
|-------------------------------------------|------------------------------------------|------------------------------------------|--------------------------------------------|--------------------------------------------|---------------------------------|---------------------------------|------------------|------------------|
|                                           | n (%)                                    | Events                                   | n (%)                                      | Events                                     | n (%)                           | Events                          | n (%)            | Events           |
| Any TEAE                                  | 270 (61.2)                               | 1575                                     | 281 (64.3)                                 | 1613                                       | 291 (65.7)                      | 1676                            | 842 (63.7)       | 4864             |
| Related                                   | 145 (32.9)                               | 556                                      | 159 (36.4)                                 | 632                                        | 177 (40.0)                      | 690                             | 481 (36.4)       | 1878             |
| Not related                               | 125 (28.3)                               | 1019                                     | 122 (27.9)                                 | 981                                        | 114 (25.7)                      | 986                             | 361 (27.3)       | 2986             |
| Mild                                      | 132 (29.9)                               | 1250                                     | 135 (30.9)                                 | 1272                                       | 142 (32.1)                      | 1321                            | 409 (31.0)       | 3843             |
| Moderate                                  | 115 (26.1)                               | 293                                      | 120 (27.5)                                 | 292                                        | 122 (27.5)                      | 311                             | 357 (27.0)       | 896              |
| Severe                                    | 23 (5.2)                                 | 32                                       | 26 (5.9)                                   | 49                                         | 27 (6.1)                        | 44                              | 76 (5.8)         | 125              |
| Leading to study drug discontinuation (a) | 58 (13.2)                                | 138                                      | 67 (15.3)                                  | 157                                        | 77 (17.4)                       | 209                             | 202 (15.3)       | 504              |
| Serious TEAEs                             | 19 (4.3)                                 | 24                                       | 22 (5.0)                                   | 30                                         | 20 (4.5)                        | 27                              | 61 (4.6)         | 81               |
| Related                                   | 1 (0.2)                                  | 1                                        | 1 (0.2)                                    | 1                                          | 1 (0.2)                         | 1                               | 3 (0.2)          | 3                |
| Not related                               | 18 (4.1)                                 | 23                                       | 21 (4.8)                                   | 29                                         | 19 (4.3)                        | 26                              | 58 (4.4)         | 78               |
| Leading to study drug discontinuation (a) | 4 (0.9)                                  | 5                                        | 4 (0.9)                                    | 6                                          | 7 (1.6)                         | 7                               | 15 (1.1)         | 18               |
| Deaths                                    | 3 (0.7)                                  | 3                                        | 1 (0.2)                                    | 1                                          | 2 (0.5)                         | 2                               | 6 (0.5)          | 6                |

Source: Table 15.3.1.1.1 and Appendix 16.2.7.1.

A TEAE in the Main Period is defined as any AE, regardless of relationship to study medication that occurs after the first dose of study medication in the Main Period and within 30 days after the last study medication in the Main Period or before the first dose of study medication in the Down-Titration Period.

For each summary only the worst case per subject is counted.

(a) TEAEs leading to study drug discontinuation include both temporary drug interruption and permanent discontinuation, with a subject counted just once for multiple internuptions and permanent discontinuation.

Down-Titration  Period: As  shown  in  Table  26,  TEAEs  occurred  in  45.0%,  50.0%,  and  65.8%  of subjects  who  entered  the  Down-Titration  Period  after  receiving  roflumilast  250  μg  OD/500  μg  OD (N=20), 500 μg EOD/500 μg OD (N=22), and 500 μg OD (N=38), respectively, during the Main Period. In 12.5% of subjects, the TEAE led to study drug discontinuation. One subject in the roflumilast 250 μg OD/500 μg OD treatment group experienced a serious and treatment-related TEAE (of COPD). There were no deaths during the Down-Titration Period.

## Table 24 . Overview of TEAEs Occurring in the Down-Titration Period in Subjects Who Did Not Tolerate Roflumilast 500 μg OD in the Main Period (SAS, DownTitration Period)

<div style=\"page-break-after: always\"></div>

|                                           | Roflumilast 250 μg OD/500 μg OD (N=20)   | Roflumilast 250 μg OD/500 μg OD (N=20)   | Roflumilast 500 μg E0D/500 μg OD (N=22)   | Roflumilast 500 μg E0D/500 μg OD (N=22)   | Roflumilast 500 μg OD (N=38)   | Roflumilast 500 μg OD (N=38)   | Total (N=80)   | Total (N=80)   |
|-------------------------------------------|------------------------------------------|------------------------------------------|-------------------------------------------|-------------------------------------------|--------------------------------|--------------------------------|----------------|----------------|
|                                           | n (%)                                    | Events                                   | n (%)                                     | Events                                    | (%) uI                         | Events                         | n (%)          | Events         |
| Any TEAE                                  | 9 (45.0)                                 | 22                                       | 11 (50.0)                                 | 41                                        | 25 (65.8)                      | 100                            | 45 (56.3)      | 163            |
| Related                                   | 5 (25.0)                                 | 7                                        | 6 (27.3)                                  | 21                                        | 20 (52.6)                      | 77                             | 31 (38.8)      | 105            |
| Not related                               | 4 (20.0)                                 | 15                                       | 5 (22.7)                                  | 20                                        | 5 (13.2)                       | 23                             | 14 (17.5)      | 58             |
| Mild                                      | 3 (15.0)                                 | 11                                       | 6 (27.3)                                  | 33                                        | 16 (42.1)                      | 87                             | 25 (31.3)      | 131            |
| Moderate                                  | 6 (30.0)                                 | 11                                       | 5 (22.7)                                  | 8                                         | 8 (21.1)                       | 12                             | 19 (23.8)      | 31             |
| Severe                                    | 0                                        | 0                                        | 0                                         | 0                                         | 1 (2.6)                        | 1                              | 1 (1.3)        | 1              |
| Leading to study drug discontinuation (a) | 2 (10.0)                                 | 2                                        | 2 (9.1)                                   | 5                                         | 6 (15.8)                       | 10                             | 10 (12.5)      | 17             |
| Serious TEAEs                             | 1 (5.0)                                  | 1                                        | 0                                         | 0                                         | 0                              | 0                              | 1 (1.3)        | 1              |
| Related                                   | 1 (5.0)                                  | 1                                        | 0                                         | 0                                         | 0                              | 0                              | 1 (1.3)        | 1              |
| Not related                               | 0                                        | 0                                        | 0                                         | 0                                         | 0                              | 0                              | 0              | 0              |
| Leading to study dnug discontinuation (a) | 0                                        | 0                                        | 0                                         | 0                                         | 0                              | 0                              | 0              | 0              |
| Deaths                                    | 0                                        | 0                                        | 0                                         | 0                                         | 0                              | 0                              | 0              | 0              |

A TEAE in the down-titration period is defined as any AE, regardless ofrelationship to study medication, that occurs after the first dose of study medication in the down-titration period and within 30 days after the last study medication in the down-titration period.

Source: Table 15.3.1.1.2A and Appendix 16.2.7.1.

For each summary only the worst case per subject is counted.

subject counted just once for multiple interruptions and permanent discontinuation.

## Overview of TEAEs by System Organ Class (SOC)

Main Period: TEAEs reported in ≥2% of subjects in any treatment group are summarized in Table 27 for the Main Period. The most frequently reported TEAEs during the Main Period were in the SOCs of Gastrointestinal disorders (36.5%, 38.2%, and 44.2% of subjects in 250 μg OD/500 μg OD, 500 μg EOD/500 μg OD, and 500 μg OD treatment groups, respectively), Nervous system disorders (27.0%, 30.9%, and 29.3% of subjects, respectively), Metabolism and nutrition disorders (23.1%, 24.9%, and 30.0%, respectively), and Psychiatric disorders (22.9%, 24.9%, and 25.5% of subjects, respectively). TEAEs  in  the  SOC  Cardiac  disorders  were  infrequent  (1.2%  of  1321  subjects),  occurring  in  1.6%, 1.1%,  and  0.9%  of  subjects  in  250  μg  OD  500  μg  OD,  500  μg  EOD/500  μg  OD,  and  500  μg  OD treatment groups, respectively. TEAEs in the SOC Infections and infestations occurred in 8.8%, 10.8%, and 9.5% of subjects in 250 μg OD/ 500 μg OD, 500 μg EOD/500 μg OD, and 500 μg OD treatment groups, respectively (9.7% of 1321 subjects).

## Table 25 . Most Frequent (≥2% of Subjects in Any Treatment Group) TEAEs Occurring in the Main Period by SOC and PT (SAS, Main Period)

<div style=\"page-break-after: always\"></div>

| SOC PT (MedDRA)                                 | Roflumilast 250 μg OD/500μgOD (N=441)   | Roflumilast 250 μg OD/500μgOD (N=441)   | Roflumilast 500 μg EOD/500μg OD (N=437)   | Roflumilast 500 μg EOD/500μg OD (N=437)   | Roflumilast 500 μg OD (N=443)   | Roflumilast 500 μg OD (N=443)   | Total (N=1321)   | Total (N=1321)   |
|-------------------------------------------------|-----------------------------------------|-----------------------------------------|-------------------------------------------|-------------------------------------------|---------------------------------|---------------------------------|------------------|------------------|
|                                                 | n (%)                                   | n*                                      | n (%)                                     | n*                                        | n (%)                           | n'                              | n (%)            | n'               |
| Subjects with any most frequent TEAEs           | 239 (54.2)                              | 1435                                    | 248 (56.8)                                | 1460                                      | 272 (61.4)                      | 1537                            | 759 (57.5)       | 4432             |
| Gastrointestinal disorders                      | 154 (34.9)                              | 573                                     | 157 (35.9)                                | 587                                       | 190 (42.9)                      | 626                             | 501 (37.9)       | 1786             |
| Diarrhea                                        | 107 (24.3)                              | 216                                     | 113 (25.9)                                | 233                                       | 134 (30.2)                      | 259                             | 354 (26.8)       | 708              |
| Nausea                                          | 87 (19.7)                               | 183                                     | 92 (21.1)                                 | 201                                       | 110 (24.8)                      | 192                             | 289 (21.9)       | 576              |
| Abdominal pain                                  | 69 (15.6)                               | 145                                     | 58 (13.3)                                 | 126                                       | 64 (14.4)                       | 141                             | 191 (14.5)       | 412              |
| Abdominal pain upper                            | 19 (4.3)                                | 29                                      | 15 (3.4)                                  | 27                                        | 27 (6.1)                        | 34                              | 61 (4.6)         | 90               |
| General disorders and                           | 4 (0.9)                                 | 4                                       | 10 (2.3)                                  | 10                                        | 5 (1.1)                         | 9                               | 19 (1.4)         | 23               |
| Fatigue                                         | 4 (0.9)                                 | 4                                       | 10 (2.3)                                  | 10                                        | 5 (1.1)                         | 9                               | 19 (1.4)         | 23               |
| Infections and infestations                     | 13 (2.9)                                | 15                                      | 15 (3.4)                                  | 15                                        | 20 (4.5)                        | 21                              | 48 (3.6)         | 51               |
| Nasopharyngitis                                 | 7 (1.6)                                 | 8                                       | 11 (2.5)                                  | 11                                        | 12 (2.7)                        | 12                              | 30 (2.3)         | 31               |
| Bronchitis                                      | 6 (1.4)                                 | 7                                       | 4 (0.9)                                   | 4                                         | 9 (2.0)                         | 9                               | 19 (1.4)         | 20               |
| Investigations                                  | 10 (2.3)                                | 10                                      | 9 (2.1)                                   | 9                                         | 17 (3.8)                        | 17                              | 36 (2.7)         | 36               |
| Weight decreased                                | 10 (2.3)                                | 10                                      | 9 (2.1)                                   | 9                                         | 17 (3.8)                        | 17                              | 36 (2.7)         | 36               |
| Metabolism and nutrition disorders              | 100 (22.7)                              | 201                                     | 105 (24.0)                                | 204                                       | 129 (29.1)                      | 251                             | 334 (25.3)       | 656              |
| Decreased appetite                              | 100 (22.7)                              | 201                                     | 105 (24.0)                                | 204                                       | 129 (29.1)                      | 251                             | 334 (25.3)       | 656              |
| Musculoskeletal and connective tissue disorders | 26 (5.9)                                | 32                                      | 27 (6.2)                                  | 30                                        | 27 (6.1)                        | 33                              | 80 (6.1)         | 95               |
| Pain in extremity                               | 20 (4.5)                                | 24                                      | 21 (4.8)                                  | 23                                        | 20 (4.5)                        | 23                              | 61 (4.6)         | 70               |
| Arthralgia                                      | 8 (1.8)                                 | 8                                       | 7 (1.6)                                   | 7                                         | 9 (2.0)                         | 10                              | 24 (1.8)         | 25               |
| Nervous system disorders                        | 117 (26.5)                              | 294                                     | 131 (30.0)                                | 299                                       | 124 (28.0)                      | 289                             | 372 (28.2)       | 882              |
| Headache                                        | 107 (24.3)                              | 278                                     | 115 (26.3)                                | 279                                       | 115 (26.0)                      | 271                             | 337 (25.5)       | 828              |
| Dizziness                                       | 16 (3.6)                                | 16                                      | 20 (4.6)                                  | 20                                        | 14 (3.2)                        | 18                              | 50 (3.8)         | 54               |
| Psychiatric disorders                           | 97 (22.0)                               | 253                                     | 100 (22.9)                                | 252                                       | 106 (23.9)                      | 234                             | 303 (22.9)       | 739              |
| Insomnia                                        | 97 (22.0)                               | 253                                     | 100 (22.9)                                | 252                                       | 106 (23.9)                      | 234                             | 303 (22.9)       | 739              |
| Respiratory, thoracic and mediastinal disorders | 47 (10.7)                               | 53                                      | 51 (11.7)                                 | 54                                        | 47 (10.0)                       | 57                              | 145 (11.0)       | 164              |
| Chronic obstructive pulmonary disease           | 34 (7.7)                                | 38                                      | 39 (8.9)                                  | 41                                        | 38 (8.6)                        | 45                              | 111 (8.4)        | 124              |
| Dyspnea                                         | 15 (3.4)                                | 15                                      | 13 (3.0)                                  | 13                                        | 11 (2.5)                        | 12                              | 39 (3.0)         | 40               |

Source: Table 15.3.1.5.1 and Appendix 16.2.7.1

A TEAE in the Main Period is defined as any AE, regardless of relationship to study medication that occurs after the first dose of study medication in the Main Period and within 30 days after the last study medication in the Main Period or before the first dose of study medication in the Down-Titration Period.

If a subject experienced more than 1 AE within a PT, the subject is counted once in that PT.

PTs are sorted in decreasing order of incidence based on the total number of subjects with AEs within that PT.

n'=number of events for specified category.

Down-Titration  Period: For  subjects  in  the  roflumilast  250  μg  OD/500  μg  OD  (N=20),  500  μg EOD/500 μg OD (N=22), and 500 μg OD (N=38) treatment groups who did not tolerate roflumilast 500 μg OD in the Main Period, the most frequently reported TEAEs during the Down-Titration Period were Gastrointestinal  disorders  (10.0%,  27.3%,  and  47.4%  of  subjects,  respectively),  Nervous  system disorders  (15.0%,  18.2%,  and  26.3% of  subjects,  respectively),  Metabolism  and  nutrition  disorders (15.0%, 18.2%, and 23.7%, respectively), and Psychiatric disorders (10.0%, 22.7%, and 15.8% of subjects, respectively). These most frequent events were consistent with those observed in the Main Period. No subjects experienced a TEAE in the SOC Cardiac disorders during the Down-Titration Period. TEAEs in the SOC Infections and infestations occurred in 15.0%, 0%, and 15.8% of subjects in 250 μg OD/500 μg OD (N=20), 500 μg EOD/500 μg OD (N=22), and 500 μg OD (N=38) treatment groups, respectively.

## Treatment-Related TEAEs

Main  Period: Overall,  145  subjects  (32.9%),  159  subjects  (36.4%),  and  177  subjects  (40.0%) receiving roflumilast 250 μg OD/500 μg OD, 500 μg EOD 500 μg OD, and 500 μg OD, respectively,

<div style=\"page-break-after: always\"></div>

experienced  a  TEAE  that  was  investigator-assessed  as  related  to  roflumilast  (Table  28).  The  most frequent  treatment-related  TEAEs  were  in  the  SOCs  Gastrointestinal  disorders,  Metabolism  and nutrition disorders, Psychiatric disorders, and Nervous system disorders (Table 28). TEAEs occurring in ≥1% of subjects in any treatment group are shown in Table 28.

Table 26 . TEAEs Investigator-Assessed as Treatment-Related Occurring in ≥1% of Subjects in Any Treatment Group During the Main Period by SOC and PT (SAS, Main Period)

| SOC                                                   | Roflumilast 250 μg OD/500 μg OD (N=441)   | Roflumilast 500 μg EOD/500 μg OD (N=437)   | Roflumilast 500 μg OD (N=443)   | Total (N=1321)   |
|-------------------------------------------------------|-------------------------------------------|--------------------------------------------|---------------------------------|------------------|
| PT (MedDRA)                                           | n (%)                                     | n (%)                                      | n (%)                           | n (%)            |
| Gastrointestinal disorder's                           | 96 (21.8)                                 | 110 (25.2)                                 | 131 (29.0)                      | 337 (25.5)       |
| Diarrhea                                              | 61 (13.8)                                 | 76 (17.4)                                  | 96 (21.7)                       | 233 (17.6)       |
| Nausea                                                | 50 (11.3)                                 | 56 (12.8)                                  | 72 (16.3)                       | 178 (13.5)       |
| Abdominal pain                                        | 38 (8.6)                                  | 34 (7.8)                                   | 43 (9.7)                        | 115 (8.7)        |
| Abdominal pain upper                                  | 11 (2.5)                                  | 10 (2.3)                                   | 17 (3.8)                        | 38 (2.9)         |
| General disorder's and administration site conditions | 4 (0.9)                                   | 11 (2.5)                                   | 1 (0.2)                         | 16 (1.2)         |
| Asthenia                                              | 1 (0.2)                                   | 5 (1.1)                                    | 1 (0.2)                         | 7 (0.5)          |
| Investigations                                        | 10 (2.3)                                  | 8 (1.8)                                    | 16 (3.0)                        | 34 (2.0)         |
| Weight decreased                                      | 9 (2.0)                                   | 7 (1.6)                                    | 15 (3.4)                        | 31 (2.3)         |
| Metabolism and nutrition disorders                    | 60 (13.6)                                 | 64 (14.6)                                  | 79 (17.8)                       | 203 (15.4)       |
| Decreased appetite                                    | 58 (13.2)                                 | 64 (14.6)                                  | 78 (17.6)                       | 200 (15.1)       |
| Musculoskeletal and connective tissue disorders       | 8 (1.8)                                   | 15 (3.4)                                   | 11 (2.5)                        | 34 (2.0)         |
| Pain in extremity                                     | 8 (1.8)                                   | 9 (2.1)                                    | 10 (2.3)                        | 27 (2.0)         |
| Nervous system disorder's                             | 49 (11.1)                                 | 58 (13.3)                                  | 61 (13.8)                       | 168 (12.7)       |
| Headache                                              | 41 (9.3)                                  | 47 (10.8)                                  | 53 (12.0)                       | 141 (10.7)       |
| Dizziness                                             | 10 (2.3)                                  | 10 (2.3)                                   | 8 (1.8)                         | 28 (2.1)         |
| Psychiatric disorders                                 | 54 (12.2)                                 | 51 (11.7)                                  | 64 (14.4)                       | 169 (12.8)       |
| Insomnia                                              | 50 (11.3)                                 | 48 (11.0)                                  | 62 (14.0)                       | 160 (12.1)       |

Source: Table 15.3.1.8.1.

A TEAE in the Main Period is defined as any AE, regardless of relationship to study medication that occurs after the first dose of study medication in the Main Period and within 30 days after the last study medication in the Main Period or before the first dose of study medication in the Down-Titration Period.

If a subject experienced more than 1 AE within a PT, the subject is counted once in that PT.

PTs are sorted in decreasing order of incidence based on the total number of subjects with AEs within that PT.

## Down-titration period

The most frequent events were consistent with those observed in the Main Period.

## Serious adverse events and deaths

## Deaths

Seven subjects died over the duration of this study. Of the 7 deaths, 6 subjects (of a total of 1321 subjects, 0.5%) died in the Main Period. The remaining death (Subject 6164/004 in treatment group 250 μg OD/ 500 μg OD) occurred ≥30 days after the last dose of study medication. None of the SAEs leading to death were investigator-assessed as related to study treatment.

## Main Period

<div style=\"page-break-after: always\"></div>

There  were  6  deaths  in  the  Main  Period:  3  subjects  (of  441  subjects,  0.7%)  in  the  roflumilast  250 μg/500 μg OD treatment group, 1 subject (of 437 subjects, 0.2%) in the roflumilast 500 μg EOD/500 μg  OD  treatment  group,  and  2  subjects  (of  443  subjects,  0.5%)  in  the  500  μg  OD  roflumilast treatment group (Table 29).

Table 27 . Fatal SAEs Occurring in the Main Period (Randomized Subjects)

| Subject Number/ Sex/Age          | MedDRA PT                        | Day of Onset                     |                                  | Investigator- Day of Assessed Death Relationship   | Comments                                                              |
|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------------------------|-----------------------------------------------------------------------|
| Roflumilast 250 μg OD/500 μg OD  | Roflumilast 250 μg OD/500 μg OD  | Roflumilast 250 μg OD/500 μg OD  | Roflumilast 250 μg OD/500 μg OD  | Roflumilast 250 μg OD/500 μg OD                    | Roflumilast 250 μg OD/500 μg OD                                       |
| 6076/006 (M/56)                  | COPD                             | 84                               | 86                               | Not related                                        | Previous AEs included concurrent moderate pneumonia (Day 84, ongoing) |
| 6178/008 (F/62)                  | Cardiac failure                  | 46                               | 51                               | Not related                                        | Previous AEs included moderate COPD (Day 27)                          |
| 6196/017 (M/78)                  | Cardiopulmonary failure          | 23                               | 23                               | Not related                                        | Previous AEs included moderate COPD (Day 10, ongoing)                 |
| Roflumilast 500 μg EOD/500 μg OD | Roflumilast 500 μg EOD/500 μg OD | Roflumilast 500 μg EOD/500 μg OD | Roflumilast 500 μg EOD/500 μg OD | Roflumilast 500 μg EOD/500 μg OD                   | Roflumilast 500 μg EOD/500 μg OD                                      |
| 6203/011 (M/71)                  | Pneumothorax spontaneous         | 82                               | 102                              | Not related                                        | No clinically relevant previous AEs                                   |
| Roflumilast 500 μg OD            | Roflumilast 500 μg OD            | Roflumilast 500 μg OD            | Roflumilast 500 μg OD            | Roflumilast 500 μg OD                              | Roflumilast 500 μg OD                                                 |
| 6084/001 (M/69)                  | Lung adenocarcinoma              | 57                               | 91                               | Not related                                        | Previous AEs included concurrent moderate hemoptysis (Days 57-91)     |
| 6163/013 (M/61)                  | Myocardial infarction            | 78                               | 78                               | Not related                                        | Previous AEs included severe syncope (Day 72)                         |

Source: Appendices 16.2.7.1 and 16.2.7.4.

F=Female, M=Male.

None of the 104 subjects who entered the Down-Titration Period died during the study.

## Other serious adverse events

In total, 61 of 1321 subjects (4.6%) experienced 81 SAEs, including 19 (4.3%), 22 (5.0%), and 20 (4.5%)  subjects  in  the  roflumilast  250  μg  OD/500  μg  OD  (24  SAEs),  500  μg  EOD/500  μg  OD  (30 SAEs), and 500 μg OD (27 SAEs) treatment groups, respectively (Table 30).

## Table 28 . Treatment-Emergent SAEs During the Main Period by SOC and PT (SAS, Main Period)

<div style=\"page-break-after: always\"></div>

| SOC                                                               | Roflumilast250μg OD/500yg OD (N=441)   | Roflumilast250μg OD/500yg OD (N=441)   | Roflumilast500μg EOD/500μgOD (N=437)   | Roflumilast500μg EOD/500μgOD (N=437)   | Roflumilast500μg OD (N=443)   | Roflumilast500μg OD (N=443)   | Total (N=1321)   | Total (N=1321)   |
|-------------------------------------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|-------------------------------|-------------------------------|------------------|------------------|
| PI (MedDRA)                                                       | n (%)                                  | Events                                 | n (%)                                  | Events                                 | n (%)                         | Events                        | n (%)            | Events           |
| Subjectswith anyseriousTEAEs                                      | 19 (4.3)                               | 24                                     | 22 (5.0)                               | 30                                     | 20 (4.5)                      | 27                            | 61 (4.6)         | 81               |
| Cardiac disorder's                                                | 3 (0.7)                                | 3                                      | 2 (0.5)                                | 2                                      | 2 (0.5)                       | 2                             | 7 (0.5)          | 7                |
| Myocardialinfarction                                              | 1 (0.2)                                | 1                                      | 0                                      | 0                                      | 1 (0.2)                       | 1                             | 2 (0.2)          | 2                |
| Myocardial ischemia                                               | 0                                      | 0                                      | 1 (0.2)                                | 1                                      | 1 (0.2)                       | 1                             | 2 (0.2)          | 2                |
| Atrialfibrillation                                                | 0                                      | 0                                      | 1 (0.2)                                | 1                                      | 0                             | 0                             | 1 (0.1)          | 1                |
| Cardiacfailure                                                    | 1 (0.2)                                | 1                                      | 0                                      | 0                                      | 0                             | 0                             | 1 (0.1)          | 1                |
| Cardiopulmonaryfailure                                            | 1 (0.2)                                | 1                                      | 0                                      | 0                                      | 0                             | 0                             | 1 (0.1)          | 1                |
| Earandlabyrinthdisorders                                          | 1 (0.2)                                | 2                                      | 0                                      | 0                                      | 0                             | 0                             | 1 (0.1)          | 2                |
| Vertigo                                                           | 1 (0.2)                                | 2                                      | 0                                      | 0                                      | 0                             | 0                             | 1 (0.1)          | 2                |
| Gastrointestinaldisorder's                                        | 2 (0.5)                                | 2                                      | 0                                      | 0                                      | 1 (0.2)                       | 2                             | 3 (0.2)          | 4                |
| Abdominalmass                                                     | 1 (0.2)                                | 1                                      | 0                                      | 0                                      | 0                             | 0                             | 1 (0.1)          | 1                |
| Colitisulcerative                                                 | 1 (0.2)                                | 1                                      | 0                                      | 0                                      | 0                             | 0                             | 1 (0.1)          | 1                |
| Femoralhermiaincarcerated                                         | 0                                      | 0                                      | 0                                      | 0                                      | 1 (0.2)                       | 1                             | 1 (0.1)          | 1                |
| Smallintestinalobstruction                                        | 0                                      | 0                                      | 0                                      | 0                                      | 1 (0.2)                       | 1                             | 1 (0.1)          | 1                |
| Infectionsandinfestations                                         | 4 (0.9)                                | 5                                      | 4 (0.9)                                | 4                                      | 3 (0.7)                       | 3                             | 11 (0.8)         | 12               |
| Pneumonia                                                         | 2 (0.5)                                | 2                                      | 1 (0.2)                                | 1                                      | 1 (0.2)                       | 1                             | 4 (0.3)          | 4                |
| Infectiveexacerbationofchronic obstructiveairwaysdisease          | 1 (0.2)                                | 2                                      | 0                                      | 0                                      | 1 (0.2)                       | 1                             | 2 (0.2)          | 3                |
| Acute sinusitis                                                   | 0                                      | 0                                      | 1 (0.2)                                | 1                                      | 0                             | 0                             | 1 (0.1)          | 1                |
| Appendicitis                                                      | 1 (0.2)                                | 1                                      | 0                                      | 0                                      | 0                             | 0                             | 1 (0.1)          | 1                |
| Bronchopneumonia                                                  | 0                                      | 0                                      | 0                                      | 0                                      | 1 (0.2)                       | 1                             | 1 (0.1)          | 1                |
| Respiratorytractinfection                                         | 0                                      | 0                                      | 1 (0.2)                                | 1                                      | 0                             | 0                             | 1 (0.1)          | 1                |
| Upper respiratory tract infection                                 | 0                                      | 0                                      | 1 (0.2)                                | 1                                      | 0                             | 0                             | 1 (0.1)          | 1                |
| Injury,poisoningandprocedural complications                       | 0                                      | 0                                      | 1 (0.2)                                | 1                                      | 0                             | 0                             | 1 (0.1)          | 1                |
| Lowerlimbfracture                                                 | 0                                      | 0                                      | 1 (0.2)                                | 1                                      | 0                             | 0                             | 1 (0.1)          | 1                |
| Metabolismandnutrition                                            | 0                                      | 0                                      | 0                                      | 0                                      | 2 (0.5)                       | 2                             | 2 (0.2)          | 2                |
| disorders Decreased appetite                                      | 0                                      | 0                                      | 0                                      | 0                                      | 1 (0.2)                       | 1                             | 1 (0.1)          | 1                |
| Gout                                                              | 0                                      | 0                                      | 0                                      | 0                                      | 1 (0.2)                       | 1                             | 1 (0.1) 1 (0.1)  | 1 1              |
| Musculoskeletalandconnective tissuedisorders                      | 0                                      | 0                                      | 1 (0.2)                                | 1                                      | 0                             | 0                             |                  |                  |
| Spinalosteoarthritis                                              | 0                                      | 0                                      | 1 (0.2)                                | 1                                      | 0                             | 0                             | 1 (0.1)          | 1                |
| Neoplasmsbenign,malignant and unspecified (incl cysts and polyps) | 0                                      | 0                                      | 1 (0.2)                                | 1                                      | 3 (0.7)                       | 3                             | 4 (0.3)          | 4                |
| Lung adenocarcinoma Malignant melanoma                            | 0                                      | 0                                      | 0                                      | 0                                      | 1 (0.2) 1 (0.2)               | 1                             | 1 (0.1) 1 (0.1)  | 1                |
| Prostate cancer                                                   | 0                                      | 0                                      | 0                                      | 0                                      |                               |                               | 1 (0.1)          | 1                |
| Transitionalcell carcinoma                                        | 0                                      | 0                                      | 1 (0.2)                                | 1                                      | 1 (0.2) 0                     | 1 0                           | 1 (0.1)          | 1                |
| Nervoussystemdisorder's                                           | 0                                      | 0                                      | 1 (0.2)                                | 1                                      | 2 (0.5)                       | 2                             | 3 (0.2)          | 3                |
| Sciatica                                                          | 0                                      | 0                                      | 0                                      | 0                                      | 1 (0.2)                       | 1                             | 1 (0.1)          | 1                |
| Syncope                                                           | 0                                      | 0                                      | 0                                      | 0                                      | 1 (0.2)                       | 1                             | 1 (0.1)          | 1                |
| Transient ischaemic attack                                        | 0                                      | 0                                      | 1 (0.2)                                | 1                                      | 0                             | 0                             | 1 (0.1)          | 1                |
| Psychiatric disorders                                             | 0                                      | 0                                      | 1 (0.2)                                | 1                                      | 0                             | 0                             | 1 (0.1)          | 1                |
| Anxiety                                                           | 0                                      | 0                                      | 1 (0.2)                                | 1                                      | 0                             | 0                             | 1 (0.1)          | 1                |
| Respiratory, thoracic and                                         | 10 (2.3)                               | 12                                     | 14 (3.2)                               | 17                                     | 11 (2.5)                      | 12                            | 35 (2.6)         | 41               |
| mediastinaldisorder's Chronic obstructive pulmonary disease       | 8 (1.8)                                | 8                                      | 13 (3.0) 0                             | 14 0                                   | 7 (1.6) 3 (0.7)               | 8                             | 28 (2.1)         | 30 6             |
| Dyspnea Acute respiratory failure                                 | 3 (0.7) 0                              | 3 0                                    | 1 (0.2)                                | 1                                      | 0                             | 3 0                           | 6 (0.5) 1 (0.1)  | 1                |
| Hemoptysis                                                        | 0                                      | 0                                      | 0                                      | 0                                      | 1 (0.2)                       | 1                             | 1 (0.1)          | 1                |
| Pleural effusion                                                  | 0                                      | 0                                      | 1 (0.2)                                | 1                                      | 0                             | 0                             | 1 (0.1)          | 1                |
| Pneumothoraxspontaneous                                           | 0                                      | 0                                      | 1 (0.2)                                | 1                                      | 0                             | 0                             | 1 (0.1)          | 1                |
| Pulmonary hypertension                                            | 1 (0.2)                                | 1                                      | 0                                      | 0                                      | 0                             | 0                             | 1 (0.1)          | 1                |
|                                                                   | 0                                      | 0                                      | 2 (0.5)                                | 2                                      |                               |                               | 3 (0.2)          | 3                |
| Vasculardisorders                                                 | 0                                      |                                        | 0                                      |                                        | 1 (0.2) 1 (0.2)               | 1 1                           | 1 (0.1)          | 1                |
| Hypertension                                                      | 0                                      | 0                                      |                                        | 0                                      |                               |                               |                  | 1                |
| Hypertensive crisis                                               |                                        | 0                                      | 1 (0.2)                                | 1                                      | 0                             | 0                             | 1 (0.1)          |                  |
| Vasculitis                                                        | 0                                      | 0                                      |                                        | 1                                      | 0                             | 0                             |                  |                  |
|                                                                   |                                        |                                        | 1 (0.2)                                |                                        |                               |                               | 1 (0.1)          | 1                |

Source: Table 15.3.1.12.1.

A TEAE inthe MainPeriod is defined as anyAE,regardless of relationship tostudy medication that occurs after the first dose of study medication in the Main Period and within 30 days after the last study medication in the Main Period or before the first dose ofstudymedicationintheDown-TitrationPeriod.

<div style=\"page-break-after: always\"></div>

Down-Titration Period: Of the 80 subjects that entered the Down-Titration Period after not tolerating roflumilast  500  μg  OD in  the  Main  Period,  1  subject  (1.3%)  who  entered this  period  in  the  250  μg OD/500  μg  OD  treatment  group  experienced  1  serious  TEAE.  The  SAE  of  (worsening)  COPD  was investigator-assessed as treatment-related.

## Other significant AEs:

## Columbia-Suicide Severity Rating Scale

No completed or attempted suicide was reported during the treatment period. Suicidal ideation was reported in 1 subject in the roflumilast 500 μg OD group during the Main Period (Subject 6146/015), and  resulted  in  discontinuation  from  the  study.  There  was  no  suicide  or  suicidal  ideation  reported during the Down-Titration Period.

## Laboratory findings

There were no clinically relevant changes in mean or median serum chemistry or hematology values from V1 at Vend for any treatment group during the Main Period, or from V1 or V0DT to VendDT in the Down Titration Period. No more than 2.2% of subjects in any treatment group had serum chemistry values  that  met  criteria  for  'markedly  abnormal'  during  the  Main  Period  and  no  more  than  2%  of subjects  in  any  treatment  group  had  hematology  values  that  met  criteria  for  'markedly  abnormal' during the Main Period (see Clinical AR).

The mean body weight loss was around 1 kg in the 3 treatment groups during the main study period. No significant mean weight loss was reported during the down-titration period. In total, 36 of the 1321 subjects (2.7%) experienced the TEAE of 'weight decreased' during the Main Period, with incidence higher in 500 μg OD than either up-titration group (3.8% versus 2.3% and 2.1% of subjects in 250 μg OD/500 μg OD and 500 μg EOD/500 μg OD, respectively). A TEAE of weight loss was only reported in 2 subjects during the Down Titration period (see Clinical AR).

## Safety in special populations

Regarding  the  primary  endpoint,  premature  discontinuations  were  more  frequent  in  patients  &gt;  65 years  (23-27%  across  treatment  groups)  than  in  patients  &lt;  65  years  (15-22%  across  treatment groups)  but  the  odds  ratio  of  discontinuations  favor  up-titration  group  1  versus  reference  both  in patients &gt; 65 years (OR point estimate 0.70) and in patients &lt; 65 years (Table 31).

The same applies for the key secondary safety endpoint of rate of patients with AEs of interest, which is    more  frequent  in  patients  &gt;  65  years  (48-56%  across  treatment  groups)  than  in  patients  &lt;  65 years (43-53% across treatment groups) but the odds ratio of discontinuations favor up-titration group 1 versus reference both in patients &gt; 65 years (47.7% vs 55.7%) and in patients &lt; 65 years (43.4% vs. 52.7%) (Table 31).

## Table 29 . Primary and Key Secondary Analysis of Safety, by Subgroup

<div style=\"page-break-after: always\"></div>

Age Group:&gt;= 65 years

```
Roflumilast Roflumilast 250 μg OD/ 500 μg EOD/ Roflumilast Endpoint/Test 500 μg OD 500 μg OD 500 μg OD No. of subjects in the SAS for Main Period, N 199 235 219 No. of subjects prematurely discontinuing Main Period, SAS 46(23.18) 53(22.6%) 60(27.48) P-value for comparison against Reference 5oo μg OD (a) 0.151 0.111 Odds Ratio [95% CI] for comparison against Reference (a) 0.70[0.43 1.14] 0.69[ 0.43,1.09] Hazard Ratio [95s CI] for comparison against Reference (b) 0.74 0.50， 1.10] 0.69[0.47,1.01] AEs of Interest to Evaluate Tolerability during Main Period, SAS No.of subjects with AEs of interest 95(47.78) 121 (51.58) 122 (55.78) No.of subjects in the SAS for Down-Titration Period, N 12 11 18 No.of subjects prematurely discontinuing Down-Titration 2(16.7%) 3(27.38) 3(16.78) Period, SAS Note 1: Down-Titration period summaries are based on a subgroup of 80 subjects (250 μg OD/500 μg OD: 20, Note2: *= Used Firth logistic regression, ^= Results not used as complete convergence not obtained, CI = Confidence Interval, AE = Adverse Event, SAS = Safety Analysis Set, NC = Not Calculated or proportional hazards models because of their significantly low counts. (a) Logistic regression model with study treatment, country and baseline FEVl as explanatory variables. (b) Cox proportional hazards model with study treatment and country as class effects,and baseline FEv1 as a continuous variable. Age Group:<65 years Roflumilast Roflumilast 250 μg OD/ 500 μg EOD/ Roflumilast Endpoint/Test 500 μg OD 500 μg OD 500 μg OD No.of subjects in the SAS for Main Period, N 242 202 224 No. of subjects prematurely discontinuing Main Period, SAS 35(14.5%) 35 (17.38) 49(21.9%) P-value for comparison against Reference 5oo μg OD (a) 0.042 0.320 Odds Ratio [95s CI] for comparison against Reference (a) 0.60[0.36,0.98] 0.78 [0.47 ，1.28] Hazard Ratio [95s Cl] for comparison against Reference （b) 0.61[0.39，0.95] 0.77 [0.49，1.19] AEs of Interest to Evaluate Tolerability during Main Period, SAS No.of subjects with AEs of interest 105 (43.48) 90(44.6%) 118 (52.78) No.of subjects in the SAS for Down-Titration Period,N 8 11 20 No.of subjects prematurely discontinuing Down-Titration 2(25.0%) 1( 9.1%) 4(20.0%) Period, SAS Note 1: Down-Titration period summaries are based on a subgroup of 80 subjects (250 μg OD/500 μg OD: 20, Note 2: CI = Confidence Interval, AE = Adverse Event, SAS = Safety Analysis Set, NC = Not Calculated or proportional hazards models because of their significantly low counts. (a) Logistic regression model with study treatment, country and baseline FEVl as explanatory variables. (b) Cox proportional hazards model with study treatment and country as class effects, and baseline FEV1 as a continuous variable.
```

## Pregnancy

There were no subjects with a positive pregnancy test throughout the duration of the study.

## Immunological events

No specific section is dedicated to immunological events in the dossier. Anyway, looking at the TEAEs by SOC, either frequent or serious, there was no indication of immunological events with roflumilast in OPTIMIZE study beyond some mild skin reactions.

<div style=\"page-break-after: always\"></div>

## Safety related to drug-drug interactions and other interactions

No  information  provided  initially.  During  the  procedure,  the  applicant  was  requested  to  show  the results  of  the  main  endpoint  and  key  secondary  safety  endpoint  by  subgroups  according  to concomitant medications (i.e.: concomitant ICS only, concomitant ICS+LABA, concomitant ICS+LAMA, concomitant ICS+LABA+LAMA) by treatment groups and to discuss whether the 250/500 microgram up-titration  regime  could  provide  a  particular  advantage  in  patients  with  multiple  concomitant medications.  The  Applicant  submitted  the  requested  subgroup  analyses  by  concomitant  medication use. The analyses were hampered by their post-hoc nature and lack of statistical power due to small sample sizes. Anyway, the analysis provided justify for all of the subgroups studied to take advantage of  the  250  µg  OD/500 µg  OD  up-titration  regimen,  regardless  of  concomitant  LAMA  or  multiple concomitant medication use.

## Discontinuation due to AES

This was an important component of the main endpoint (all withdrawals) in OPTIMIZE. Please see the outcomes estimation in the efficacy section.

## 2.9.5. Discussion on clinical safety

The comparative results of the main and key secondary (safety) study endpoints (rate of withdrawals and TEAEs of interest have already been described in the efficacy section. The following sections will focus  on  the  description  of  patient  exposures,  adverse  events,  laboratory  findings,  safety  in  special populations, safety related to drug-drug interactions and post-marketing experience.

The roflumilast up-titration groups (250 μg OD/500 μg OD and 500 μg EOD/ 500 μg OD) tended to have a greater number of subjects (378 and 375 subjects; 85.7 and 85.8%, respectively) who received treatment  for  &gt;8  weeks  compared  with  the  standard  treatment  group  (355  of  443;  80.1%).  The roflumilast  500  μg  OD  treatment  group  tended  to  have  a  greater  number  of  subjects  (72  of  443 subjects,  16.3%)  who  received  treatment  for  ≤4  weeks  compared  with  the  up-titration  treatment groups  (7.9%  and  9.6%,  respectively).  This  is  consistent  with  the  results  of  the  primary  endpoint, showing less early withdrawals with the 250 μg OD/500 μg OD dosing regimen than with the other dosage schedules.

Most patients (63.7%) experienced TEAEs during treatment with roflumilast (61.2% in group 1, 64.3% in group 2 and 65.7% in control group). Most frequent TEAEs were gastrointestinal (diarrhoea, nausea, abdominal pain) (occurring in 37.9% of patients overall) (34.9% in group 1, 35.9% in group 2 and 42.9% in control group). SAES were reported in 4.6% of subjects. Only 0,2% of patients had a SAE related to study medication (1 patient in each group).

Overall, 145 subjects (32.9%), 159 subjects (36.4%), and 177 subjects (40.0%) receiving roflumilast 250 μg OD/500 μg OD, 500 μg EOD 500 μg OD, and 500 μg OD, respectively, experienced a TEAE that was investigator-assessed as related to roflumilast. The most frequent treatment-related TEAEs were in  the  SOCs  Gastrointestinal  disorders  (diarrhoea  17.6%,  nausea  13.5%,  abdominal  pain  11.6%), Metabolism  and  nutrition  disorders  (decreased  appetite  15.1%),  Psychiatric  disorders  (insomnia, 12.1%)  and  Nervous  system  disorders  (headache  10.7%,  dizziness  2.1%).  The  benefit  of  the roflumilast  250  μg  OD/500  μg  OD  up-titration  regime  versus  the  standard  roflumilast  500  μg  OD

<div style=\"page-break-after: always\"></div>

regime was largely driven by less related TEAEs of diarrhoea (13.8% vs. 21.7%; -7.9% difference) and nausea (11.3% vs. 16.3%; -5% difference).

Seven subjects died over the duration of this study. Of the 7 deaths, 6 subjects (of a total of 1321 subjects, 0.5%) died in the Main Period. The remaining death (Subject 6164/004 in treatment group 250 μg OD/ 500 μg OD) occurred ≥30 days after the last dose of study medication. None of the SAEs leading to death were investigator-assessed as related to study treatment.

In total, 61 of 1321 subjects (4.6%) experienced 81 SAEs, including 19 (4.3%), 22 (5.0%), and 20 (4.5%)  subjects  in  the  roflumilast  250  μg  OD/500  μg  OD  (24  SAEs),  500  μg  EOD/500  μg  OD  (30 SAEs), and 500 μg OD (27 SAEs) treatment groups, respectively. Most SAES were related to worsening COPD. No safety signal is apparent from these data.

There were no clinically relevant changes in mean or median serum chemistry or hematology values from V1 at Vend for any treatment group during the Main Period, or from V1 or V0DT to VendDT in the Down Titration Period. No more than 2.2% of subjects in any treatment group had serum chemistry values  that  met  criteria  for  'markedly  abnormal'  during  the  Main  Period  and  no  more  than  2%  of subjects  in  any  treatment  group  had  hematology  values  that  met  criteria  for  'markedly  abnormal' during the Main Period.

The mean body weight loss was around 1 kg in the 3 treatment groups during the main study period. No significant mean weight loss was reported during the down-titration period. In total, 36 of the 1321 subjects (2.7%) experienced the TEAE of 'weight decreased' during the Main Period, with incidence higher in 500 μg OD than either up-titration group (3.8% versus 2.3% and 2.1% of subjects in 250 μg OD/500 μg OD and 500 μg EOD/500 μg OD, respectively). A TEAE of weight loss was only reported in 2 subjects during the Down Titration period.The dossier has no dedicated section to safety in special populations or in the elderly. The only data available is about primary and key secondary analysis of safety  by  age  group  in  the  subgroup  analysis  of  the  main  endpoint  (withdrawals  in  patients  &gt;  65 years)  and  in  some  tables  in  the  appendixes.  Looking  at  subgroups  of  primary  and  key  secondary endpoint,  premature  discontinuations  were  more  frequent  in  patients  &gt;  65  years  (23-27%  across treatment groups) than in patients &lt; 65 years (15-22% across treatment groups), but the odds ratio of  discontinuations  favoured  up-titration  group  1  versus  reference  both  in  patients  &gt;  65  years  (OR point estimate 0.70) and in patients &lt; 65 years (Table 31). The same applies for the key secondary safety endpoint of rate of patients with AEs of interest, which tended to be more frequent in patients &gt; 65 years (48-56% across treatment groups) than in patients &lt; 65 years (43-53% across treatment groups), but consistently less frequent in the up-titration group 1 versus reference both in patients &gt; 65 years (47.7% vs. 55.7%) and in patients &lt; 65 years (43.4% vs. 52.7%) (Table 31). During the procedure, the applicant wa also invited to discuss about the apparent under-representation of elderly patients  in  the  pivotal  OPTIMIZE  study,  particularly  taking  into  account  that  they  are  a  special population  at  the  highest  risk  of  having  a  primary  outcome  study  event  (i.e.:  withdrawal  due  to intolerability). The applicant clarified that only 115 patients were between 75 to 84 years and only 2 patients were &gt;85 years old. With the limitations of small sample sizes, the data showed some small increases in adverse events with age with all dosing regimes, but the benefit of the new dosing regime in  avoiding  adverse  events  and  discontinuations  was  consistently  in  favour  of  the  new  roflumilast regime regardless of age.

No specific section is dedicated to immunological events in the dossier. Anyway, looking at the TEAEs by SOC, either frequent or serious, there was no indication of immunological events with roflumilast in OPTIMIZE study beyond some mild skin reactions.

<div style=\"page-break-after: always\"></div>

With respect to safety related to drug-drug interactions, the company is also requested to show the results  of  the  main  endpoint  and  key  secondary  safety  endpoint  by  subgroups  according  to concomitant medications (i.e.: concomitant ICS only, concomitant ICS+LABA, concomitant ICS+LAMA, concomitant ICS+LABA+LAMA) by treatment groups and to discuss whether the 250/500 microgram up-titration  regime  could  provide  a  particular  advantage  in  patients  with  multiple  concomitant medications. This analysis is of special interest, as a higher incidence in weight decrease, decreased appetite, headache and depression has been reported with roflumilast in patients receiving concomitant LAMA as compared to those not receiving LAMA (REACT study data already included in the SmPC) (see also efficacy section).

During the procedure, the applicant was invited to comment on the potential benefit of recommending the  administration  of  roflumilast  with  food  in  reducing  gastrointestinal  intolerability.  The  applicant answered that clinical data available with roflumilast does not indicate a protective effect of meal on gastrointestinal  adverse  effects  or  other  intolerability  symptoms.  Therefore,  it  is  endorsed  that  a specific recommendation to take roflumilast with food is not needed.

The cumulative clinical trial exposure to roflumilast in the COPD program, asthma program and other indications (tablet and cream formulations) is 17396 patients, as of 5 January 2017. Cumulative postmarketing exposure to roflumilast globally since first marketing launch in 2010 has been estimated to be over 804,498 patient-years, with the majority of exposure occurring in North America and Europe. Post-marketing  surveillance  data  with  roflumilast  at  the  time  of  this  submission  shows  that  the  AE pattern  in  post-marketing  surveillance  reports  does  not  deviate  from  the  experience  from  clinical studies. The most frequently reported ADRs from roflumilast post-marketing reports are well-known reactions associated with PDE-4 inhibitors (i.e.: gastrointestinal adverse reactions, insomnia, decreased appetite) and/or are expected events for this patient population, clinical manifestations of the  underlying  disease  and  its  progression.  Weight  decrease,  psychiatric  disorders  including  suicide risk, and angioedema as important identified risks, and cardiac safety, malignancy and infection risks to be clinically important potential risks for roflumilast. No new safety data have been received during the latest post-marketing safety reporting period to alter the current understanding and assessment of these safety risks.

## 2.9.6. Conclusions on clinical safety

The analysis of safety data from OPTIMIZE study does not raise any new concern about the safety of roflumilast.  Most  patients  (63.7%)  experienced  TEAEs  during  treatment  with  roflumilast  (61.2%  in group  1,  64.3%  in  group  2  and  65.7%  in  control  group),  with  most  frequent  TEAEs  being gastrointestinal (diarrhoea, nausea, abdominal pain) (occurring in 37.9% of patients overall) (34.9% in group 1, 35.9% in group 2 and 42.9% in control group). SAES were reported in 4.6% of subjects. Only 0,2% of patients  had  a  SAE  related  to  study  medication  (1  patient  in  each  group).  These  data  are consistent with the known safety profile of roflumilast.

The analysis of TEAEs related to study drug indicated a safety advantage of the roflumilast 250 μg OD/500  μg  OD  up-titration  regime  versus  the  standard  roflumilast  500  μg  OD  regime,  which  was largely  driven  by  less  related  TEAEs  of  diarrhoea  (13.8%  vs.  21.7%;  -7.9%  difference) and  nausea (11.3% vs. 16.3%; -5% difference).

The summary of safety concerns after the addition of the 250 microg dose remain the same as for the 500 microgram dose, which is endorsed, because no new safety concerns related to new or increased adverse reactions are expected with the use of a lower roflumilast dose. However, with respect to the

<div style=\"page-break-after: always\"></div>

safety specification, the main concern due to the availability of the new (ineffective) 250 microgram dose, is the potential for off-label use with respect to the maintenance dose.

On the one hand, the information included in the RMP provides evidence that up-titration has been done off-label since the approval of roflumilast 500 microgr with the use every second day or half a tablet each day. Therefore, current line extension is expected to put in the SmPC a practice already extended among prescribers, but now with evidence from a randomized trial. The product information was  ammended  during  the  procedure  to  reinforce  the  message  that  the  250  micrograms  dose  is subtherapeutic and should not be used for maintenance treatment.

## 2.9.7. PSUR cycle

The PSUR cycle remains unchanged.

The annex II related to the PSUR, refers to the EURD list which remains unchanged.

## 2.10. Risk Management Plan

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                          |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Weight decrease                                                                                                                                     |
|                              | Psychiatric disorders (insomnia, anxiety, panic attack, nervousness, depression, suicidal ideation and behaviour)                                   |
|                              | Angioedema                                                                                                                                          |
| Important potential risks    | Malignant tumours                                                                                                                                   |
|                              | Infections                                                                                                                                          |
|                              | Cardiac safety                                                                                                                                      |
|                              | Risk of triggering suicide                                                                                                                          |
|                              | Serious Diarrhoea                                                                                                                                   |
|                              | Gynaecomastia                                                                                                                                       |
|                              | Pancreatitis                                                                                                                                        |
|                              | Persistent intolerability in high exposure populations                                                                                              |
|                              | Off-label use: • Asthma adult • Asthma paediatric • COPD other than indicated • Alpha 1 anti-trypsin deficiency • Use at lower than indicated doses |
| Missing information          | Use during pregnancy and lactation                                                                                                                  |
|                              | Intake of immunosuppressive medication (excl. short-term systemic corticosteroids)                                                                  |
|                              | Severe immunological diseases (e.g. HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy)             |

<div style=\"page-break-after: always\"></div>

| Summary of safety concerns   | Summary of safety concerns                                                     |
|------------------------------|--------------------------------------------------------------------------------|
|                              | Mild, moderate or severe hepatic impairment classified as Child Pugh A, B or C |
|                              | Combination of roflumilast with theophylline for maintenance therapy           |
|                              | Long-term treatment                                                            |

## Pharmacovigilance plan

| Study/ activity Type, title and category (1- 3)                                                                  | Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Safety concerns addressed                                                                                                                                  | Status (planned, started)   | Date for submission of interim or final reports (planned or actual)                                        |
|------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|------------------------------------------------------------------------------------------------------------|
| Long-term post-marketing observational study of roflumilast (D7120R00003 [RO-2455-403- RD]); Category 1 (FUM002) | To evaluate the long-term safety of roflumilast in the treatment of COPD, with focus primarily on all- cause mortality. In addition, the study will evaluate potential risks, including potential safety issues identified during the clinical trials of roflumilast. Specifically this study aims to compare the incidences of all-cause mortality, major cardiovascular events, new diagnosis of cancer, all-cause hospitalisation, hospitalisation related to respiratory disease, suicide or hospitalisation for suicide attempt, abnormal, unexplained weight loss, serious diarrhoea of non-infections origin and new diagnosis of depression, tuberculosis or viral hepatitis B or C in roflumilast treated (exposed) COPD patients compared with matched COPD patients not treated with roflumilast (non- exposed). The exposed and non- exposed cohorts will be followed for five to nine years. | Long-term treatment safety data will be generated aiming at investigating the 5-year mortality and morbidity of roflumilast in the COPD patient population | Started                     | The first interim analysis is planned for 2017; The final study report is planned to be available in 2021. |

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

| Safety concern            | Routine risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Additional risk minimisation measures                                                                                  |
|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|
| Important identified risk |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                        |
| Weight decrease           | Section 4.4 of the SmPC: In 1-year studies (M2-124, M2-125), a decrease of body weight occurred more frequently in patients treated with Daxas/Daliresp/Libertek compared to placebo-treated patients. After discontinuation of Daxas/Daliresp/Libertek, the majority of patients had regained body weight after 3 months. Body weight of underweight patients should be checked at each visit. Patients should be advised to check their body weight on a regular basis. In the event of an unexplained and clinically concerning weight decrease, the intake of Daxas/Daliresp/Libertek should be stopped and body weight should be further followed-up. SmPC section 4.8: Weight decreased is included as common adverse reaction. | Educational material for prescribers and patients is distributed at market introduction and made available thereafter. |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                                                    | Routine risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Additional risk minimisation measures                                                                                                                                                                                                                                                                                                                                                        |
|-------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Psychiatric disorders (insomnia, anxiety, panic attack, nervousness, depression, suicidal ideation and behaviour) | SmPC section 4.4 states: Daxas/Daliresp/Libertek is associated with an increased risk of psychiatric disorders such as insomnia, anxiety, nervousness and depression. Rare instances of suicidal ideation and behaviour, including suicide, have been observed in patients with or without history of depression, usually within the first weeks of treatment. The risks and benefits of starting or continuing treatment with Daxas/Daliresp/Libertek should be carefully assessed if patients report previous or existing psychiatric symptoms or if concomitant treatment with other medicinal products likely to cause psychiatric events is intended. Daxas/Daliresp/Libertek is not recommended in patients with a history of depression associated with suicidal ideation or behaviour. Patients and caregivers should be instructed to notify the prescriber of any changes in behaviour or mood and of any suicidal ideation. If patients suffered from new or worsening psychiatric symptoms, or suicidal ideation or suicidal attempt is identified, it is recommended to discontinue treatment with Daxas/Daliresp/Libertek. Section 4.8 of the SmPC: Insomnia is considered as common adverse reaction of Daxas/Daliresp/Libertek treatment. Anxiety is labelled as uncommon adverse reaction and panic attack, nervousness, depression, and suicidal ideation and behaviour as rare adverse reactions. Furthermore, a statement is included to point out that in clinical studies and post-marketing experience, rare instances of suicidal ideation and behaviour (including suicide) were reported. Patients and caregivers should be instructed to notify the prescriber of any suicidal ideation. | Educational material was updated and re- distributed after adding the risk of triggering suicide. A system for tracking the distribution of the Educational Material was implemented at the same time. For suicidal ideation and behaviour, the success of the risk minimisation activities will also be evaluated in the interim and final analyses of the long- term post-marketing study. |

<div style=\"page-break-after: always\"></div>

| Safety concern           | Routine risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                        | Additional risk minimisation measures                                                                                              |
|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| Angioedema               | Angioedema is considered a rare adverse reaction of roflumilast treatment (section 4.8 of the SmPC). No further risk minimisation activities are considered necessary.                                                                                                                                                                                                                                    | Not applicable.                                                                                                                    |
| Important potential risk |                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                    |
| Malignant tumours        | Section 4.4 of the SmPC states that due to lack of relevant experience, treatment with Daxas/Daliresp/Libertek should not be initiated and existing treatment with Daxas/Daliresp/Libertek should be stopped in patients with cancers (except basal cell carcinoma).                                                                                                                                      | Educational material for prescribers and patients is distributed at the time of market introduction and made available thereafter. |
| Infections               | Section 4.4 of the SmPC states that due to lack of relevant experience, treatment with Daxas/Daliresp/Libertek should not be initiated and existing treatment with Daxas/Daliresp/ Libertek should be stopped in patients with severe acute infectious diseases. Experience in patients with latent infections such as tuberculosis, viral hepatitis, herpes viral infection or herpes zoster is limited. | Educational material for prescribers and patients is distributed at the time of market introduction and made available thereafter. |
| Cardiac safety           | Section 4.4 of the SmPC states that patients with congestive heart failure (NYHA grades 3 and 4) have not been studied and therefore treatment of these patients is not recommended.                                                                                                                                                                                                                      | Educational material for prescribers is distributed at the time of market introduction and made available thereafter.              |

<div style=\"page-break-after: always\"></div>

| Safety concern             | Routine risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Additional risk minimisation measures                                                                                                                                                                                                                                                                                                                              |
|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Risk of triggering suicide | In section 4.4 of the SmPC a warning is included concerning rare instances of suicidal ideation and behaviour, including suicide which have been observed in patients with or without a history of depression, usually within the first weeks of treatment. The risks and benefits of starting or continuing treatment with Daxas/Daliresp/Libertek should be carefully assessed if patients report previous or existing psychiatric symptoms or if concomitant treatment with medicinal products likely to cause psychiatric events is intended. Daxas/Daliresp/Libertek is not recommended in patients with a history of depression associated with suicidal ideation or behaviour. Patients and caregivers should be instructed to notify the prescriber of any changes in behaviour or mood and of any suicidal ideation. If patients suffered from new or worsening psychiatric symptoms, or suicidal ideation or suicidal attempt is identified, it is recommended to discontinue treatment with Daxas/Daliresp/Libertek. In section 4.8 of the SmPC a statement is included to point out that in clinical studies and post-marketing experience, rare instances of suicidal ideation and behaviour (including suicide) were reported. Patients and caregivers should be instructed to notify the prescriber of any suicidal ideation. | Educational material for prescribers and patients is provided at market introduction. For those countries where this risk was not included in the original materials, materials have been updated and redistributed. Materials are also made available thereafter. Effectiveness is assessed through periodic evaluation of spontaneous ADRs received from the EU. |
| Serious Diarrhoea          | Diarrhoea is considered a common adverse reaction of roflumilast treatment (section 4.8 of the SmPC).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Not applicable                                                                                                                                                                                                                                                                                                                                                     |
| Gynaecomastia              | Gynaecomastia is considered a rare adverse reaction of roflumilast treatment (section 4.8 of the SmPC). No further risk minimisation activities are considered necessary.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Not applicable.                                                                                                                                                                                                                                                                                                                                                    |
| Pancreatitis               | Not applicable (a potential need for risk minimisation measures will be assessed with each PSUR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Not applicable                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                                                                                       | Routine risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Additional risk minimisation measures                                                                                 |
|------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| Persistent intolerability in high exposure populations                                                                                               | Use of Daxas/Daliresp/Libertek in populations such as black, non-smoking females, might lead to an increase of exposure and persistent intolerability. In this case, Daxas/Daliresp/Libertek treatment should be reassessed (see section 4.4 of the SmPC).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Educational material for prescribers is distributed at the time of market introduction and made available thereafter. |
| Off-label use: • Asthma adult • Asthma paediatric • COPD other than indicated • Alpha 1 anti- trypsin deficiency • Use at lower than indicated doses | The indication is defined in section 4.1 of the SmPC as: Daxas/Daliresp/Libertek is indicated for maintenance treatment of severe COPD (FEV 1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment. The posology is defined in section 4.2 of the SmPC as: Starting dose - The recommended starting dose is one tablet of 250 micrograms roflumilast to be taken once daily, for 28 days. This starting dose is intended to reduce adverse events and patient discontinuation when initiating therapy, but it is a sub- therapeutic dose. Therefore, the 250 micrograms dose should be used only as a starting dose. Maintenance dose - After 28 days of treatment with the 250 micrograms starting dose, patients must be up-titrated to one tablet of 500 micrograms roflumilast, to be taken once daily. Section 4.2 of the SmPC: There is no relevant use of Daxas/Daliresp/Libertek in the paediatric population (under 18 years). | Educational material for prescribers is distributed at the time of market introduction and made available thereafter. |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                                                                          | Routine risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Additional risk minimisation measures                                                                                              |
|-----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| Missing information                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                    |
| Use during pregnancy and lactation                                                                                                      | Section 4.6 of the SmPC: There are limited amount of data from the use of roflumilast in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Daxas/Daliresp/Libertek is not recommended during pregnancy and in women of childbearing potential not using contraception. Roflumilast has been demonstrated to cross the placenta in pregnant rats. Breastfeeding Available pharmacokinetic data in animals have shown excretion of roflumilast or its metabolites in milk. A risk to the suckling child cannot be excluded. Daxas/Daliresp/Libertek should not be used during breast-feeding. Pregnancies will be monitored according to the procedures described in Part III.2 of this document. Considering the very low likelihood of a pregnancy in the indicated patients, no further risk minimisation activities were considered necessary. | Not applicable.                                                                                                                    |
| Intake of immunosuppressive medication (excl. short- term systemic corticosteroids)                                                     | Section 4.4 of the SmPC states that due to lack of relevant experience, treatment with Daxas/Daliresp/Libertek should not be initiated and existing treatment with Daxas/Daliresp/ Libertek should be stopped in patients being treated with immunosuppressive medicinal products (except short-term systemic corticosteroids).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Educational material for prescribers and patients is distributed at the time of market introduction and made available thereafter. |
| Severe immunological diseases (e.g. HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy) | Section 4.4 of the SmPC states that due to lack of relevant experience, treatment with Daxas/Daliresp/Libertek should not be initiated and existing treatment with Daxas/Daliresp/ Libertek should be stopped in patients with severe immunological diseases.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Educational material for prescribers and patients is distributed at the time of market introduction and made available thereafter. |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                 | Routine risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                    | Additional risk minimisation measures                                                                                              |
|--------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| Mild, moderate or severe hepatic impairment classified as Child Pugh A, B or C | Sections 4.2, 4.3 of the SmPC state that patients with moderate or severe hepatic impairment classified as Child Pugh B or C, respectively should not take Daxas/Daliresp/Libertek, i.e. that these patients are contraindicated. Section 4.2 of the SmPC mentions that clinical data are considered insufficient to recommend a dose adjustment for mild hepatic impairment (Child- Pugh A). Caution is thus considered necessary in these patients. | Educational material for prescribers is distributed at the time of market introduction and made available thereafter.              |
| Combination of roflumilast with theophylline for maintenance therapy           | Section 4.4 of the SmPC: There are no clinical data to support the concomitant treatment with theophylline for maintenance therapy. Therefore, the concomitant treatment with theophylline is not recommended.                                                                                                                                                                                                                                        | Educational material for prescribers and patients is distributed at the time of market introduction and made available thereafter. |
| Long-term treatment                                                            | Section 4.2 of the SmPC: Daxas/Daliresp/Libertek has been studied in clinical trials for up to one year. Long term data will be acquired in an epidemiological long-term study.                                                                                                                                                                                                                                                                       | Not applicable.                                                                                                                    |

## Conclusion

The CHMP and PRAC considered that the risk management plan version 18.3 is acceptable.

## 2.11. Pharmacovigilance

## Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the MAH fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out  in  the  list  of  Union  reference  dates  (EURD  list)  provided  for  under  Article  107c(7)  of  Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## 2.12. Product information

## 2.12.1. User consultation

A justification  for  not  performing  a  full  user  consultation  with  target  patient groups  on  the  package leaflet has been submitted by the MAH and has been found acceptable for the following reasons: the changes to the patient leaflet as a result of the introduction of 250 μg tablet are minor and do not change the readability of the document.

## 2.12.2. Additional monitoring

Pursuant  to  Article  23(1)  of  Regulation  No  (EU)  726/2004,  Daxas  (roflumilast)  is  included  in  the additional monitoring list as it has a PASS imposed either at the time of authorisation or afterwards; [REG Art 9(4)(cb), Art 10a(1)(a), DIR Art 21a(b), Art 22a(1)(a)].

Therefore the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## Place of roflumilast in therapy

Roflumilast is a selective phosphodiesterase type 4 (PDE4) inhibitor. PDE4 is an important regulator of cyclic  AMP  in  most  cell  types  involved  in  inflammatory  processes.  Inhibition  of  PDE4  reduces  the breakdown of cAMP, which in turn down-regulates the inflammatory process. It has a mechanism of action that is complimentary to the anti-inflammatory effect of ICS and the bronchodilatory effect of LABA and LAMA, which are the standard of care in patients with severe COPD at risk of exacerbations. Exacerbations of COPD are worsenings of the patient's respiratory symptoms beyond normal day-today variation that lead to changes in medication, and possibly, hospitalization and death.

<div style=\"page-break-after: always\"></div>

Current GOLD guidelines recommend adding roflumilast to treatment regimens for patients in Group D who have chronic bronchitis and forced expiratory volume in 1 second (FEV1) &lt;50% of predicted whose exacerbations are not adequately controlled on a triple combination of a long-acting β2adrenergic agonist (LABA), a long-acting muscarinic antagonist (LAMA), and inhaled corticosteroid (ICS). The indication for roflumilast in clinical practice is therefore for patients with GOLD spirometric grade 3-4 and group D.

Roflumilast was approved for use in 2010. During clinical studies, the rate of discontinuations with roflumilast in pivotal studies was quite high, around 30%, with withdrawals due to intolerability accounting for the majority of discontinuations (Daxas EPAR, 2010). As follow-up measure (FUM004), the MAH was encouraged to present a program exploring the feasibility of developing alternative doses to minimize the risk of drug interactions and poor tolerability. This line extension application is the result of studies aimed to address this issue.

## 3.1.1. Disease or condition

Roflumilast, at a 500 microgram once-daily dose, is authorised in the EU since 05-Jul-2010 for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment.

COPD is the fourth leading cause of death in Europe, and is a major public health problem. COPD is generally but not exclusively associated with tobacco smoking. Tobacco smoke is considered the most important risk factor for COPD worldwide. Prevalence and morbidity data greatly underestimate the total burden of COPD because the disease is usually not diagnosed until it is clinically apparent and moderately advanced.

COPD comprises pathological changes in four different compartments of the lungs (central airways, peripheral airways, lung parenchyma, pulmonary vasculature), which, in turn, give rise to the physiological abnormalities in COPD: mucous hypersecretion and cilliary dysfunction, airflow limitation and hyperinflation, gas exchange abnormalities, pulmonary hypertension, and systemic effects.

The most widely accepted classification of the severity of COPD is according to The Global Initiative for Chronic Obstructive Lung Disease (GOLD) (GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD; Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosismanagement-prevention-copd/). It includes a spirometric and symptoms classification.

The GOLD classification of airflow limitation severity (spirometric classification) recognizes four grades (1: mild; 2: moderate; 3: severe; 4: very severe), being categories 3-4 those corresponding to severe (FEV1 ≤ 50% predicted) and very severe (FEV1 ≤ 30% predicted) airflow limitation, respectively.

It should be noted that there is only a weak correlation between FEV1, symptoms and impairment of a patient's health status. For this reason, formal symptomatic assessment is also required.

Current GOLD guidelines recommend the symptomatic classification of COPD patients regarding symptoms and risk of exacerbations using the 'ABCD' assessment tool. Group D are patients with more symptoms at high risk of exacerbations. The prognosis of COPD is poorer in patients with severe/very severe airflow limitation and it is correlated with the degree of dyspnoea (GOLD 2017).

## 3.1.2. Available therapies and unmet medical need

The most important aspect of management of the condition is educational and social: the avoidance and cessation of tobacco smoking. The medications for COPD currently available can reduce or abolish symptoms, increase exercise capacity, reduce the number and severity of exacerbations, and improve health  status.  At  present  no  treatment  is  shown  to  modify  the  rate  of  decline  in  lung  function. Combining different agents produces a greater change in spirometry and symptoms than single agents alone.

<div style=\"page-break-after: always\"></div>

## 3.1.3. Main clinical studies

This submission is based on data from a single study (Study RO 2455 302-RD [OPTIMIZE]) conducted to fulfill a Committee for Medicinal Products for Human Use (CHMP) post-authorization measure (FUM004) to explore alternative doses of roflumilast to minimize the risk of poor tolerability, and to explore the influence of factors such as gender, age, and smoking status on the bioavailability of the product in patients with chronic obstructive pulmonary disease (COPD).

OPTIMIZE was a multicenter, randomized, double-blind, 3-arm, parallel group, phase 3 study with an open-label Down-Titration Period for subjects who withdrew from the Main Period of the study. During the Main Period, subjects were randomized receive 1 of the 3 treatments consisting of 2 up-titration treatment groups: 250 μg OD or 500 μg EOD for the first 4 weeks followed by 500 μg OD for 8 weeks, and the currently approved roflumilast regimen of 500 μg OD administered for 12 weeks. All subjects discontinuing from the Main Period were permitted to enter an 8-week open-label Down-Titration Period where they received roflumilast 250 μg OD.

Inclusion and exclusion criteria in OPTIMIZE study were in line with the indication (severe COPD and a history of exacerbations) and contraindications/non-recommendation of use detailed in the Daxas SmPC. Study medications included  roflumilast 250 μg tablet, 500 μg tablet and placebo of identical appearance. Placebo was used only during the 4-week up-titration period (the only phase that was double-blinded) (the 8 week continuation after initial 4-week up-titration was single blinded, as investigators knew that all patients were receiving the roflumilast 500 μg tablet, although they were unaware of the type of initial 4-week treatment that patients had received).

Primary Endpoint was the percentage of subjects prematurely discontinuing study treatment due to any reason during Main Period. Key Secondary Endpoints included the percentage of subjects with adverse events (AEs) of interest to evaluate tolerability during Main Period,  the change in prebronchodilator (pre-BD) FEV1 during Down-Titration Period (V0DT to VendDT) and the percentage of subjects prematurely discontinuing study treatment due to any reason during Down-Titration Period (V0DT to VendDT). Other secondary endpoints were:  change in pre-BD FEV1 during Main Period of the study, change in pre-BD FVC during Main Period and also including Down-Titration Period; change in subject-assessed treatment satisfaction scores during Main Period of the study and also including Down-Titration Period.

Study methods were appropriate, and one study site was closed due to GCP non compliance issues.

## 3.2. Favourable effects

Compared with roflumilast 500 μg OD [H01] the odds of discontinuing the Main Period using a logistic regression model were statistically significantly lower in the roflumilast 250 μg OD/500 μg OD treatment group at the 5% significance level (24.6% vs. 18.4% of subjects, OR=0.66, 95% CI: 0.47, 0.93; p-value 0.017, primary endpoint). At the 5% significance level, there was no statistically significant difference between roflumilast 500 μg OD and roflumilast 500 μg EOD/500 μg OD treatment groups [H02] (OR 0.76, 95% CI: 0.55, 1.07; p-value 0.114). Supportive analysis Cox proportional hazards model found a similar result for roflumilast 250 μg OD/500 μg OD (HR=0.68, 95 % CI: 0.51, 0.92) and roflumilast 500 μg EOD/500 μg OD (HR=0.77, 95% CI: 0.58, 1.02) versus roflumilast 500 μg OD. A per-protocol analysis also supported the robustness of the results on the primary study endpoint.

The results of the main endpoint based on the logistic regression model with region as a covariate, instead of country, were consistent with the primary analysis results. Compared with roflumilast 500 μg OD [H01The odds of discontinuing from the Main Period were lower in the roflumilast 250 μg OD/500 μg OD treatment group (OR=0.70, 95% CI: 0.50, 0.97; p-value 0.032). The results of the sensitivity analyses by excluding the South African site  for the primary endpoint supported the results of the primary analysis also yielded significant differences (OR=0.66, 95% CI: 0.47, 0.93; p-value 0.017). Most subgroups trended towards favouring the 250/500 microg OD up-titration regimen.

<div style=\"page-break-after: always\"></div>

The analysis of TEAEs of Interest during the Main Period (Key Secondary Safety Endpoint) was entirely consistent with those of the primary endpoint. Compared with roflumilast 500 μg OD, the odds of experiencing a 'TEAE of interest' was significantly lower in the roflumilast 250 μg OD/500 μg OD treatment group (54.2% versus 45.4% of subjects, OR=0.63, 95% CI: 0.47, 0.83; p-value = 0.001). This difference was not observed between roflumilast 500 μg EOD/500 μg OD (48.3% of subjects) and the roflumilast 500 μg OD (54.2%) treatment groups in the analysis of AEs of interest.

During the main treatment period  (D0-D84Vend), all the 3 treatment groups experienced statistically significant and relevant absolute mean improvements in pre-BD FEV1 versus baseline (group 1: +117 ml; group 2: +141 ml; group 3, control = +122 ml), having in mind that they were patients who had a baseline pre-BD FEV1 around 1018 ml to 1028 ml (≈10% relative increase.  There were no statistically significant differences for the change in pre-bronchodilator FEV1 from baseline to end of treatment visit, between roflumilast 250 μg OD/500 μg OD versus roflumilast 500 μg OD (LS mean for treatment difference 0.02 L, 95% CI: -0.17, 0.20; p=0.871) or roflumilast 250 μg EOD/500 μg OD  versus roflumilast 500 μg OD-group 3 (LS mean for treatment difference 0.13 L, 95% CI: -0.05, 0.32; p=0.162), thus suggesting that all treatment approaches had similar efficacy. Per-protocol analysis based on the VCS also found similar results.

There were numerically more patients in up-titration group that are very satisfied or satisfied (89.1%) than in the control group (85.7%). On the contrary, there were more patients dissatisfied in the control group (7.5%) than in the up-titration group 1 (3.7%). Therefore, it seems that patient's satisfaction tended to be improved with the up-titration regime than with the standard regime, and this is consistent with the primary endpoint of treatment withdrawals and the key secondary endpoint of AEs of interest (less risk of diarrhoea, insomnia, nausea). Patient's satisfaction with up-titration probably reflects a better tolerability (less adverse events with the 250 micrograms to 500 micrograms up-titration) at similar efficacy in terms of lung function improvement (i.e.: similar improvement in pre-BD FEV1 regardless of dosing schedule, close to +100 ml). However, no definitive conclusions can be drawn due to the exploratory nature of the analysis.

## 3.3. Uncertainties and limitations about favourable effects

About 67% of patients was receiving a dual ICS+LABA combination during the main period, and 63% of patients were receiving a LAMA. However, no data about the aggregated number of patients receiving the ICS+LAMA combination or ICS+LABA+LAMA combination were reported initially. Submitted subgroup analyses by concomitant medication use submitted during the procedure were hampered by its post-hoc nature and lack of statistical power due to small sample sizes. Anyway, the analysis provided justify for all of the subgroups studied to take advantage of the 250 µg OD/500 µg OD up-titration regimen, regardless of concomitant LAMA or multiple concomitant medication use. In addition, patients on polypharmacy (on ≥4 concomitant medications) had a small increase (approximately 10%) in the predicted tPDE4i and could not explain the observed increase in number of AEs of interest for these patients. Therefore, no conclusion can be drawn on higher benefit of the new roflumilast dosing regime  in patients on polypharmacy.

Strictly speaking, the single pivotal trial supporting this application does not fulfill with the level of statistical significance (considerably stronger than &lt;0.05) normally required for application based on a single pivotal trial (Points to consider on application with 1. meta-analyses; 2. one pivotal study; CHMP/EWP/2330/99). However, on the one hand, the results on the primary safety endpoint were quite robust, with all sensitivity and ancillary analyses of the main endpoint showing a benefit, and with key secondary endpoint showing also a benefit in safety (e.g.: significant lower rates of TEAEs of interest) and patient's satisfaction, with no detrimental effect on efficacy (pre-BD FEV1). On the other hand, the line extension is restricted to improve the initial tolerability and decrease early withdrawal rates with treatment by starting with a lower dose.

<div style=\"page-break-after: always\"></div>

There are no data to ascertain whether the benefit shown at 3 months will be sustained in the long term. Even if the effect is sustained overtime, and while recognizing that a streamlined posology aimed to minimize adverse events and treatment discontinuations is a positive goal. It is agreed with the applicant that a 6.2% reduction of discontinuations in the current population treated with roflumilast would translate into a 12.9% reduction in exacerbations during the first year. According to market share of roflumilast in different regions, this would translate in the prevention of additional 340 exacerbations in Europe and 1031 exacerbations globally, compared with starting with the 500 microg dose. This benefit is added to the adverse events prevented (mainly gastrointestinal).

Although most subgroups trended towards favouring the 250/500 microg OD up-titration regimen, there were two exceptions (i.e.: non-European region and Asian race in the comparison versus roflumilast 500 μg OD). Asian patients tend to have a lower body weight than patients from Western countries.  Asian race was not a significant covariate in population PK analysis, whereas in subgroup analyses of pivotal studies, the effect of roflumilast versus placebo on the rate of moderate or severe exacerbations showed no heterogeneity depending on race.  Results from the new population PK model on the combined REACT and OPTIMIZE dataset identified no clinically relevant changes of systemic exposure levels in other populations of particular interest (eg, elderly patients, current smokers, female patients, or patients with high [&gt;80 kg] or low [&lt;60 kg] baseline body weight). Therefore, the approved maintenance dose of roflumilast 500 μg OD does not need to be adjusted in these populations.

Elderly patients seem under-represented in the OPTIMIZE study, and they are a special population at risk of adverse events and withdrawals. The applicant clarified that only 115 patients were between 75 to 84 years and only 2 patients were &gt;85 years old. With the limitations of small sample sizes, the subgroup analyses by age showed some small increases in adverse events with age with all dosing regimes, but the benefit of the new dosing regime in avoiding adverse events and discontinuations was consistently in favour of the new roflumilast regime regardless of age.

The analysis of main interest for the down-titration phase was for those patients who did not tolerate roflumilast 500 μg OD during the Main Period and subsequently entered the down-Titration period (n=80), in order to ascertain whether a the 250 microgram dose, administered to all of them, could be effective (i.e.: whether it could produce improvements in pre-BD FEV1 from the start of down-titration to end of down-titration). Eighty subjects (of 1321 subjects, 6.0%) who did not tolerate roflumilast 500 μg OD in the Main Period were treated with roflumilast 250 μg OD for 8 weeks (n=20 for the roflumilast 250 μg OD/500 μg OD group, n=22 for roflumilast 500 μg EOD/500 μg OD group, and n=38 for the roflumilast 500 μg OD group at Baseline, V0DT). The analyses indicated no effect of the 250 microgram low-dose roflumilast in pre-BD FEV1. The lack of effect on pre-BD FEV1 of a lower roflumilast maintenance dose was consistent in the per-protocol analysis based on the VCS and in several sensitivity analyses. Product information was ammended to reinforce the message that the 250 micrograms dose is subtherapeutic and should not be used for maintenance treatment.

The results of the statistical analysis of TEAEs of Interest (diarrhea, nausea, headache, reduced appetite, insomnia, or abdominal pain) during the Main Period are supportive and consistent with the results on the main study endpoint. However, they are considered exploratory based on insufficient evidence to reject the null hypothesis for the primary endpoint at the 5% significance level [H02] in the framework of hierarchical testing (i.e.: no statistically significant differences were found for the comparison between groups 2 and 3 for the primary endpoint of premature discontinuations).

## 3.4. Unfavourable effects

The analysis of safety data from OPTIMIZE study does not raise any new concern about the safety of roflumilast. Most patients (63.7%) experienced TEAEs during treatment with roflumilast (61.2% in group 1, 64.3% in group 2 and 65.7% in control group), with most frequent TEAEs being gastrointestinal (diarrhoea, nausea, abdominal pain) (occurring in 37.9% of patients overall) (34.9% in group 1, 35.9% in group 2 and 42.9% in control group). SAES were reported in 4.6% of subjects. Only

<div style=\"page-break-after: always\"></div>

0,2% of patients had a SAE related to study medication (1 patient in each group). These data are consistent with the known safety profile of roflumilast.

The analysis of TEAEs related to study drug indicated a safety advantage of the roflumilast 250 μg OD/500 μg OD up-titration regime versus the standard roflumilast 500 μg OD regime, which was largely driven by less related TEAEs of diarrhoea (13.8% vs. 21.7%; -7.9% difference) and nausea (11.3% vs. 16.3%; -5% difference).

## 3.5. Uncertainties and limitations about unfavourable effects

Although the OPTIMIZE study showed a benefit of the roflumilast 250 μg OD/500 μg OD up-titration regime versus the standard roflumilast 500 μg OD regimen, it was based on the assessment at 3 months.  The first 4 weeks of treatment represents the dosing period most relevant to the aims of the study (i.e., to improve tolerability of roflumilast through use of alternative dosing regimens).  After this time, there is no evidence to support a need for further improvements, as the frequency of AEs with roflumilast is not higher than with placebo, and the rate of withdrawals from study treatment are low.

The 250 micrograms dose is subtherapeutic and should not be used for maintenance treatment.

## 3.6. Effects Table

Table 30 . Effects Table for roflumilast 250 microg tablets OD for up-titration phase to 500 microg OD (effective dose for severe COPD patients at risk of exacerbations despite ICS and LABD)

<!-- image -->

| Effect                                           | Short Description Unit                                                                                            | Treatment (250 microg OD                         | Treatment (250 microg OD                         | Control (500 microg                              | Uncertainties/ Strength of evidence              | References                                       |                                                  |
|--------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Favourable Effects                               | Favourable Effects                                                                                                | Favourable Effects                               | Favourable Effects                               | Favourable Effects                               | Favourable Effects                               | Favourable Effects                               | Favourable Effects                               |
| Premature discontinuations                       | Subjects prematurely discontinuing main period. Intent to treat (Full analysis set: FAS), from baseline to day 84 | N (%)                                            | 81 (18.4%)                                       | 109 (24.6%)                                      | OR: 0.66; 95%CI: 0.47 to 0.93                    | OPTIMIZE study report                            |                                                  |
| AEs events of interest                           | Subjects with AEs of interest Intent to treat (Full analysis set: FAS), during the 8-week main period             | N (%)                                            | 200 (45.4%)                                      | 240 (54.2%)                                      | OR: 0.63; 95%CI: 0.47 to 0.83                    | OPTIMIZE study report                            |                                                  |
| Unfavourable Effects (lack of beneficial effect) | Unfavourable Effects (lack of beneficial effect)                                                                  | Unfavourable Effects (lack of beneficial effect) | Unfavourable Effects (lack of beneficial effect) | Unfavourable Effects (lack of beneficial effect) | Unfavourable Effects (lack of beneficial effect) | Unfavourable Effects (lack of beneficial effect) | Unfavourable Effects (lack of beneficial effect) |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Effect                                                                                                     | Short Description                                                                                                           | Unit         |   Treatment (250 microg OD for 4 weeks followed by 500 microg OD for 8 weeks) |   Control (500 microg OD for 12 weeks) | Uncertainties/ Strength of evidence   | References            |
|------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|--------------|-------------------------------------------------------------------------------|----------------------------------------|---------------------------------------|-----------------------|
| Effect on pre-BD FEV1 in intolerants to roflumilast who received the 250 microg dose during down-titration | Change in pre-BD FEV1 (L) versus baseline during the 8-week down- titration period Intent to treat (Full analysis set: FAS) | Litres, mean |                                                                          0.01 |                                      0 | 0.02 (-0.17 to 0.20)                  | OPTIMIZE study report |

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Adherence to COPD medications is a key goal in the management of COPD, as it is associated with reduced risk of death and admission to hospital due to COPD exacerbations [Vestbo et al. Thorax. 2009;64:939-43]. Therefore, any measure to improve adherence to roflumilast is welcomed to minimize the high withdrawal rates, about 30%, found in pivotal studies with roflumilast (Daxas EPAR, 2010).

The OPTIMIZE pivotal study was designed to answer that question. The study showed a better adherence (less early withdrawals: 18.4% vs. 24.6%; Diff: -6.2%) with the roflumilast 250 μg OD/500 μg OD up-titration regime versus the standard roflumilast 500 μg OD regimen. The results were further supported by a lower risk of TEAEs of interest (45.4% vs. 54.2: Diff.: -8.8%) and trend towards a better patients' satisfaction with treatment, probably related to a better tolerability.

## 3.7.2. Balance of benefits and risks

The analysis of TEAEs related to study drug indicated a safety advantage of the roflumilast 250 μg OD/500 μg OD up-titration regime versus the standard roflumilast 500 μg OD regime, which was largely driven by less related TEAEs of diarrhoea (13.8% vs. 21.7%; -7.9% difference) and nausea (11.3% vs. 16.3%; -5% difference). The positive effect is further supported by sensitivity analyses of the main endpoint as well as for the results of secondary endpoints of TEAEs of interest and patientreported outcomes.

The analysis of safety data from OPTIMIZE study does not raise any new concern about the safety of roflumilast. Most patients (63.7%) experienced TEAEs during treatment with roflumilast (61.2% in group 1, 64.3% in group 2 and 65.7% in control group), with most frequent TEAEs being gastrointestinal (diarrhoea, nausea, abdominal pain) (occurring in 37.9% of patients overall) (34.9% in group 1, 35.9% in group 2 and 42.9% in control group). SAES were reported in 4.6% of subjects. These data are consistent with the known safety profile of roflumilast.

Finally, there is a risk of off-label use with the roflumilast 250 microgram as maintenance dose. The 250 micrograms dose is sub-therapeutic and should not be used for maintenance treatment. This has been adequately mentioned in section 4.2 of the SmPC.

<div style=\"page-break-after: always\"></div>

## 3.7.3. Additional considerations on the benefit-risk balance

Although the OPTIMIZE study showed a benefit of the roflumilast 250 μg OD/500 μg OD up-titration regime versus the standard roflumilast 500 μg OD regime for withdrawals and TEAEs of interest, the study does not provide data beyond 3 months.   In roflumilast clinical trials, Kaplan-Meier plots of time to onset of AEs show that the majority of events in the roflumilast treated-patients occur early, and that there is a plateau after 4 weeks. Therefore, the first 4 weeks of treatment represents the dosing period most relevant to the aims of the study (i.e., to improve tolerability of roflumilast through use of alternative  dosing  regimens).    After  this  time,  there  is  no  evidence  to  support  a  need  for  further improvements, as the frequency of AEs with roflumilast is not higher than with placebo, and the rate of withdrawals from study treatment are low . With a 6.2% reduction of discontinuations in the current population treated with roflumilast would translate into a 12.9% reduction in exacerbations during the first  year.  According  to  market  share  of  roflumilast  in  different  regions,  this  would  translate  in  the prevention of additional 340 exacerbations in Europe and 1031 exacerbations globally, compared with starting with the 500 microg dose. This benefit is added to the adverse events (mainly gastrointestinal) prevented.

## 3.8. Conclusions

The overall B/R of Daxas is positive for the lower strength 250 μg in the currently approved indication.

## 4. Recommendations

## Outcome

Based  on  the  CHMP  review  of  data  on  quality  and  safety  and  efficacy,  the  CHMP  considers  by consensus that the risk-benefit balance of Daxas 250 μg, is favourable in the following indication:

Daxas is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment.

The CHMP therefore recommends the extension of the marketing authorisation for Daxas subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to medical prescription.

## Conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out  in  the  list  of  Union  reference  dates  (EURD  list)  provided  for  under  Article  107c(7)  of  Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk Management Plan (RMP)

The Marketing Authorisation Holder shall agree the content and format of the updated educational material with the national competent authority.

The Marketing Authorisation Holder (MAH) should ensure that all Healthcare Professionals who are expected to prescribe Daxas are provided with an updated Educational pack.

The educational pack should contain the following:

- Summary of Product Characteristics and Patient Information Leaflet for Daxas
- Educational material for the physician.
- Copies of the patient card to be given to patients or caregivers before they receive Daxas

The educational material for the prescriber should include information on the following key elements:

-  The specific indication approved.
-  The fact that Daxas is not indicated for the treatment of COPD patients outside of the approved indication, nor for use in patients with asthma or alpha-1 antitrypsin deficiency.
-  The need to inform patients about the risks of Daxas and the precautions for safe use including:
-  The risk of weight decrease in underweight patients and the need to monitor the body weight at each visit and to stop the treatment in the event of an unexplained and clinically concerning weight decrease. Patients should be advised to weigh themselves at regular intervals and record the weight in the patient card.
-  The risk of psychiatric disorders such as insomnia, anxiety, depression in patients receiving Daxas and the potential risk of suicide. Rare instances of suicidal ideation and behaviour, including completed suicide, have been observed in patients with and without a history of depression, usually in the first weeks of treatment. Physicians should carefully assess the benefit risk balance of this treatment in patients with existing psychiatric symptoms or with history of depression. Daxas is not recommended in patients with a history of depression associated with suicidal ideation or behaviour. If patients suffer from new or worsening psychiatric symptoms, or suicidal ideation or suicidal attempt, it is recommended to discontinue treatment with Daxas.
-  Patients and caregivers should be requested to report any changes in the patient`s behaviour or mood or suicidal ideation.
-  The potential risk of malignant tumours and the lack of experience in patients with past history of cancer. Daxas should not be initiated or should be stopped in patients with cancers (except basal cell carcinoma).
-  That increased exposure might occur in certain populations and increase the risk of persistent intolerability:
- o Special populations who have increased PDE4 inhibition such as black non smoking females;
- o Patients concomitantly treated with CYP1A2/2C19/3A4 inhibitors (such as fluvoxamine and cimetidine) or CYP1A2/3A4 inhibitors (such as enoxacin).
-  The potential risk of infections: Daxas should not be initiated, or treatment should be stopped, in patients with severe acute infectious diseases. The limited experience in patients with latent infections such as tuberculosis, viral hepatitis or herpes infections.

<div style=\"page-break-after: always\"></div>

-  The lack of experience in patients with HIV infection or active hepatitis, with severe immunological diseases (e.g. multiple sclerosis, lupus erythematosus, multifocal leukoencephalopathy) or treated with immunosuppressive therapy (other than short-term systemic corticosteroids) and that Daxas should not be initiated or should be stopped in these patients.
-  The potential cardiac risk: Daxas has not been studied in patients in congestive heart failure (NYHA grade 3 and 4); hence, it is not recommended in this population.
-  The limited or missing information in patients with liver impairment. Daxas is contraindicated in patients with moderate or severe liver impairment (Child-Pugh B or C). Clinical data are considered insufficient to recommend dose adjustment and caution should be observed in patients with mild liver impairment (Child-Pugh A).
-  The lack of clinical data to support the combination with theophylline and that such combination is not recommended.

## Patient Card

The patient card should contain the following key elements:

That they should tell their doctor if they have a history of any of the following conditions

- cancer
- insomnia, anxiety, depression, suicidal ideation or behaviour
- multiple sclerosis or SLE
- infection with tuberculosis, herpes, hepatitis, HIV

That patients or their caregivers should tell their doctor if the patient develops symptoms indicative of:

- insomnia, anxiety, depression, changes in behaviour or mood, suicidal ideation or behaviour
- severe infection

That patients should tell their doctor if they are taking any other medicines.

That Daxas may cause weight loss and patients should weigh themselves regularly and record their weight on the patient card.

The patient card should include an area where patients can record their weight and the date they weighed themselves and they should be asked to bring the patient card with them at each visit.

## · Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

| Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Due date                                                                |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| ANX 2.1 - The MAH commits to conduct a long-term comparative observational safety study. This study should be appropriate to compare the incidences of all-cause mortality, major cardiovascular events, new diagnosis of cancer, all-cause hospitalisation, hospitalisation related to respiratory disease, suicide or hospitalisation for suicide attempt, and new diagnosis of depression, tuberculosis or viral hepatitis B or C in roflumilast treated COPD patients compared with COPD patients not treated with roflumilast. | Interim Study Reports - with each PSUR Final study report by 31/03/2021 |

Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable